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Abstract  
The research project discussed in this PhD thesis concerns the development of drug delivery 
and theranostic systems for nanomedicine applications in cancer treatments. 
In the first part, polymeric nanoparticles have been exploited as drug delivery systems for the 
treatment of Glioblastoma Multiforme. For this purpose, two different biomolecules, in one 
case Cholotoxin, a small peptide, and in the other case an antiPDGFRs-aptamer (GINT.4), 
have been employed as targeting agents conjugated on the polymeric nanoparticles surface. 
The second section of the project has been focused on the development of metallic 
nanoparticle for photothermal therapy, a cancer treatment consisting in the exposition of body 
tissue to an increasing of temperature (42-45°C) to induce cytotoxic effects on cancer cells.  
For this purpose, gold nanorods (GNRs) have been investigated as photothermal agent for the 
treatment of Barrett’s esophageal. On the other hand, one pot-synthesis of chitosan coated 
magnesium nanoparticle has been fine-tuned in order to obtain high biocompatible 
nanoparticles characterized by a promising unexpected photothermal behaviour.  
In the last part of the project, the synthesis of multicomponent nanosystems suitable for 
multimodal imaging or theranostic agents have been investigated. Two different 
multifunctional nanomaterials based on the incorporation of iron oxide and gold nanoparticles 
in the same nanosystem, have been realized. The first system consisted in dumbbell-like gold-
iron oxide nanoparticles coated with chitosan that showed photothermal behaviour and also 
good capabilities as photoacoustic imaging contrast agents. The second system consisted in 
core−shell Fe3O4@SiO2@Au NPs entrapped in polymeric nanoparticles decorated with folic 
acid, have been tested in vivo for photoacoustic and magnetic resonance imaging detection of 
ovarian cancer. 
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Table of acronyms  Acronym Significance AAS atomic absorption spectroscopy Ag-nps silver nanoparticles Ag-nps-1 silver nanoparticles coated with 11-(4-mercaptobenzamido)undecanoate Ag-nps-PVP silver nanoparticles coated with polyvinylpyrrolidone Ag-PNP silver nanoparticles Ag-PNP-CTX silver nanoparticles entrapped in polymeric nanoparticles functionalized with chlorotoxin APTMS (3-aminopropyl)trimethoxysilane ATP adenosine triphosphate BAR-T Barrett’s esophageal toumor BBB blood−brain barrier BODI-PY BODIPY505-515, lipophilic dye BODI-PY@PNPs-Gint4.T polymeric nanoparticles containing the lipophilic dye BODIPY505-515 functionalized on the surface with the aptamer Gint4.T BODI-PY@PNPs-SCR polymeric nanoparticles containing the lipophilic dye BODIPY505-515 functionalized on the surface with the scrambled aptamer SCR BODY-PY@PNPs polymeric nanoparticles containing the lipophilic dye BODIPY505-515  CDI 1,1-carbonyldiimidazole Chit-Mg MPs chitosan coated magnesium microparticles CT computed tomography CTAB cetyltrimethylammonium bromide CTX chlorotoxin Curc@PMs polymeric nanomicelles containing curcuma molecules cw continuous wave DCC N,N’-dicyclohexylcarbodiimide DCM  dichloromethane DIPEA N,N-diisopropylethylamine dl-AuFe NPs dumbbell-like gold–iron oxide nanoparticles dl-AuFe3O4@Chit chitosan coated dumbbell-like gold–iron oxide nanoparticles DLS dynamic light scattering DMF dimethylformamide DPSSL diode pumped solid state laser EAC esophageal adenocarcinoma EC50 half maximal effective concentration values EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EMA European Medicine Agency EPR enhanced permeability and retention FA folic acid FDA US Food and Drug Administration Fe3O4 NPs iron oxide nanoparticles Fe3O4@SiO2@Au NPs core−shell iron oxide−silica−gold nanoparticles 
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Fe3O4@SiO2@Au@PMs core−shell iron oxide−silica−gold nanoparticles coated with the 11-(4-mercaptobenzamido)undecanoate entrapped in polymeric micelles Fe3O4@SiO2@Au@PMs−FA core−shell iron oxide−silica−gold nanoparticles coated with the 11-(4-mercaptobenzamido)undecanoate entrapped in polymeric micelles functionalized with folic acid  Fe3O4@SiO2@Au@PMs−FA/fluo core−shell iron oxide−silica−gold nanoparticles coated with the 11-(4-mercaptobenzamido)undecanoate entrapped in polymeric micelles functionalized with folic acid and fluorescein Fe3O4@SiO2@Au-1 core−shell iron oxide−silica−gold nanoparticles coated with the 11-(4-mercaptobenzamido)undecanoate FTIR fourier transform infrared spectroscopy GBM glioblastoma multiforme Gint4.T aptamer able to recognize platelet-derived growth factor receptors β on the blood−brain barrier GNPs gold nanoparticles GNRs gold nanorods GNRs-1 Gold nanorods coated with 11-(4-mercaptobenzamido)undecanoate) GNRs-1/Curc@PMs polymeric nanomicelles containing lipophilic gold nanorods and curcuma GNRs-1@PMs polymeric nanomicelles containing liphophilic GNRs-1 GNRs-CTAB gold nanorods coated with cetyltrimethylammonium bromide Gy gray HAADF-STEM high angle annular dark field scanning transmission electron microscopy HCA hydrocaﬀeic acid HCA hydrocaffeic acid MES Buffer 2-(N-morpholino)ethanesulfonic acid Buffer Mg MPs magnesium microparticles Mg NPs magnesium nanoparticles MMP-2 matrix metalloproteinase-2  MPS mononuclear phagocytic system MRI magnetic resonance imaging MTEOS methyltriethoxysilane NaOH sodium hydroxide NHS N-hydroxysuccinimide NIR near-infrared spectroscopy NMR nuclear magnetic resonance NPs Nanoparticles NVP-BEZ235@PNPs polymeric nanoparticles containing the lipophilic drug NVP-BEZ235 NVP-BEZ235@PNPs-Gint4.T polymeric nanoparticles containing the lipophilic drug NVP-BEZ235 functionalized on the surface with the aptamer Gint4.T NVP-BEZ235@PNPs-SCR polymeric nanoparticles containing the lipophilic drug NVP-BEZ235 functionalized on the surface with the scrambled aptamer  
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OI optical imaging PAI photoacoustic imaging PDGFRβ platelet-derived growth factor receptors β PDI polydispersity index PET positron electron tomography PLGA-PEG poly(d,l-lactic-co-glycolic acid)-b-poly(ethylene glycol) PMs polymeric micelles PNPs polymeric nanoparticles PTT photothermal therapy PVP polyvinylpyrrolidone RES reticuloendothelial system RT-qPCR real-time quantitative polymerase chain reaction analysis SAM self-assembled monolayer SCR scrambled aptamer SELEX systematic evolution of ligands by exponential enrichment method SPECT single-photon emission computed tomography SPIONs super paramagnetic iron oxide nanoparticles TEM transmission electron microscopy TGA thioglycolic acid TGA thermogravimetric analysis THF tetrahydrofuran US ultrasound  VSM vibrating-sample magnetometer XRD X-ray diffraction  
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 1. Introduction  1.1 State of the art in Cancer Nanomedicine   Nanotechnology is the science that concerns the study, the development and the production of 
systems characterized by any dimension between 1-100 nanometres. Indeed, small dimension 
confers to nanomaterials unique chemical-physical properties different from the bulk 
materials, and for this reason, in the last decades the use of nanomaterials in different area of 
researches such as electronic, engineering, biotechnology, biology and medicine, allowed a 
real technological revolution. Although IUPAC definition of nanoparticles is a particle with 
any shape of dimension in the 1-100 nm range, the term “nanoparticle” is commonly applied 
to structures that are up to several hundred nanometres in size.1  
Because cancer is set to become a major cause of morbidity and mortality in the coming 
decades in every region of the world, there is the necessity to better understand its biology in 
order to improve diagnostic devices and treatments.2,3 
Nowadays, the main cancer therapies consist of surgical intervention, radiation and 
chemotherapeutic drugs, which are often not efficacy and implicate different side effect as the 
death of healthy cells that cause the toxicity to the patients. In chemotherapy, the main 
complication is represented by the pharmaceutical properties of therapeutic molecules, such 
as the stability and the solubility, which can addict the circulating half-life and tumour 
accumulation making less efficient the therapy. 
The nanotechnologies innovations applied to medicine allowed the development of 
nanomedicine and led to the possibility to overcome some of the main concerns of traditional 
cancer treatments by taking advantage by the interaction between the nanoparticles and 
biological systems but also discovering the therapeutic nature of some nanomaterials 
themselves.4 Cancer nanomedicine provides not only the use of nanoagents as drug delivery 
systems or diagnosis tools to improve the efficacy of traditional methodologies, but also the 
development of medical devices such as micro/nanoelectromechanical (MEM/NEM) device-
based drug delivery or nanothechnology-based sensors for the detection of biomarkers. 5  
In the last years, nanotherapies have been developed by employing the use of several 
nanoparticles platforms such as liposomes, albumin nanoparticles and polymeric micelles as 
drug delivery systems, and developed innovative technologies based on nanomaterials able to 
6  
be used in hyperthermia, radiation, gene and RNA interference (RNAi) therapy and 
immunotherapy (Figure 1).  
 
 
Figure 1. Historical timeline of major developments in the field of cancer nanomedicine. EPR, enhanced permeability and retention; FDA, US Food and Drug Administration; nab, nanoparticle albumin-bound; NP, nanoparticle; PLGA-PEG, poly(d,l-lactic-co-glycolic acid)-b-poly(ethylene glycol); PRINT, particle replication in non-wetting template; siRNA, small interfering RNA adapted from Nat. Rev. Cancer 17, 20–37 (2016). 
At now, few nano-drugs and nano-therapies have been available in clinic. Doxil® and 
Myocet®, consistent in doxorubicin encapsulated into liposomes, were the first class of 
therapeutic nanosystems to receive the clinical approval for cancer treatments. These 
formulations showed the possibility to reduce the dose-related cardiac toxicity concerning the 
doxorubicin and allowed the enhancement of its anticancer efficacy by enhancing patients 
tolerability.6 
The second class of commercialized nanodrugs are represented by the Abraxane which 
consists in nanoparticles made of albumin-bound paclitaxel able to overcome the problems 
associated with administering hydrophobic taxol that induced hypersensitivity reactions.7 
The mentioned examples of nanodrugs show as the nanotechnologies can deal with the 
challenges of cancer, improving the pharmacokinetic and the biodistribution of a 
chemotherapeutic drug or reducing the side effect associated to a therapy. However, clinical 
trials results revealed that the nanoformulations did not show an enhancement of efficacy 
compared with the conventional chemotherapeutic drug.8 In order to obtain an improvement 
of clinical efficacy of cancer treatment, the enhancement of the nanosystems design and 
nanomedicine strategy is necessary. 
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Polymeric micelles (as Genexol PM and NK105) and polymeric nanoparticles (CRLX101 and 
BIND-014) represent the new classes of cancer nanotherapeutic agents under clinical 
investigations.9,10 
However, recently discordant clinical trials results showed the necessity to improve the 
delivery strategies and also the possibility to involve a patients selection to identify those 
most likely to respond to the nanotherapy.11 
On the other hand, nanoparticles are largely investigated in the developing of “molecular 
imaging” in order to visualize and quantify biological processes at molecular and cellular 
levels in a non-invasive manner.12  The possibility to combine in the same nanosystem 
therapy and the diagnostic functionalities led to the development of theranostic systems. This 
represents a promising strategy to monitor the pharmacokinetic, the accumulation of 
therapeutics and the progression of disease, giving important insights into heterogeneities 
both within tumour and between patients for potential personalized therapies.13 
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 1.2 Drug Delivery and theranostic nanosystems  
Drug delivery nanosystems are nanoparticles able to encapsulate a therapeutic agent in order 
to improve their therapeutic index by increasing its efficacy and reducing the toxicity. For this 
reason, a nanocarrier can represent a “second chance” for rejected chemodrugs, bringing out 
several advantages such as: 
 
 the protection of the encapsulated drug from degradation due to the interactions 
with the biological environment; 
 the enhancement of the pharmaceutical properties of therapeutic molecules (for 
example solubility, stability, circulating half-life and tumour accumulation); 
 transocytosis of drugs across tight epithelial and endothelial barriers; 
 
Because the accumulation of drug delivery nanosystems in the cancer site can be achieved by 
two main mechanisms: the passive targeting and active targeting. 
To explain these mechanisms, the development of an efficient drug delivery system needs to 
take in account biological features of the tumour tissue (Figure 2). Generally, tissue in 
advanced cancer grade tends to develop new blood vessels from existing ones in order to 
transport oxygen and nutrients to the new cells in a process defined angiogenesis, which is the 
principal cause of the rapid growth of a tumour.14 The formed tumour vessels are 
characterized by a disorganized vasculature and numerous openings in the walls such as 
vesicles and transcellular holes, inter-endothelial junctions, and a discontinuous basement 
spaces between endothelial cells.15 These factors lead to the enhanced permeability and 
retention (EPR) effect, responsible of an enhancement of the permeability of tumour vessels 
compared to normal tissue. This phenomenon allows the passage of blood plasma components 
and other macromolecules into the interstitial space of the tumour, contributing to longer 
retention of these molecules. 
The passive targeting, a mechanism involved in the drug delivery system pharmacokinetic, is 
a consequence of the enhanced permeability and retention (EPR) effect. This mechanism 
induces nanoparticles accumulation in the tumour tissue by the extravasation from their leaky 
vasculature and allows the release of the encapsulated agents into the vicinity of the tumour 
cells. Consequently, nanoparticles build up reaching higher concentration due to lack of 
efficient lymphatic drainage in solid tumour. Therefore, through passive targeting, a drug 
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delivery nanosystem can reduce the side effects caused by the diffusion of the conventional 
small-molecule in normal tissue, improving the accumulation of nanoparticles in the tumour 
tissue at a concentration five to ten times higher than in normal tissue in 1-2 days.16 The 
nanoparticles size has a great influence on the accumulation with the EPR effect; as reported 
in literature, nanoparticles with a diameter between 10 - 500 nm exhibit a good tendency to 
extravasate and accumulate within the tumor interstitium but other studies showed that 
particles with diameters lower than 200 nm are more effective.17 However, passive targeting 
showed significant drawbacks caused by the tumour heterogeneity, vascular permeability and 
different pharmakinetic of each nanomaterials.18 The main problem consists in the clearance 
of nanoparticles from the bloodstream ascribable to the reticuloendothelial system (RES), 
which consists of phagocytic cells like monocytes and macrophages that are located in the 
spleen, lymph nodes, and Kupffer cells in the liver.  
 
Figure 2. Passive targeting, active targeting, and combinatorial delivery. In passive targeting (left), nanoparticles (NPs) passively extravasate though the leaky vasculature via the enhanced permeability and retention (EPR) effect and preferentially accumulate in tumours. In active targeting (middle), targeting ligands on the surface of the NP trigger receptor-mediated endocytosis for enhanced cellular uptake. In combinatorial delivery (right), two or more therapeutic agents inhibit different or identical disease pathways for a synergistic effect from Trends Mol. Med. 21, 223–232 (2015). 
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This phenomenon cause the high accumulation of the nanoparticles in the liver or spleen and 
can increase the toxicity of the nanomaterials due to the high dose.19 
For this reason, the use of targeting agents able to be conjugated on the surface of 
nanosystems and to guide them to bind specific cells after extravasations, can improve the 
efficacy of the therapy by increasing their accumulation into the cancer site and by decreasing 
the collateral effect as toxicity in the health tissue.20 To maximize the unique characteristic of 
the active targeting mechanism, the use of an active agent able to bind with high selectivity a 
surface marker (antigen or receptor) overexpressed on target cells relative to normal cells is 
required. Several classes of bio-agents such as, antibodies, engineered antibody fragments, 21 
proteins,22 peptides,23 and aptamers,24 have been employed as targeting agents, also different 
chemistry reactions have been developed to conjugate the these agent on nanoparticles 
surface. In the last years, the development of several nanocarriers for nanomedicine 
applications have been reported in literature (Figure 3).25  
 
 
 
 
Figure 3. Images of nanocarriers for targeting cancer adapted from Nat.Nanotechnol. 2, 751-760 (2007). The main components of delivery nanosystems typically include a nanocarrier, a targeting moiety conjugated to the nanocarrier, and a cargo (such as the desired chemotherapeutic drugs).  
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The main research regarded the chemical components employed in the synthesis and 
formulation of these systems, that might be biocompatible and biodegradable materials and 
able to form nanocarriers with high efficiency of encapsulation of the therapeutic agents and 
with good robustness against degradation.  
Carrier materials are classified in two main classes: the organic nanocarriers and inorganic 
nanocarriers. The first class includes nanocarriers constituted by smaller organic molecules, 
synthetic or natural bio-polymers, lipids and prefabricated dendrimers.26 Among these, 
liposomes constituted by lipids, or polymeric micelles obtained with the self-assembled of 
amphiphilic polymers, represent common organic nanocarriers. These systems are constituted 
by an inner hollow space where a hydrophilic or hydrophobic therapeutic agent can be loaded 
(depending on the degree of hydrophilicity of the inner surface), and an outer hydrophilic 
shell able to stabilize the systems in the biologic environment. However, the major drawbacks 
of organic based- nanocarriers consist in their premature degradation in the body, which can 
cause undesired side effects due to drug loss. On the other hand, because their robustness, 
inorganic nanomaterials result less easily degraded during delivery compared to organic 
nanoparticles, and in addiction, could provide additional functions, such as imaging contrast 
agent or therapeutic abilities, due to their peculiar physical properties. For example, optical 
properties of gold nanomaterials, based on surface plasmon resonance, have been investigated 
for the development of therapeutic agents in photothermal ablation therapy (paragraph 1.3) 
but also as contrast agents for photoacoustic imaging (paragraph 1.4.1). Magnetic properties 
of iron oxide nanoparticles have been largely studied in order to find efficient contrast agents 
for magnetic resonance imaging (MRI) (paragraph 1.4.4), but also as therapeutic agents in 
hyperthermia therapy after the application of an alternating magnetic field. In particular, these 
two examples show the possibility to integrate diagnostic and therapeutic functions into a 
single nanoparticle formulation, led to the development of theranostic nanosystems. By 
adopting Ferrari’s classification, a theranostic nanoparticle can be dissected into at least three 
components: biomedical payload, carrier, and surface modifier, depending on both their roles 
and their physical locations, as shown in Figure 4.27 
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Figure 4. Schematic illustration of a multifunctional nanocomposite from Nat. Rev. Cancer 5, 161–171 (2005). 
The biomedical payload includes organic molecules or inorganic nanoparticles characterized 
by therapeutic or diagnostic functions. In particular, for specific materials, inorganic 
nanoparticles can be use their-self to make the therapy and the diagnosis of a specific 
pathological site, after an opportune surface functionalization able to improve their 
biocompatibility. Theranostic nanomedicine show the possibility to develop innovative 
strategies to investigate the pharmacokinetic and accumulation of nanocarriers, but also to 
monitor the progression of disease with imaging techniques. This represents the opportunity 
to achieve important insights into heterogeneities both within tumours and between patients 
for potential personalized treatment. 
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1.2.1 Polymeric nanoparticles as drug delivery and theranostic nanosystems  Polymeric nanoparticles represents a platform able to load chemotherapic drug or active 
molecules in order to improve their physiochemical and pharmacological properties; in 
addition, they can be chemically modified on the surface by introducing an active targeting 
able to guide the final systems to a specific pathological site.  
Several materials have been investigated in order to realize an ideal polymeric based drug 
delivery system characterized by an efficient drug load ability and, at the same time, chemical 
physical properties able to give stability and to improve biodistrubution in vivo of the final 
system. 
At the beginning, non-biodegradable polymers such as poly(methyl methacrylate) (PMMA), 
polyacrylamide, polystyrene, and polyacrylates have been used as polymeric materials for 
medicine applications, including drug delivery, wound healing and antimicrobial activity. 
These systems have been designed in order to exhibit a rapid and efficiently clearance through 
faeces and urine and do not accumulate or distribute in tissues at toxic level because they 
cannot be easily degraded and excreted.28 However, biological studies observed chronic 
toxicity and inflammatory reactions with the use of non-biodegradable materials. After these 
evidences, nanomedicine research has been focused in selecting polymer materials for drug 
delivery, which showed bioavailability, biocompatibility, straightforward production, 
sustained release and tunable degradation rate.29 For these purposes, synthetic biodegradable 
polymers, such as poly(lactide) (PLA), poly(lactide-co-glycolide) copolymers (PLGA), poly 
(ε-caprolactone) (PCL), and poly(amino acids), and natural polymers such as chitosan, 
alginate, gelatine and albumin, have been extensively explored. 
Beyond the research in the materials, nanoparticles biodistribution and internalization in 
tumour cells are deeply influenced by their size and surface properties.30 Once injected in the 
body, nanoparticles are subjected to a mechanism of recognition and clearance by the 
reticuloendothelial system (RES) or mononuclear phagocytic system (MPS). These 
mechanisms consist of three steps: opsonisation, phagocytosis and clearance. 
The opsonisation involves the coating of a foreign organism or particle by proteins called 
opsonins, which allows recognition of the particles by phagocytic cells and subsequent 
clearance from the bloodstream. Particle size can affect the mechanism of elimination, 
influencing on opsonin adsorption and therefore on phagocytosis.31 It is reported in literature 
that larger nanoparticles are usually cleared by the RES organs (lung, liver, or spleen), while 
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the smaller nano-objects, characterized by a retention time in the bloodstream, are removed by 
the renal system. In particular, nanoparticles with a diameter between 10–20 nm, show wide 
spread in various organs by crossing the tight endothelial junctions and are rapidly excreted 
through the glomeruli of kidney.  Nanoparticles larger than 20 nm in diameter avoid filtration 
by the kidney, and smaller than 100 nm avoid a specific sequestration by sinusoids in spleen 
and fenestra of liver, which are approximately 150–200 nm in diameter.31,32 On the other 
hand, particles characterized by a diameter of 100–200 nm are usually taken up by receptor-
mediated endocytosis while larger particles are internalized by phagocytosis (Figure 5).  
 
 
Figure 5. Size of the spherical nanoparticles determines the mechanism and rate of clearance. Spheres that are smaller than 20 nm readily pass through the tight endothelial junctions, resulting in a relatively rapid rate of clearance from the circulation. For large particles (e.g., > 1 μ m), momentum forces begin to dominate and wall collisions become more common, resulting in rapidly uptake by the mononuclear phagocytic system. However, when the particle size falls between two extremes, all of these clearance mechanisms are minimized and circulation times are prolonged (the thickness of arrows represents the strength of the force) from Small 9, 1521–1532 (2013). 
The size can affect also the adhesion and the interaction with tumour cells and several studies 
in literature tried to identify the “right size” for a drug delivery system. Nevertheless, 
controversial results have been obtained. This outcome can be explained by considering the 
heterogeneity of tumour tissue that can diverge for cancer type, stage of disease, site in the 
body, causing different vasculature fenestrations for each tumour.  
For this reason, it is hard to generalize the effect of the size on the internalization in the 
tumour cells that can be affected also by other nanoparticles parameters such as surface 
properties. Indeed, surface charge of nanoparticles can influence the absorption of plasma 
proteins (opsonins), leading to their recognition by macrophages, followed by phagocytosis 
and elimination. However, also in this case, the studies regarding the effect of surface charge 
on the circulation and biodistribution of nanoparticles led to inconsistent results due to the 
difference of nanoparticle types, the nature of charged groups, and other confounding factors 
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such as inhomogeneous particle size.7,33,34 In order to establish stability of colloidal 
suspension, might take in account Zeta Potential value, which consists in the measurement of 
the electric potential at the surface of the hydrodynamic layer. Nanoparticles with a zeta 
potential value higher than (+ /−) 30 mV are stable in suspension, because high negative or 
positive zeta potential values tend to repel each other reducing aggregation.35 
Surface hydrophobicity is the other parameter that might be considered in the design of drug 
delivery nanosystems. Indeed, the hydrophilic–lipophilic balance of nanomaterials influences 
the mechanism of opsonisation that results faster for the particles more hydrophobic due to the 
enhanced “adsorbability” of blood serum proteins onto their surface. 
In order to reduce the clearance by opsonisation, shielding groups can be introduced onto the 
nanoparticles surface. Polyethylene glycol (PEG) represents the most widely material used in 
the constitution of a hydrophilic outer shells of drug delivery systems.36 The “PEGylated” 
process can be achieved by grafting, entrapping, adsorbing or covalently binding to 
nanoparticles these molecules. Due to their flexibility and hydrophilicity, PEG molecules are 
able to stabilize nanoparticles by steric and not ionic effects especially, adopting an extended 
conformation able to repel the opsonins away from the nanoparticles (Figure 6). PEG 
molecules characterized by a molecular weight higher or equivalent to 2000 Da showed the 
optimal chain length necessary for reducing the RES clearance.37 
 
 
 
Figure 6. Representation of how PEGylation avoids clearance of NPs by the RES from Adv. Mater. 23, (2011). 
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1.2.2 Poly(d,l-lactic-co-glycolic acid)-b-poly(ethylene glycol)  
In the last years, polymeric nanoparticles constituted by the di-block copolymer 
poly(d,l-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG) have been one of the 
most studied drug delivery systems. PLGA-b-PEG is constituted by a lipophilic portion made 
of PLGA, which confers it biodegradability and biocompatibility properties, and a hydrophilic 
portion made of PEG, which confers it the stealth behaviour. 
Poly(lactic-co-glycolic acid) (PLGA) is a linear aliphatic polyester approved in 1989 by the 
FDA for drug delivery application, synthetized through the random ring-opening 
copolymerization of two cyclic dimers of glycolic and lactic acid, linked together by ester 
linkage in a casual order during copolymerization (Figure 7). 
 
 
Figure 7. Chemical structure of poly(lactic-co-glycolic acid) (PLGA) constituted by m units of lactic acid and n units of glycolic acid. 
It has been showed that the molar ratio of the individual monomer components (lactide and 
glycolide) in the polymer chain influences many properties of PLGA, such as degree of 
crystallinity, mechanical strength, swelling behaviour, and capability to hydrolyze.38 
Because these properties can affect the biodegradability of the material, an investigation of 
the optimal molar ratio has been carried out. The results showed that PLGA copolymer with a 
50:50 molar ratio of the two monomer is hydrolysed much faster in comparison with the one 
containing higher quantity of either of two monomers.39 
Once the PLGA chains are released in aqueous media, such as in the body, undergo a 
hydrolytic degradation of the ester linkages. This process led to the formation of the two 
original monomers, lactic and glycolic acids that in body can be metabolized and eliminated 
as carbon dioxide and water or excreted unchanged in the kidney.40 
On the other hand, poly(ethylene glycol) (PEG) is a non-ionic hydrophilic polyether 
synthesized in a wide range of molecular weight from 300 to 100,000 Da, through 
polymerization of the monomer ethylene glycol (Figure 8). PEG is a biocompatible polymer 
but not biodegradable, indeed in the body, PEG chains are excreted unchanged in the kidney 
and does not undergo biodegradation process. 
17  
As discussed in the previous paragraph, PEG polymer is characterized by high hydrophilicity 
properties and for this reason is used to stabilize nanoparticles in aqueous media, to increase 
solubility, and to avoid aggregation of them by steric hindrance in production, storage, and 
applications.41  
 
Figure 8. Chemical structure of poly(ethylene glycol) (PEG). 
Beyond the biodegradability and biocompatibility of its components, PLGA-b-PEG assumes 
amphiphilic properties that make it suitable for the formation of polymeric nanoparticles and 
micelles. In the formation of polymeric nanoparticle, the PLGA-b-PEG chains undergo to a 
self-assemble generating a system in which the hydrophobic PLGA remains inside the 
micelles and the hydrophilic PEG goes outside creating a stabilizing shell. 
Because the PEG molecules can be characterized by several terminal function groups (such as 
carboxylic ammine, maleimide, thiol groups), it is possible to obtain a functionalized 
copolymer PLGA-b-PEG-X (Figure 9). In this way, the obtained polymeric nanoparticles 
will characterize by the PEG functional groups on the surface able to conjugate specific target 
agents.  
 
Figure 9. Chemical structure of poly(lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) with indicated the characteristic final functional groups. 
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1.2.3 Methods of preparations for polymeric nanoparticles   The main strategies developed for the synthesis of drug delivery systems based on polymeric 
nanoparticles (PNPs) are divided in two different approaches, methods in with preformed 
polymers are used or methods that involve the direct polymerization of monomers using 
classical polymerization or polyreactions.42 
The common techniques based on the use of preformed polymers are solvent evaporation, 
salting-out, dialysis and supercritical fluid technology.  
In order to choose the suitable method for the synthesis, must be consider the chemical 
properties of polymeric material and/or of the agent that should be encapsulated, such as 
solubility and stability in organic solvent or in water. 
PLGA-b-PEG is soluble in several organic solvents and due its amphiphilic properties, the 
synthesis of polymeric nanoparticles not required large amount of surfactant agents, able to 
stabilize in water the formed polymeric nanoparticles characterized by high hydrophobic 
properties. In particular, solvent evaporation and nanoprecipitation methods have been widely 
used for PLGA-b-PEG nanoparticles synthesis. 41 
The solvent evaporation technique consists in the preparation of emulsion with a not-miscible 
organic solvent and water. Based on the solubility properties of the agents that should be 
encapsulated, two main strategies for the formation of emulsions have been developed: the 
preparation of single-emulsions (oil-in-water (o/w)) or double-emulsions ((water-in-oil)-in-
water, (w/o/w)).43 
In the oil-in-water (o/w) technique, an organic solution is prepared by dissolving polymer and 
lipophilic agents, which should be encapsulated, in volatile and water-immiscible organic 
solvents. The common solvents used for the solvent evaporation methods are 
dichloromethane, chloroform and ethyl acetate. Once prepared, the organic phase is added to 
a large amount of water, and the obtained biphasic solution is emulsionated with high-speed 
homogenization or ultrasonication, followed by evaporation of the solvent, by continuous 
magnetic stirring at room temperature or under reduced pressure (Figure 10). 
In order to stabilize the formed polymeric nanoparticles, surfactant agents are usually 
solubilized in the aqueous phase, such as sodium cholate, polyvinylalcohol (PVA), 
polyvinylpyrrolidone (PVP), poloxamers, or other molecules. During the emulsion process, 
the strong energy provided from homogenizator or ultrasonicator allows the formation of 
organic nanosized droplets in the surrounding water phase. 
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Figure 10. On the left, a picture of tip probe sonicator using for the solvent evaporation method, on the right a schematic representation of oil-in-water technique. 
Because of the amphiphilic properties, PLGA-b-PEG molecules dissolved in the organic 
phase can form micelles without the presence of surfactant agents, constituted by an inner 
core, made of the hydrophobic PLGA portion, and surrounded by an external shell made of 
hydrophilic PEG chains, able to stabilize the nanomicelles in aqueous environment. 
Depending on the lipophilic agents entrapped, this method allows the obtainment of 
nanospheres with good index of polydispersity (PDI) and a diameter in the range 100–500 
nm. In order to encapsulate hydrophilic agents, the solvent evaporation can be used by 
following the double-emulsions ((water-in-oil)-in-water, (w/o)/w) strategy, which involves 
two emulsion processes. First, a water phase is prepared by dissolving the hydrophilic agents 
in a small volume of water (W1). The first emulsion process consists in the emulsion of the 
prepared aqueous phase W1 with an organic phase prepared by dissolving the polymer in an 
organic solvent, as in the oil-in-water technique. In this case, the organic phase is in the 
majority compared to the aqueous phase, so an opposite situation respect to the oil-in-water 
emulsion is created and the water phase with the drugs dissolved-in remains inside the 
micelles core, while the oil phase constitutes the external environmental. After that a bigger 
amount of a second aqueous phase (W2) is added to the previous emulsion and the entire 
system is re-emulsified to obtain the w1/o/w2 double emulsion; in this case, the secondary 
aqueous phase always contains surfactants or stabilizing agents. During this secondary 
emulsion, the organic phase remains entrapped between the two aqueous phases, the W1 in the 
inner core and the W2 that constitutes the external ambient. The organic solvent can be now 
removed by evaporation and the final system, dispersed in water with water in the inner core, 
can be obtained. In addition, when lipophilic agents are dissolved with the polymer in the 
organic phase, the w/o/w technique allows entrapping two different agents in the same 
polymeric nanoparticles, suitable for the development of theranostic nanosystems. 
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On the other and, in nanoprecipitation method the organic phase in prepared by dissolving the 
polymer and lipophilic agents, in organic solvent miscible with water such as ethanol, 
tetrahydrofuran, acetone, hexane, dimethyl sulfoxide or dimethylformamide. This organic 
solution is mixed under vigorous stirring into water, which may contain surfactant or 
stabilizing agents. This method is based on the interfacial deposition of a polymer after 
displacement of a semipolar solvent, miscible with water, from a lipophilic solution. Rapid 
diffusion of the solvent into water results in the decrease of interfacial tension between the 
two phases, which increases the surface area and leads to the formation of small droplets of 
organic solvent (Figure 11).44 The polymer dissolved in these droplets forms small 
macromolecules, that begins the nucleation process based on the aggregation of this nuclei 
which leads to the formation of polymeric nanoparticle.41 Particles formed with this technique 
can be obtained with small diameter (50–250 nm) and good polydispersity index (PDI).45 
 
Figure 11. Schematic representation of the nanoprecipitation technique. 
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1.3 Hyperthermia therapy   
Hyperthermia therapy (defined also thermal therapy) is a cancer treatment that consists in the 
exposition of body tissue to an increasing of temperature, just above the physiological 
temperature (42-45°C) to induce cytotoxic effects on cancer cells.  
Indeed, cancer cells are more sensitivity to heat compared to healthy cells, and at those 
temperature, tend to undergo in apoptosis caused by denaturation of membrane and 
cytoplasmic proteins.46 This phenomenon can be explained by considering the physiological 
differences between normal and tumour tissues; the disorganised and abnormal vasculature 
caused by angiogenesis, leads to a lower vessel density in tumour tissues, that makes heat 
dissipation hindered in comparison to healthy tissues.47 For this reason, when hyperthermia is 
applied at temperatures over 42 °C, the temperature of tumour rises higher than that in normal 
tissue, because during heating tumour blood flow tends to decrease while in normal tissue it 
significantly increases. On the other hand, hyperthermia treatment at lower temperature than 
42°C, tends to generate an increasing in the tumour blood flow, making cancer cells more 
sensitive to radiotherapy (radiosensitivity is favoured by good tissue oxygenation) and 
chemotherapy (drug delivery is increased by higher perfusion).48 The synergic effect of 
hyperthermia with other traditional therapies has been investigated in clinical trials in the 
treatments of many types of cancer, showing a significant reduction in tumour size.49 
However, not all of these studies have shown increased survival in patients receiving the 
combined treatments. 
There are three main types of hyperthermia treatments, whole-body, regional or local, which 
depend on the location, the depth and the stage of malignancy. Whole-body hyperthermia is 
used to treat metastatic cancer that has spread throughout the body and consists in the heating 
of the entire body through hot water baths, thermal chambers or infrared radiators. However, 
because the temperature increasing is not selective, this treatment can lead to major side 
effects due to regional differences in tissue characteristics, causing the production of 
dangerous temperatures in normal tissue. Regional hyperthermia consists to heat large areas 
of tissue (as a body cavity, organ or limb), generally affected by an advanced stage of tumour, 
by using external applicators or arrays of multiple applicators (microwave antennas). On the 
other hand, local hyperthermia is applied to treat small area, in particular localized tumours 
either superficially or in accessible body cavities, using various techniques that deliver energy 
to heat the cancer cells. Depending on the tumour location, there are several approaches to 
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local hyperthermia, which involve different types of energy used to apply heat, including 
microwave, radiofrequency, and ultrasound.50 
Because the limited spatial and temporal control, traditional hyperthermia treatments can 
cause burns to surrounding healthy tissues. For this reason, nanotechnology advantages have 
been largely investigated, in order to develop nano-sized heat agents able to promote localized 
temperature increasing in cancer cells.  
The first approach of nanomedicine in hyperthermia therapy consisted in the use of magnetic 
nanoparticles as generators of heat, leading to the development of magnetic fluid 
hyperthermia (MFH).51 This technique, based on the conversion from magnetic energy into 
thermal energy in the supermagnetic nanoparticles subjected to an external alternative 
magnetic field, led to the development of the first hyperthermia clinical nanotherapy. In 2011, 
the nanomedicine company MagForce launched NanoTherm®, a clinical therapy based on  
ultrasmall (~12 nm) iron-oxide magnetite (Fe3O4) coated by aminosilane for hyperthermia 
therapy of solid tumours (Figure 12).  
 
 
Figure 12. Image of NanoTherm® produced by MagForce. 
The treatment consists in the directly injection of NanoTherm® into the tumour and the 
subsequently application of an alternating magnetic field to generate heat, combined with 
fractionated stereotactic radiotherapy. Clinical trials results conducted in the treatment of 
multiform glioblastoma, an aggressive brain tumour, showed that thermotherapy using 
magnetic nanoparticles in conjunction with a reduced radiation dose is safe and effective and 
leads to longer over survival of patients, compared to conventional therapies.52 
Despite the good results obtained by using MFH, nanotechnology is also exploring other 
alternatives. In particular, the recent development of nanoparticles capable of efficient heat 
generation under illumination with laser radiation has attracted much attention for the last few 
years. Photothermal therapy (PTT) is an hyperthermia therapy based on the use of near-
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infrared (NIR) laser photoabsorbers to generate heat in order to induce thermal ablation of 
cancer cells upon NIR laser irradiation.53 
PTT offers solutions to the limitations affecting other thermal therapies, for example, the 
possibility of eradicating tumours located nearby intrabody cavities by the use of low-loss and 
flexible optical fibers.54 However, PTT of sub-tissue tumours non accessible by optical fibers 
is very restricted, due to the fact that human tissues show strong extinction coefficients in the 
optical range of the electromagnetic spectrum. This fact limits PTT only to the treatment of 
superficial tumours. In order to overcome this limitation, PTT must be performed by using 
specific excitation wavelengths at which human tissues are partially transparent. This can be 
achieved by using laser excitation wavelengths lying in the so-called biological windows 
(BW): the first Biological Window (I-BW, which extends from 700 up to 950 nm) and the 
second Biological Window (II-BW, 1000–1350 nm) (Figure 13).55 
 
 
Figure 13. Extinction coefficient of a representative tissue. The different effects leading to light attenuation (such as the presence of haemoglobin, water and optical scattering) have been indicated. The spectral extensions of the two biological windows are also indicated. Figure adapted from Nanoscale, 2014, 6, 9494. 
Therefore, nanoparticles able to absorb laser excitation wavelengths lying in the biological 
windows are suitable candidates as photothermal therapy agents, reducing the non-selective 
heating of healthy tissue and, at the same time, allowing a deep tissue penetration. 
For these purpose, several studies have been conducted in order to design a nanosystems able 
to be used in clinical photothermal therapy. In 2008, Nanospectra Biosciences developed 
AuroLase® Therapy (Figure 14), a thermal ablation therapy of solid tumours based on the 
use of silica nanoparticles coated by a gold metal shell able to absorb near infrared laser 
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energy delivered by a fibre. This therapy is under clinical investigational at this current time 
for the treatments of head and neck cancer treatments.56 
 
 
Figure 14. Bag for the intravenously administration of AuroShell particles used in AuroLase® Therapy. 
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1.3.1 Metallic nanoparticle as photothermal agents in hyperthermia 
therapy 
 
Metal nanoparticles have been largely studied as agents in photothermal cancer therapy (PTT) 
because of their ability to absorb light and rapidly convert it to heat.  
This ability is ascribed to the resonant collective oscillation of the free electrons on the metal 
surface of the nanostructure in the presence of luminous radiation, a phenomenon called 
localized surface plasmon resonance (LSPR), which is common to all the nanoparticles but is 
particularly pronounced in those derived from transition metals (Figure 15). 
 
 
Figure 15. Schematic diagrams of localized surface plasmon (LSPR) 
In PTT, when a nanoparticle is irradiated by laser beam, some of the incident photons are 
scattered by the nanoparticle while others are absorbed. The absorbed photons are responsible 
for heat production and luminescence. The total number of photons interacting with the 
metallic nanoparticles is determined by its extinction coefficient (αext), that is given by the: 
  
αext = αabs + αsct  
 
where αabs is the absorption coefficient and αsct is the scattering coefficients 
 
The extinction coefficient depends on the concentration of illuminated nanoparticles and on 
the extinction cross section (σext = σabs + σsct, where σabs and σsct denote the absorption and 
scattering cross-sections, respectively).  
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The absorption efficiency, Φ abs, of a given nanoparticle is traditionally defined as the number 
of absorbed photons divided by the total number of incident photons interacting with the 
nanoparticle (being either absorbed or scattered). 
 
Φ abs = αabs/αext  
 
The energy absorbed by the nanoparticles (energy of incident photons multiplied by the total 
number of absorbed photons) can be released by either the emission of photons of different 
energy from that of incident photons (luminescence) or by the emission of phonons (i.e. by 
generating heat) (Figure 16).53 
 
 
Figure 16. Schematic representation of the different processes activated when a light beam interacts with a nanoparticle. The presence of scattering, luminescence and heat generation are included. Heat and luminescence occur as a result of light absorption. Figure from Nanoscale 6, 9494–9530 (2014). 
However, the optical properties of metallic nanoparticles are strongly influenced by size, 
shape and environment. Indeed, the phenomenon of the LSPR can be described in details 
thank to the theory of Gustav Mie (1908), who solved the Maxwell equations giving a 
quantitative explanation of the resonance. Generally, simplified equations deriving from Mie 
theory are used to explain the importance of many parameters that strongly affects LSPR 
intensity and wavelength.57 By way of illustration, for many metals in the bulk state free 
electron behaviour is predominant and the wavelength of the plasmon absorption peak 
depends on the equation:  
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λ2 = λp2 (ε∞ + 2εm) 
 
 
where  
 
λp2 = (2πc)2/ωp2 
 
is the metal's bulk plasma wavelength, ε∞ is the high frequency dielectric constant due to 
interband and core electrons’ transitions, εm is the dielectric constant of the surrounding 
medium and the resonance frequency (ωp) is given by:58  
 
ωp= (N*e2/ε0*me)1/2 
 
where N is the concentration of free electrons in the metal, e is the charge of the electron, m is 
the mass of the electron and ε0 is the vacuum permittivity.  
The equations shows that the LSPR is strongly affected by several factors such as size and 
shape of the nanoparticles and most of all by the nature of the surrounding environment due to 
a direct dependence on the dielectric constant of the medium (εm) in which the nanoparticles 
are dispersed. Therefore, every modification in the interface with the surrounding 
environment of these particles leads to significant shifts to the LSPR wavelength and 
intensity.  
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1.3.2 Gold nanorods as photothermal agents  
Since from 5th B.C., the use of colloidal gold as a colorant has been known for its use in 
making ruby glass and providing reddish tinge to ceramics.59 
In 1857, the most important article in both the history of colloidal science and in the 
discussion of how light interacts with matter has been published by Faraday, who reported 
that the ruby glass was coloured because of the presence of finely dispersed gold particles.  
Nowadays, it is well known that gold nanoparticles assume a peculiar red colour in solution 
due to the localized surface plasmon resonance (LSPR) at visible range of UV-Vis spectrum. 
In the last decades, several studies have been focused on the development of gold 
nanostructures characterized by different size and the shape, in order to move the spectral 
location of surface plasmon resonance wavelength from the visible to the near infrared region. 
At macroscopic level, the change in colour of colloidal solution of gold nanoparticles is an 
evidence of the increase of nanoparticles size or change of nanoparticles shape. For example, 
an aqueous dispersion of spherical gold nanoparticles with a diameter around 10 nm is 
characterized by a red colour; otherwise, when gold nanoparticles size increases to nearly 100 
nm or changes in shape, such as a rod-like shape with aspect ratio of 3 (length 30 nm, 
diameter 10 nm), the colloidal dispersion appears bluish.  
This phenomenon can be explained by considering the movement of λSPR in the UV-Vis 
spectra of gold nanostructures characterized by a different size and shape. 
The possibility of tailoring the λSPR in a very wide range (from visible to infrared) by the 
adjustment of their dimensions, led to the development of GNPs with a great variety of 
geometries (nanocages, nanostars, nanoshells, and nano- hexapods).  
Their unique optical properties, in addition to their biocompatibility, make gold nanomaterials 
promising candidates as light-activated heating nanoparticles in PTT applications. For this 
purpose, gold nanorods (GNRs) have been the most studied nanoparticles among the different 
non-spherical metallic nanoparticles. 
Indeed, GNRs are characterized by the presence of two main absorption bands in the UV-Vis 
spectrum (Figure 17a):  
 An intense absorption band at near infrared wavelengths, corresponding to electron 
oscillations along the longest dimension of the GNRs; 
 A weak absorption band at visible wavelengths, corresponding to surface electron 
oscillations along the short dimension of the GNRs;  
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Figure 17. (a) Diagram depicting the conduction band electron oscillation (gray arrows) upon transverse and longitudinal localized surface plasmon resonances of gold nanorods. (b) Visible/near infrared extinction spectra of gold nanorods with different aspect ratios (ARs) showing transverse (★) and longitudinal (◆) extinction peaks. TEM images of gold nanorods (c) AR 1.1, (d) AR 2.0, (e) AR 2.7, (f) AR 3.7, and (g) AR 4.4. Scale bars are 50 nm. Figure adapted from Langmuir 32, 9905–9921 (2016).  
Several methodologies have been fine-tuned in order to obtain gold nanorods characterized by 
a rational control over the aspect ratio (AR). The aspect ratio, corresponding to ratio between 
length and width of GNRs, is primarily responsible for the change in their optical properties. 
By increasing the aspect ratio, the longitudinal plasmon resonance of GNRs moves towards 
high wavelengths up to 1200 nm (Figure 17 b and c).60 
This phenomenon is very important for the developing of photothermal agents based on gold 
nanostructures, which might be characterized by λSPR close to 800 nm, in other words placed 
in the first biological window in order to lead the minimum collateral heating effect on the 
healthy surrounding tissue. 
In order to study the absorption efficiency of this particular gold rod geometry and size, 
several simulation studies have been carried out. The studies of El-Sayed et al. reported that 
GNRs usually show absorption efficiencies above 90% except when the GNR radius exceeds 
20 nm. In particular, the results showed that the heating efficiency remains above 90%, when 
the GNR width (diameter) is kept close to 15 nm independently of the GNR length (at least 
for lengths as large as 160 nm). However, the absorption efficiencies predicted decrease down 
to 60% for GNRs characterized by a diameter greater than 15 nm.61 
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Usually, GNRs synthesis is based on the two-step ‘‘nuclear’’ method discovered by 
Zsigmondy, combining his synthesis technique with the Faraday’s method. Later this method 
has been fine-tuned and was defined ‘‘seed-mediated’’ method. 
The method consists the synthesis in aqueous medium with the assistance of various 
surfactants, which act as both template and stabilizer for the growing nanoparticles against 
aggregation phenomena. Once the process is completed, the surfactant molecules remain 
adsorbed or deposited onto the surface of the nanoparticles, avoiding the post- synthesis 
collapse of the created nanoparticles. However, most of these surfactants are strongly toxic or 
simply not suitable for biomedical applications because they do not allow further synthetic 
medications. The removal of surfactants requires the development of specific ligands that 
would be able to replace them, to prevent the aggregation phenomena, and at the same time 
ensure that the specific desired final properties of GNRs are retained (paragraph 1.5). 62 
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1.3.3 Magnesium nanoparticles as photothermal agents  
Magnesium is one of the most abundant element in the human body, in particular its form as 
divalent cation (Mg2+) is involved in more than 300 known enzymatic reactions, playing an 
important role in many cellular processes.63 In addition magnesium has role in many reactions 
involving ATP, protein and nucleic acid synthesis, mitochondrial activity and integrity, ion 
channel modulation, plasma membrane stabilisation and translational processes, as well as 
many other cellular functions.64 
Due to its biocompatibility, the use of magnesium in biomedical application has been largely 
investigated. The modern applications of magnesium-based biomaterials are similar to those 
that were attempted historically. At the beginning of 1900, numerous physicians studied the 
application of magnesium and magnesium alloy devices in vascular, orthopaedic and general 
surgery. However, without the ability to accurately alloy magnesium, and before the common 
application of coatings on implants, the corrosion could not be controlled sufficiently to 
promote its use as biomaterial. 
Indeed, magnesium-based materials revealed a quickly degradation that affects their 
mechanical integrity for long time and showed the production of hydrogen gas in the organs 
able to cause tissue disruption. For these reasons, the most effective results were obtained 
from non-orthotopic applications, such as the suturing of organs.65 
In the late 1930s, Earl McBride conducted studies regarding the use of magnesium alloy as 
orthopaedic implants. During his studies, he found that corrosion of magnesium based 
materials resulted in a tissue reaction, could represent an advantage for specific applications 
in which the rapid corrosion of the implant materials utilized would outweigh the effect on the 
surrounding tissue.66 Based on these results, the field of magnesium biomaterials has been 
growing exponentially, especially in the fields of investigation regarding the development of 
magnesium alloys for vascular applications, and the field devoted to identifying appropriate 
magnesium based materials for orthopaedic applications. 
In the last decades, the properties of magnesium nanoparticles have been investigated in 
nanotechnology research, fascinated by the high biocompatibility of this nanomaterial related 
of its biodegradation into magnesium ions, which are completely absorbable by the human 
body. In particular, recent studies demonstrated that magnesium nanoparticles exhibit a 
pronounced plasmonic response that is tunable throughout the whole visible wavelength 
range.67,68 In particular, Sterl et al. reported that plasmonic response of magnesium nanodisks 
can be tuned by adequate choice of the disk diameter throughout the visible wavelength range, 
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from resonance wavelengths below 500 nm up to 800 nm and further into the near-infrared 
(Figure 18).69 
 
Figure 18. Magnesium nanodisks as a model system for magnesium plasmonics. (a−c) Colorized SEM images of magnesium nanodisks with average diameters of 80, 160, and 220 nm, respectively. (d) The resonance wavelength of such nanodisks can be tuned throughout the visible wavelength range by varying the diameter. Figure adapted from Nano Lett. 15, 7949–7955 (2015).  
Due to their plasmonic properties, magnesium nanoparticles has been studied as suitable 
agents for photothermal tumour therapy.70,71,72,73 
In 2012, Wang et al., tested the direct injection of the magnesium nanoparticles into the 
tissues to measure the temperature changes of the materials subjected to laser heating (Figure 
19).72 The obtained results showed the high ability of magnesium nanoparticles in 
hyperthermia applications and the related advantages comparing to other popular 
nanosystems. Compared to gold-based nanomaterials, the density of magnesium is much 
lower and therefore more particles can be loaded into the target tissues leading a more 
efficient treatment. Moreover, magnesium is beneficial to human health and its high abundant 
in nature makes magnesium cost-effective for clinical utilization. 
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Figure 19. Thermal images of the pig tissue injected with water (A) 0.01 g/mL fresh magnesium nanoparticle aqueous solution (B) and 0.02 g/mL fresh magnesium nanoparticle aqueous solution (C) taken after 1 minute of laser irradiation at 1W. Figure from Int. J. Nanomedicine 7, 4715–4725 (2012). 
 Nevertheless, the results highlighted that there are still many problems to overcome in order 
to use magnesium nanoparticles as photothermal agents in clinics. First of all, the heating 
ability of magnesium nanoparticles is affected by variable sizes, structures of these particles 
and oxidation grade, therefore the influence of each parameter must be deeper investigated. 
Regarding the oxidation grade, they showed that only pure magnesium nanoparticles, which 
are often black in colour, are able of absorb light differently from oxidized magnesium 
nanoparticle (MgO nanoparticles), which are often white in colour. Because of their high 
reduction potential and high affinity toward oxidation, the synthesis of magnesium 
nanoparticles is quite challenging, and several synthetic methodologies have been developed 
in order to improve the process.  
In addition, the electrode potential of magnesium can affected also heat generation ability of 
nanoparticles and their stability in vivo.  Once magnesium nanoparticles are injected into the 
tissue, heat energy is produced because of chemical reaction between magnesium 
nanoparticles and water contained in the tissue.  
However, magnesium nanoparticles showed a low reactivity with water below a certain 
temperature, such as the body core temperature of 37°C. Therefore, a suspension fluid 
containing the nanoparticles with an initial temperature around room temperature (25°C) can 
be easily injected into the target sample or tissues. 
Because this phenomenon leads to a certain level of corrosion of the material, the control of 
the degradation rate of the magnesium nanoparticles used in hyperthermia is an important 
requirement. Indeed, the rapid corrosively degradation of the material represents an advantage 
considering the rapid absorption of magnesium ions into the body; however, if the rate of 
material degradation is too fast, the heating enhancement effect may not be maintained for 
long or fully occur. Regarding this, a protective coating on the nanoparticles might be a 
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feasible way to avoid their reacting with water as well as to control the degradation rate and 
further improve biocompatibility. Moreover, the surface coating formation can allow the 
possibility to introduce an active targeting on the nanoparticles surface, making the final 
system suitable for diagnostic and theranostic applications. For example, the study of Jin et 
al., developed a laser scanning based thermography strategy for detecting the skin cancer by 
using magnesium nanoparticles conjugated with biomolecules (for example antibody) as 
active targeting.73 
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1.4 Nanomaterials as diagnostic and imaging tools in nanomedicine  
For a non-invasive diagnosis of patients, in vivo imaging techniques are powerful tools to 
visualize the abnormal state of the body and monitor biological situations at the target site. 
Several imaging techniques have been developed for this purpose, such as magnetic resonance 
imaging (MRI), positron electron tomography (PET), computed tomography (CT), single-
photon emission computed tomography (SPECT), optical imaging (OI), ultrasound (US) and 
photoacoustic imaging (PAI). Because of the several physical processes behind each of these 
techniques, they are characterized by different depth of penetration and spatial resolution 
abilities.74 
 
Figure 20. Table dealing the properties of imaging modalities adapted from Chem. Soc. Rev. 41, 2656–2672 (2012). 
As shown in Figure 20, microscopy and other techniques that use un-scattered photons 
provide high-resolution (~1 μm) images, but only to a maximum depth of ~1 mm in most 
tissues. On the other hand, diffuse optical techniques such as fluorescence and near-infrared 
optical tomography, that exploit multiply scattered photons, can reach a depth of several 
centimetres but a lower spatial resolution (>1 mm).75 
For this reason, the combination of different imaging techniques in multimodality approach, 
showed the possibility to accomplish high sensitivity and high resolution simultaneously, 
providing more detailed anatomical or biological information about the target disease. The 
first example of multimodalities techniques is represented by PET/CT in 1998, while the first 
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commercial prototype of PET/MRI for a human scale hybrid scanner has been realized in 
2007.76 These finding showed the possibility to integrate high sensitivity of PET, used as a 
whole body screen to identify regions of interest, with high-resolution images for anatomical 
information of CT and MRI. In particular, MRI allowed the reduction of the volume of tissue 
that needs to be scanned and, consequently, the scan time required for high-resolution 
imaging. In order to take advantage from multimodal imaging, researchers focused their 
attention on the development of contrast imaging agents able to overcome the limitations of a 
single imaging modality, to provide more detailed information of the target site through 
targeted delivery.74 For this purpose, nanotechnology showed the possibility to produce 
nanoscale multimodal imaging agents, constituted by inorganic nanoparticles, characterized 
by intrinsic imaging abilities, or organic nanoparticles (liposomes, micelles and polymeric) 
able to integrate more than two imaging agents on their surface or inside the core. Dealing 
with this, magnetic properties of iron oxide nanoparticles, led to the development of new 
contrast agents in magnetic resonance imaging (MRI).12 On the other hand, the optical 
properties of gold nanomaterials make them suitable contrast agents in computed tomography 
(CT) imaging and photoacoustic imaging (PAI).  
In addition, the possibility to combine in the same nanosystem, therapy and the diagnostic 
functionalities led to the development of theranostic systems. This strategy could be used to 
monitor the pharmacokinetic, the accumulation of therapeutics and the progression of disease, 
giving important insights into heterogeneities both within tumour and between patients for 
potential personalized therapies.13 
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1.4.1 Photoacoustic imaging (PAI)  Photoacoustic imaging (PAI) technique is an emergent imaging method based on the 
photoacoustic effect, a physical phenomenon that consists in the generation of acoustic waves 
from an object illuminated by pulsed (or intensity-modulated) electromagnetic continuous-
wave (CW), especially light. Alexander Graham Bell discovered for the first time the 
photoacoustic effect in 1880, thanks to his studies on long-distance sound transmission.  
During his experiments, he found out that when a solid sample was exposed to pulsed light 
beam, sound waves were directly produced by the bulk sample. The observed acoustic signal 
was noticed to be dependent on the sample material, suggesting the involvement of light 
absorption processes, which subsequently heat the sample generating a piston-like pressure 
wave in the surrounding gas. Later, further investigations showed that the sound could also be 
generated by materials exposed to ultraviolet (UV) or near-infrared (NIR) light. 
However, the application of photoacoustic imaging to biomedicine date back to the last 
decade of the twentieth century, when more powerful light sources and more sensitive sound 
detectors were developed. These progresses demonstrated the presence of photoacoustic effect 
in optically scattering media and biological tissue, leading to the development of PA imaging 
(PAI). Nowadays, PAI is one of the largest research areas in the field of biomedical optics, 
showing the possibility to combining the advantages of both optical excitation and acoustic 
detection in a hybrid imaging technique able to achieve high sensitivity to optical absorption 
and the capability for deep imaging in soft tissue. In photoacoustic imaging (PAI), ultrasound 
waves are generated by irradiating tissues with modulated or pulsed laser light. Because 
sound waves are less scattered in tissue than photons they can propagate to a greater distance 
without losing their original propagation directions, providing PAI with high spatial 
resolution at depths.  The absorption of photons by the chromophores in the sample results in 
the generation of an acoustic wave, which is then processed to form an image. The 
mechanism consists in a short laser pulse on the pathological tissue, which release photons 
able to propagate into the tissue and to be absorbed by endogenous chromophores 
(biomolecules, such as haemoglobin, DNA-RNA, lipids, water, melanin, and cytochromes). 
The absorption mechanism involved can be electronic, vibrational, stimulated Raman and 
surface plasmon resonance, depending on the molecules or agents stimulated by the 
irradiation. After laser irradiation, the absorbed optical energy is partially or completely 
converted into heat, through non-radiative relaxation of exited molecules (Figure 21a). The 
heat-produced generates pressure waves able to diffuse in tissue as ultrasound waves, which 
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can be detected outside the tissue by an ultrasonic transducer or transducer array to form an 
image that maps the original optical energy deposition inside the tissue (Figure 21b).77 
 
 
Figure 21 - Principles of photoacoustic tomography (PAT). (a) Jablonski diagram, illustrating the photon energy transfer in one-photon fluorescence microscopy, two-photon fluorescence microscopy, and PAT. The most common electronic absorption in the visible and ultraviolet spectral regions is shown. (b) Imaging principle of PAT. Figure from Nat. Methods 13, 627–638 (2016). 
 
Although PA and US image formation and the factors that affect spatial resolution and fidelity 
are mostly the same, the contrasts that generate the images are essentially different. A US 
image provides description of the acoustic impedance mismatch between different tissues: US 
contrast, therefore, depends on morphological features of the tissues, whilst PA represents the 
initial pressure distribution produced by the absorption of a pulse of laser light. With this 
configuration, it is possible to obtain two overlapped images: an explorative US trace and a 
PA contrast image, to make easier localization of the contrast into the sample (Figure 22). 
Photoacoustic tomography (PAT) is referred to PAI as cross-sectional or three-dimensional 
(3D).78 The spatial resolution and imaging depth within the reach of diffusive photons in PAT 
are highly scalable, offering the possibility to multiscale living biological structures ranging 
from organelles to organs. In particular, by using a laser irradiation in the NIR (620–950 nm) 
window, PAT can achieve a penetration depth of several centimetres with resolution on the 
order of a few hundred micrometres, scaling to <100 μm for shallower (<1 cm) penetration 
depths. 
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Figure 22. Photoacoustic/ultrasound images. The images on the right (b and d) show anatomical structures revealed by the ultrasound. The images on the left (a and c) show the photoacoustic data overlaying the ultrasound data. The bright yellow and red at the top of the finger show the skin and blood vessels running parallel to the finger. Figure from Biomed. Opt. Express 7, 5081 (2016).79 
In the last years, the potential of PAT for breast cancer imaging, brain imaging, and sentinel 
lymph node mapping have been investigated in pre-clinical studies.  
Breast PAT imaging is under clinical application phase; recently, studies regarding the 
clinical feasibility of PAmammography, showed the possibility to identify the presence of 
malignant lesions.80,81 The investigators also discussed removal of imaging artefacts 
contributed by the skin surface signal and suggested that dark-field light delivery and 
multiview detection would probably help. In addition, methylene blue has been studied as 
contrast PAI imaging, for sentinel lymph node mapping a biopsy, highlighting high 
penetration depth and spatial resolution of this imaging technique.82 
Otherwise, PAT imaging of the human brain is still in the preclinical study phase. However, 
promising improve elements have been achieved in the past few years, raising confidence that 
PAT can be a highly useful clinical tool for non-invasive functional brain imaging.83,84 
40  
1.4.2 Contrast agents for photoacoustic imaging (PAI)  
In photoacoustic imaging (PAI), ultrasound waves are generated by irradiating tissues with 
modulated or pulsed laser light. In order to achieve penetration depths up to several 
centimetres, applications in biology and biomedicine need the use of optical wavelengths in 
the near-infrared (NIR, 700 – 1500 nm), due to high transparency of tissues in this range 
(Figure 23). Indeed, biomolecules in the tissue, such as haemoglobin, lipids, water and 
melanin, are able to absorb laser irradiation and generate a photoacoustic signal defined 
“endogenous contrast”. The endogenous contrast can be exploited to provide structural and 
functional information of tumour tissue for different applications in cancer research,75 
allowing the development of in vivo preclinical photoacoustic imaging methods for the 
tumour detection and molecular characterization,85,86 for therapeutic monitoring and for the 
identification and for the assessment of metastatic lymph nodes have been reported.82 
 
 
Figure 23. Photoacoustic imaging of endogenous chromophores. 
For example, haemoglobin, the iron-containing oxygen-transport metalloproteins, present in 
the red blood cells assigned to deliver oxygen throughout the body, can be used as 
endogenous contrast agent in PAI for studying tumour angiogenesis. Indeed, when 
haemoglobin binds oxygen, it undergoes under structural and electronic modifications that 
cause changes in its absorption spectrum. This difference can be exploited in photoacoustic 
imaging in order to measure total haemoglobin concentration and oxygen saturation.87 On the 
other hand, the absorption peaks at 930 and 1210 nm, relative to the second overtone of 
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abundant C–H bonds, can be use in PAI for mapping the lipid and collagen distribution in 
vivo, that are two critical markers for many kinds of diseases.88 Although the intrinsic 
chromophores are useful to understand biological processes and provide structural and 
functional information of human tissues, they generate a background absorption in the 
photoacoustic signal that might be overcome through the design of exogenous contrast agents.  
An ideal contrast agent should be composed by a signalling compound, which produces the 
signal for imaging, and a targeting moiety able to identify a specific biological entity or 
process. In photoacoustic imaging the signalling compound correspond to an exogenous agent 
able to absorb light in the near infrared (NIR) region (620 – 950 nm), in order to obtain an 
intensive photoacoustic signal besides a high penetration depth.  In addition, PAI contrast 
agent must be biocompatible for the organism, and this prerogative can be achieved whether 
minimizing the toxicity, through the control of the administration route, dose and the immune 
response or optimizing elimination from the circulatory system and target tissue penetration, 
in order to reduce the accumulation in off-target tissues. In addition, they might be 
characterized by specific photophysical properties: 
 
 high molar extinction coefficient to maximize the amount of light absorbed; 
 sharply absorption peak to ensure unambiguous identification by spectral un-mixing 
even at low molar concentrations; 
 high photostability to ensure that spectral features are not changed by light irradiation;  
 low quantum yield to maximize the non-radiative conversion of light energy to heat;  
 efficient conversion of heat energy to produce acoustic waves; 
 
PAI exogenous agents can be small-molecule dyes, metallic or semiconducting 
nanostructures, and organic nanostructures, characterized by high chemical, physical and 
biochemical flexibility. Because their molar extinction coefficients are usually higher 
compared to those of small-molecule dyes nanoparticles, these agents are currently the largest 
class of contrast agents for molecular PAI. Indeed, nanosystems are characterized by a large 
surface area that can be chemical modified by introducing a large number of targeting 
moieties in order to increase the probability of target-binding. Different nanostructures 
characterized by different shapes and sizes (<1,000 nm, usually ~10–100 nm) and materials 
have been investigated as contrast agents in PAI. Among these gold nanomaterials, carbon 
nanotubes and graphene-based nanomaterials showed the most promising results. 
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1.4.3 Gold nanostructures as PAI contrast agents 
 
Due to their inert nature and their unique optical and physicochemical properties, gold 
nanomaterials are the most promising candidates as PAI contrast agents. 
As reported previously, the optical properties of gold nanomaterials are ascribed to the 
“localized surface plasmon resonance” (LSPR) (paragraph 1.3.1 and 1.3.2, Figure 16). This 
phenomenon, concerning the plasmon formations after a laser irradiation at an appropriate 
wavelength, consists in the oscillation of conduction electrons of gold nanostructure relative 
to the core. Plamons convert the substantial part of the oscillation energy into heat detectable 
with PAI. Acting as a macroscopic dipole, gold nanostructures show higher extinction 
coefficient in the NIR range and higher PA conversion efficiency than organic small-molecule 
dyes.  For example, the study of Wu et al. showed that the absorption of a single nanoshell 
with a diameter of 20 nm, corresponds to the absorption of 40000 molecules of indocyanine 
green, one of the most used NIR dye used for PAI. 89 
The extinction coefficient (Qext) depends on the nanostructures morphologies and dimensions, 
usually gold nanorods show a higher Qext respect to gold nanoshells, which are characterized 
by a Qext comparable to gold nanospheres (Figure 24). An additional advantage of the use of 
gold nanostructure as PAI contrast agents is their photostability, which avoid the 
photobleaching phenomena, affecting conventional fluorophores.90 In-depth studies have been 
carried out in order to fine-tune methodologies for synthetizing gold nanostructures 
characterized by different morphology and λSPR, in order to improve PAI application.  
 
 
Figure 24. Calculated extinction (top curve), absorption (middle curve) and scattering (bottom curve) efficiencies for: (a) a 80 nm - diameter gold nanosphere; (b) a 70 nm - radius gold nanoshell with a 60 nm silica core; and (c) a 59.6 × 15.3 nm gold nanorods. Figure from Nanomaterials for the life Science Vol. 3: Mixed Metal Nanomaterials 3, (2007). 
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Among these, gold nanorods and gold nanoshells revealed a great potential in PAI 
applications. Gold nanoshell are spherical particles with diameters typically ranging in size 
from 10 to 200 nm composed of a dielectric core coated by a thin gold shell. One of the most 
popular approach to construct gold nanoshells involves attaching small gold particles to the 
surface of silica core and, subsequently, using these sites as nuclei to seed shell growth when 
a gold salt is reduced in their presence (Figure 25).  
 
 
Figure 25. TEM images of gold nanoshell: initial (left) to complete (right) growth of gold shell around silica nanoparticle. Figure from J. Control. Release 155, 344–357 (2011). 91 
 
In this type of synthesis, it should be possible to control the shell thickness by adjusting the 
amount of reducible salt present in solution. This thickness influences the plasmon modes of 
the particles and the position of λSPR which can be selectively tuned from 600 nm to greater 
than 1000 nm (Figure 26).92 
 
 
Figure 26. Gold nanoshell plasmon resonances for a 120-nm core with indicated shell thickness. Figure from J. Pharm. Bioallied Sci. 2, 282 (2010). 93 
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In particular, the position of the extinction (plasmon resonance) peak, and the relative 
contributions of absorption and scattering to total extinction, can be tuned by changing two 
parameters:  
 
 the radius of the inner core (r1);  
 the radius of outer shell (r2); 
 
For a given r2, the position of the extinction peak is determined by the core to shell ratio 
(r1/r2); for greater core to shell ratios (thinner gold shells), the peak becomes shifted to longer 
wavelengths. 
In addition, due to the strong-affinity between gold and thiol group, the gold nanoshells 
surface can be chemical functionalized with organic molecules in order to enhance their 
biocompatibility and stability or to introduce active targeting. 
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1.4.4 Magnetic Resonance Imaging (MRI)  
Magnetic resonance imaging (MRI) is a non-invasive diagnostic tool, that in the last decades 
have shown a great potential in the visualization of structural and functional information 
involving the human body. It is based on the nuclear magnetic resonance (NMR) phenomenon 
and on the development of a technique able to measure the magnetic characteristic of atomic 
nuclei.  
The mechanism involves the application of an external strong magnetic field, able to induce 
the nuclei of protons to align their spins either parallel or antiparallel to the direction of 
magnetic field. During their alignment, the spins process under a specified frequency, known 
as the Larmor frequency (ω0, Figure 27 a).  
 
 
Figure 27. Principle of magnetic resonance imaging. a) Spins align parallel or antiparallel to the magnetic field and process under Larmor frequency (ω0). b) After induction of RF pulse, magnetization of spins changes. Excited spins take relaxation process of c) T1 relaxation and d) T2 relaxation. Figure from Adv. Mater. 21, 2133–2148 (2009).  When a ‘resonance’ frequency in the radio-frequency (RF) range is introduced to the nuclei, 
the protons absorb energy and are excited to the antiparallel state. After the disappearance of 
the radio-frequency pulse, the excited nuclei relax to their initial, lower-energy state (Figure 
27 b). There are two different relaxation pathways, the first, called longitudinal or T1 
relaxation, involves the decreased net magnetization (Mz) recovering to the initial state 
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(Figure 27 c); the second, called transverse or T2 relaxation, involves the induced 
magnetization on the perpendicular plane (Mxy) disappearing by the dephasing of the spins 
(Figure 27 d).94 
This technique was discovered by Dr Isodor Rabi awarded noble prize in physic in 1944.95 
Thanks to Rabi’s studies, Dr Damadian used for the first time NMR in biomedical 
applications to measure T1 and T2 relaxation times in rat tumours. In 1971 his results, 
published on Science, revealed that tumour tissue possessed longer T2 times than those of a 
normal tissue, and showed the possibility to use NMR technique for detecting malignant 
tumour. These studies constituted the foundation of magnetic resonance imaging (MRI) and 
leading to the production of the first MR images human in 1977 and the development of the 
first commercial whole-body MR scanner in 1980. 
Although images obtained by purely MRI result sufficiently detailed, the small differences in 
relaxation time between normal tissues and lesions can be not enough clear, leading to a not 
accurate diagnosis. Indeed, MRI technique is characterized by a superb spatial resolution, but 
shows a limited sensitivity of its probes. For these reason, the use of contrast agents able to 
influence the proton relaxation times, can increase the visibility of organs or body regions, 
improving the signal differences between adjacent regions, such as “tissue and tissue”, “tissue 
and vessel”, and “tissue and bone”.96 
Nowadays, the development of efficient and safe contrast agents represents a crucial point for 
the MRI sensitivity enhancement. MRI contrast agents act by shortening T1 (longitudinal) 
and T2 (transversal) relaxation time of surrounding water protons in order to indirectly 
produce a signal-enhancing effect. The efficiency of an agent to shorten relaxation times is 
called relaxivity, which is calculated by ratio between the change in the relaxation rate and the 
concentration of the contrast agent. In MRI application on human body, the relaxivity can be 
affect by extrinsic factors including temperature, magnetic field strength and the tissue 
surroundings (water, plasma or blood). 97 
Beyond an adequate relaxivity and susceptibility effects, in clinical application a contrast 
agent has to satisfy several requirements, such as tolerance, safety, low toxicity, stability, 
optimal bio-distribution, and elimination. T1 contrast agents are paramagnetic agents, 
composed of a metal ion, which has a permanent magnetic moment due to unpaired electrons 
(gadolinium (Gd3+) or manganese (Mn2+)). Because of their toxicity, paramagnetic lanthanide 
ions are usually chelated by organic ligand, able to reduce their toxic effects caused by tissue 
accumulation in the body.98 They produce positive contrast and create bright images (Figure 
28).  
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Figure 28. T1 weighted image (on the left) and T2 weighted image (on the right) of the same brain tissue. Figure from http://casemed.case.edu/clerkships/neurology/NeurLrngObjectives/MRI.htm 
Gadolinium complexes are the most widely T1 contrast agents used in clinical applications, in 
particular for the detection of the breakage of the blood brain barrier (BBB) and of the 
changes in vascularity, flow dynamics, and perfusion. In the last decade, several organic 
molecules characterized by different chemical properties (ionic or non-ionic) and structures 
(linear or not lineal), have been developed to chelate gadolinium ion, in order to improve the 
stability and the in vivo biodistribution of the final complex. Currently, several gadolinium-
based contrast agents have been approved by the FDA (Food and Drug Administration) and 
EMA (European Medicine Agency), such as gadobenate (MultiHance), gadobutrol 
(Gadavist), gadodiamide (Omniscan), gadopentetate (Magnevist), gadoterate (Dotarem), 
gadoteridol (ProHance), gadoversetamide (OptiMARK), gadoxetate (Eovist), and 
gadofosveset (Ablavar, US only). However, recent studies showed that in patients affected by 
renal impairment, the administration of gadolinium contrast agents lead to the development of 
nephrogenic systemic fibrosis (NSF). In addition, deepened investigations have showed the 
accumulation of gadolinium in various tissues of patients not affected by renal impairment, 
including bone, brain, and kidneys. These evidences led to modifications in clinical practices 
in order to reduce the potential side effect associated to gadolinium tissue accumulation.99 
Because of their non-toxicity and rapidly clearance from the organism, super paramagnetic 
iron oxide nanoparticles (SPIONs) have been investigated as novel contrast agents in MRI.  
In comparison with paramagnetic ions, SPIONs are T2 contrast agents made up of an iron 
oxide core or an iron/manganese (Fe/Mn) composite metal core covered by an external shell 
constituted by biomaterials able to prevent aggregation, but also to improve their 
biocompatibility and biodistribution in vivo. These contrast agents are able to form a 
significantly larger magnetic moment than the paramagnetic agents and produce a “negative 
contrast with a dark effect on MRI image (Figure 28).100 
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1.4.5 Super paramagnetic nanoparticles as MRI contrast agents  
Super paramagnetic iron oxide nanoparticles (SPIONs, usually magnetite (Fe3O4) or 
maghemite (γ-Fe2O3)) are nanoparticles that consist of a core of ferric (Fe3+) and ferrous 
(Fe2+) iron. They represent the first used magnetic nanoparticle-based contrast agents due to 
their chemical stability, lack of toxicity and biodegradability. 
Under an external magnetic field, individual magnetic moments of SPIONs produce a 
fluctuating magnetic field, which is large in comparison to that produced by gadolinium. This 
allows the perturbation of the magnetic relaxation processes of the water protons diffused into 
SPIONs outer sphere, leading to a decrease of the spin–spin relaxation time (T2) that involves 
the darkening of the corresponding area in T2-weighted MR images (Figure 29).12  
 
 
Figure 29.  Magnetic resonance contrast effects of MNPs. Under an external field (B0), magnetic nanoparticles are magnetized with a magnetic moment of µ and generate and induced magnetic field which perturbs the nuclear spin relaxation processes of the water protons. This perturbation leads to MR contrast enhancement, which appears as a darkening of the corresponding section of the image. Figure from Angew. Chemie - Int. Ed. 47, 5122–5135 (2008).  
SPIONs can alter the relaxation of local protons in a more efficient way than gadolinium, 
allowing the use of lower concentrations than Gd3+-based agents. Also because they are iron-
based agent with not potential for causing nephrogenic systemic fibrosis, they may be useful 
as an alternative to gadolinium-based contrast agents in patients with compromised renal 
function.101 However, SPIONs magnetic properties are influenced by the iron content of the 
core and the size. In the nanoscale regime, magnetism is influenced by the size, because the 
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surface spins are not-perfectly aligned to the external magnetic field (canted surface spin) and 
form a magnetically disordered spin-glass-like surface layer (Figure 30). On the other hand, 
in the ideal case, all of the magnetic spins in a bulk magnetic material are aligned parallel to 
the external magnetic field. 
 
 
Figure 30. Surface spin canting effect of a nanoparticle upon magnetization (M= magnetic moment, H = external magnetic field). Figure adapted from Angew. Chemie - Int. Ed. 47, 5122–5135 (2008).  The surface effect becomes more pronounced when the nanoparticles decrease, causing a 
dependence of the net magnetic moment with the nanoparticles size. 
In particular, it has been demonstrated that the relaxivity coefficient (r2) gradually increases 
for 4 nm, 6 nm, 9 nm, and 12 nm sized nanoparticles, and lead to an enhancement of the MR 
contrast signal.102 In addition, the magnetic properties of iron oxide nanoparticles can be 
greatly increased by doping with magnetically susceptible elements the native nanostructure, 
leading to shortening of T2. In particular, it has been showed that manganese-doped ferrite 
nanoparticles (MnFe2O4) have higher magnetic susceptibility, as compared with other divalent 
transition metal dopants (nickel or cobalt).  
The synthesis methodologies used to obtain iron oxide nanoparticles characterized with high 
magnetization properties, lead to the formation of nanoparticles with hydrophobic properties, 
due to presence of the organic ligands on the surface. In order to enhance their solubility and 
stability in water at physiological pH, several molecules, polymers and biomaterials have 
been studied to find an ideal coating for making magnetic nanoparticles suitable for 
biomedical applications. However, it has been showed that the nature of this coating and the 
procedure followed to anchor it on the surface of the nanoparticles can affect the magnetic 
properties and relaxivity of the particulate contrast agents.103 
Among these, iron nanoparticles coated with biomaterials, such as dextran or polysaccharide, 
have showed promising results in clinical trials. In the middle of 1990, several iron-based MR 
contrast agents were developed for imaging of the liver and other cells of 
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the reticuloendothelial system (RES), because the selectively taken of SPIONs by Kupffer 
cells in the liver, spleen, and bone marrow after intravenous injection. 
Among these T2-constrast agents commercial available consisted in dextran coated-SPIONs 
having diameters between 20 to 3,500 nm (Ferumoxsil or AMI-121, Ferucarbotran, OMP) 
and ultrasmall SPIO (USPIO) agents having diameters of less than 50 nm (AMI-277, MION-
47, Sinerem®, Combidex®, Clariscan™). 
However, in 2009 the commercial production of all of these RES agents has been ceased 
because of the lack of sales and poor performance in clinical trials. After that, several a deeper 
investigation has been carried out in order to overcome the challenges regarded the use of 
SPIONs as T2 contrast agents. 
Currently, the potential of Ferumoxytol (Feraheme, AMAG Pharmaceuticals, Cambridge, 
MA) as iron-based MRI contrast agent is under clinical investigation (Figure 31).104  
 
 
Figure 31. Ferumoxytol susceptibility-weighted imaging at 7 T in human brain Vasculature MRI before ferumoxytol (a) and after 4 mg/kg ferumoxytol (b). 
Ferumoxytol is a commercially available ultrasmall superparamagnetic iron oxide (USPIO) 
agent surrounded by a carbohydrate coat, which has been originally used as an iron 
replacement therapy for patients with anaemia related to chronic renal insufficiency (Figure 
32).101 
 
Figure 32 Feraheme produced by AMAG Pharmaceuticals, consists in elemental iron 30mg/mL (as ferumoxytol 510mg/17mL). 
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1.5 Surface chemistry of metal nanoparticles  1.5.1 Self-assembled monolayer (SAM)  
As highlighted several times in the previous paragraphs, a fundamental requirement for the 
use of metallic nanoparticles in biomedical application is their biocompatibility and their 
stability in aqueous medium at physiological conditions. Depending on the synthesis, metallic 
nanoparticles and metal oxide nanoparticles can be synthetized with hydrophobic or 
hydrophilic properties. In the both cases, the replacement of the original surfactants with 
specific organic ligands is necessary in order to improve their biocompatibility, and also 
enhance their stability. Indeed, these molecules can alter interfacial properties and have a 
significant influence on the stability of nanostructures of metals and metal oxides, also they can 
act as a physical or electrostatic barrier against aggregation, decreasing the reactivity of the 
surface atoms, or acting as an electrically insulating film.105 
Dealing with noble metal based nanostructures, such as gold and silver nanoparticles, they 
usually are synthetized in water medium with the assistance of various kind of surfactants, 
which stabilize the growing nanoparticles against aggregation phenomena.60 These surfactants 
remain adsorbed or deposited onto the nanoparticles surface once the process is finished, 
avoiding post-synthesis collapse of the created nanoparticles. Unfortunately, most of these 
surfactants are strongly toxic or simply not suitable for biomedical application. In the case of 
gold nanorods, the synthesis is carried out in water in the presence of the 
cetyltrimethylammonium bromide (CTAB). However, it is demonstrated that this cationic 
surfactant in physiological conditions have a strong cytotoxic effect on healthy cells. For 
these reason, the development of specific ligands able to replace CTAB molecules, preventing 
the aggregation phenomena, and at the same time keeping unchanged the specific optical 
properties of GNRs, have been largely investigated.62 
On the other hand, iron oxide nanoparticles characterized by high quality and low size 
polydispersion, are usually synthetized through thermal decomposition in non-aqueous media, 
with the use of surfactants, which confer them hydrophobic properties. In this case, the 
surface modification of these metal oxide nanoparticles is necessary to make them suitable for 
nanomedicine applications. A suitable method to coat nanostructures is the formation of the 
so-called self-assembled monolayer (SAM). SAM consisted of organic molecules able to 
interact with the nanostructures surface and organize spontaneously into an ordinated well-defined 
monolayer.  
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Figure 33. Schematic diagram of an ideal self-assembled monolayer (SAM). Figure from Chemical Reviews 105, (2005). 
The molecules or ligands able to form SAMs have a chemical functionality, or headgroup, with a 
specific affinity for specific metals or metal oxides. In many cases, the headgroup also has a high 
affinity for the surface and can displace the surfactants from the surface. In addition, these 
molecules are characterized with a central body usually constituted by a long chain and finally a 
functional group, or tail, which will determine the properties both of the monolayer formed and of 
the entire system (Figure 33). 
For what concerns the functional group that must bind to the metal surface, several studies have 
been performed in order to evaluate their affinity with different kinds of metal. The thiol group is 
the most used functional group to bind gold and silver surface, due to the great affinity of to the 
transition and noble metals. On the other hand, organic ligand characterized by “head groups” as 
catechol, 2,3-dihydroxybenzamide, phosphonic acid, and carboxylic acid have been investigated 
to bind the metal oxide nanostructures surface.103 
As regards the chain which constitutes the "body" of the ligand, previous studies 
demonstrated the importance of the presence of amide junctions and aromatic components, 
the first capable of forming hydrogen bridges between the various chains, the second able to 
give π-stacking interactions that ensure greater stability to the structure.46  
Finally, the terminal functional group of the ligand must confer the desired properties to the 
entire system. By introducing appropriate functional groups at the end of the ligands it is 
possible to obtain stability in different solvents or, for instance, make them react with 
common reactions of organic chemistry once they are already firmly anchored to the 
nanoparticles surface. 
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1.5.2 Silica shell as coating of metallic nanoparticles   
As mentioned in the previous paragraph, in few cases the synthesis of metallic nanoparticles 
are carried out in non-aqueous solvents, obtaining nanoparticles with hydrophobic properties. 
In particular, the synthesis of magnetic nanoparticles, such as iron oxide nanoparticles or 
manganese doped iron oxide nanoparticles, can involve high-temperature (up to 305 °C) 
reactions of metal precursors (such as acetylacetonate) with 1,2-hexadecanediol, oleic acid, 
and oleylamine. These methods allow obtaining magnetic nanoparticles characterized by high 
magnetization and controlling the size of the oxide nanoparticles by varying the reaction 
temperature or changing metal precursors. 
However, in these reactions are formed hydrophobic nanoparticles, not suitable for 
nanomedicine applications and not characterized by functional groups suitable for 
bioconjugation. To solve this problem, hydrophobic nanoparticles might to be transferred into 
aqueous media by entrapping them in polymeric micelles, or by realizing surface 
modification, as the formation of self-assembled monolayer with hydrophilic ligands, or a 
silica coating.  The silica coating approach consists in the formation a cross-linked silica shell 
on nanoparticles surface, in order to protect and stabilize the core nanoparticles in aqueous 
environment, and to enhance their biocompatibility due to its nontoxicity. It can be used for 
hydrophilic and hydrophobic nanoparticles of metals,106 metal oxides,  and quantum dots 
(QDs) in a size range of 1-100 nm.107 By adjusting the reaction conditions, it is possible to 
obtain a silica coating characterized by a specific layer thickness and provide the 
nanoparticles surface of various functional groups in order to conjugate an active targeting 
(Figure 34).  
 
 
Figure 34. TEM images of iron oxide nanoparticles (a) and gold nanorods (b) coated by silica shell 
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Indeed, the specific properties of core nanoparticles, such as the saturation magnetization, 
luminescence intensity, the intensity of surface-enhanced Raman scattering signal, will 
decrease as the inert silica shells thickness increases, although silica shells can effectively 
prevent core nanoparticles from corrosion of the surrounding media, and an ultrathin silica 
shell is helpful in avoiding this decrease.108 
In particular the study of Chen et al. showed that silica coated gold nanorods can produce 3-
fold higher photoacoustic signals than nanorods without silica coating characterized by the 
same optical properties.109 This results showed how a dielectric shell on gold nanorods 
surface has a strong influence on the amplitude of the generated photoacoustic signal and also 
avoid the reshaping phenomenon of gold nanorods caused by laser irradiation and affect their 
absorption efficiency.110 
Several kinds of functional silanes have been used in order to coat nanoparticles made of 
different materials. These molecules are characterized of trimethoxysilyl or silanol groups at 
one end, which undergo hydrolysis in a basic/acidic medium to form a silica shell, and a 
functional group at the other end, able to bind an active targeting on the core-shell systems 
surface. Two different strategies can be used to initiate the silica polymerization on the 
nanoparticles surface: the Stöber synthesis and the reverse microemulsion methods. The 
former cannot be applied to nanoparticles insoluble in the polar media, while the latter is an 
excellent alternative strategy for making silica coating on hydrophobic nanoparticles. 
The Stöber method is based on sol-gel process and consists in two consecutive reactions that 
essentially govern the growth of silica particles. In the first step, TEOS undergoes hydrolysis 
in a mixed ethanol/ammonia solution to produce silanol monomers, in which the ethoxyl 
groups (-Si-OEt) are replaced with silanol groups (-Si-OH) (1). Subsequently, the silanol 
monomers undertake condensation between two silanol groups (2) to generate branched 
siloxane clusters, which are further linked to trigger the nucleation and growth of silica 
particles. Simultaneously, the silanol monomers may also react with the unhydrolyzed ethoxyl 
groups of TEOS via condensation between silanol and ethoxyl groups (3) to participate in the 
nucleation and growth of silica particles as well.108 
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Because of the hydrolysis of TEOS is ammonia-catalysed, the size of silica particles can be 
readily tuned in a wide range from 10 to 500 by changing the ammonia concentration. 
For the formation of core-shell systems, Stöber condition can be applied to nanoparticles 
soluble in the alcohol-water media, because in the silica coating formation the first step of 
hydrolysis reaction takes place with the hydroxyl groups on the nanoparticles surface (Figure 
35).  
 
 
Figure 35. Silane conjugation chemistry for nanoparticles soluble in alcohol-water media 
 
For this reason, different approaches have been developed in order to realise silica coating of 
hydrophobic nanoparticles. Among these, modification of Stöber’s condition have been 
applied in order to develop new methods based on the formation of reverse micelle (reverse  
microemulsion method), methods based on the use of lipophilic silane monomers or 
trialkoxysilanes, able to minimize the shell thickness, and also the use of hydrophilic silanes 
able to confer water solubility to the final nanoparticles.107 
In particular, Ding et al. described the mechanism of reverse microemulsion method used to 
coat hydrophobic iron oxide nanoparticles, and deeply investigated the coating mechanism in 
the formation of core-shell systems (Figure 36). 
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Figure 36. Illustration of the coating mechanism of SiO2 on the surface of hydrophobic Fe3O4 nanoparticles. Figure from Chem. Mater. 24, 4572–4580 (2012) 
 
In this method, surfactant molecules (Igepal CO-520) are mixed in cyclohexane solution, and 
spontaneously aggregate and form the micelles in the organic solution. After that, 
hydrophobic nanoparticles (Fe3O4 NPs) are added to the solution, and the ligand exchange 
reaction between oleic acid and fractional surfactant molecules occurs on the surface of the 
Fe3O4 NPs with part of the surfactants still in the micelle form. The formed micelles will then 
be filled with ammonia upon its addition, and the micelle size is enlarged and forms a reverse 
microemulsion system. Subsequently, the added TEOS will hydrolyse at the oil/water 
interface and perform the ligand exchange with surfactant molecules chemically absorbed on 
the Fe3O4 NPs surface and then transfer the NPs to the water phase. Finally, the hydrolysed 
TEOS on the Fe3O4 NPs surface undergoes a condensation process and forms silica shells. 
57  
2. Aim  The aim of this project has been carried out a deep investigation on the potential of polymeric 
nanoparticles and metallic nanoparticles as theranostic nanosystems for cancer treatment. 
For this purpose, several kinds of metallic nanoparticles have been designed, synthetized, 
modified on the surface and characterized, such as silver nanopartilces, gold nanorods, iron 
oxide nanoparticles, magnesium nanoparticles, and also multifunctional nanomaterials as 
dumbbell-like gold-iron oxide nanoparticles and iron-gold core-shell systems.  
Indeed, as deepened in the introduction, metallic nanoparticles show intrinsic chemical-physic 
properties that make them suitable for therapeutic and/or diagnostic applications in medicine 
thus, in the last decades, their used in clinical applications has been largely investigated.  
For this purpose, optical properties of gold nanomaterials have been employed in this project 
for the development of photothermal agents for hyperthermia therapy as well as photoacoustic 
imaging contrast agents. Furthermore, the incorporation of magnetic iron oxide nanoparticles 
with gold nanomaterials in the same nanosystem, led to the formation of multifunctional 
nanosystems that showed promising properties as theranostic and dual-imaging agents. 
Additionally, a one pot-synthesis of chitosan coated magnesium nanoparticle has been fine 
tuned in order to obtain nanoparticles characterized by high biocompatibility and unexpected 
photothermal behaviour. 
However, a crucial point for metallic nanoparticles consists in their superficial coating that 
can affect the biocompatibility, stability and the toxicity of the whole final nanosystem. For 
this purpose, different strategies and different biomaterials have been employed in order to 
functionalize the metallic nanoparticles surface. 
About this, one strategy consisted in the ligand exchange reaction, in which organic ligands 
can be chemically anchored or physically adsorbed on the nanoparticles surface to form a 
single or double layer, able to create repulsive (mainly steric) forces balancing the attractive 
forces acting on the nanoparticles. 
In this way, the synthetized metallic nanoparticles have been coated with biomaterials or with 
specific designed organic molecules able to bind their surface. In particular, the use of organic 
molecules as coating can confer hydrophobic properties to metallic nanoparticles, allowing 
their entrapment in polymeric nanoparticles.  
Indeed, the delivery via polymeric nanovectors of metallic nanoparticles or chemotherapeutic 
drugs characterized by hydrophobic properties, was the other strategy employed in this project 
for the development of theranostic platforms. For this purpose, the FDA approved copolymer 
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poly(lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) has been used in 
order to form polymeric nanoparticles characterized by high biocompatibility and able to 
conjugate on surface a biomolecule as active targeting. Another strategy consisted in the 
formation of a silica layer on metallic nanoparticles able to be further functionalized 
achieving the realization of a multifunctional nanosystems. 
In the end, the biological properties of all the developed nanosystems have been tested in vitro 
and in vivo, in order to investigate their potential as drug delivery and theranostic systems in 
nanomedicine applications. 
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3. Discussion  3.1 Synthesis of the precursors  In order to achieve the surface functionalization of the synthetized metallic nanoparticles, 
specific organic molecules and biopolymers have been synthetized or opportunely modified. 
Indeed, these molecules must be characterized by specific functional groups and molecular 
structures, in order to bind the metal atoms on the nanoparticles surface and to form a self-
assembled monolayer able to stabilize the final nanosystems (paragraph 1.5).   
In this section, the synthetic strategies developed to obtain the organic materials used in the 
surface functionalization of the metallic nanoparticles, have been reported. 
In particular, the synthesis of organic ligand (ethyl 11-(4-mercaptobenzamido)undecanoate), 
the organic functionalization of chitosan chains and the synthesis of the copolymer 
poly(lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) will be described.  
 
3.1.1 Synthesis of the organic ligand 11-(4-mercaptobenzamido)undecanoate (ligand 1)  
With the intent to coat noble metal nanostructures surface, the organic ligand 11-(4-
mercaptobenzamido)undecanoate (ligand 1) has been designed and synthetized by the 
research group where I worked during my PhD.111 
In order to allow the formation of a good self-assembled monolayer, the ligand molecular 
structure is composed by a thiol as head group, due of its high affinity towards noble metals, a 
long chain and an ester ending group (paragraph 1.5). 
The synthesis of this ligand requires four steps. The first step consisted the synthesis of 4,4'-
disulfanediyldibenzoic acid realized through the oxidation of commercially available 4-
mercaptobenzoic acid with iodine in ethanol in order to obtain the corresponding disulphide 
(Scheme 1). 
 
Scheme 1. Synthesis of 4,4’-disulfanediyldibenzoic acid 
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This allows the protection of the thiol group and simultaneously it ensures the non-reactivity 
of the same as nucleophile during the following steps. The second step of this synthesis 
consisted in esterification of the commercially available 11-aminoundecanoic acid with 
ethanol, giving in this way the corresponding ethyl ester (Scheme 2).    
 
 
Scheme 2. Synthesis of ethyl 11-aminoundecanoate 
 Once obtained, the two precursors were linked through an amide junction using 1,1-
carbonyldiimidazole (CDI) as activating agent for the carboxylic acids present into the 
disulphide, and anhydrous tetrahydrofuran (THF) as solvent (Scheme 3).    
 
 
Scheme 3. Synthesis of bis-ethyl 12-(4-benzamido)undecanoate disulfide 
 
Finally, the disulphide was reduced with sodium borohydride in order to restore the original 
thiol group and to obtain the final desired ligand (Scheme 4).  
This ligand, having an ester-ending group, will ensure great stability to the coated 
nanostructures in organic solvents, allowing a good entrapment into polymeric nanoparticles. 
 
 
Scheme 4. Synthesis of ethyl 11-(4-mercaptobenzamido)undecanoate 
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3.1.2 Organic functionalization of chitosan  
Due to its biocompatible, biodegradable, and bioactive properties, chitosan has been widely 
investigated as biomaterials for biomedical and pharmaceutical applications. 
Chitosan, a natural polymer constitutes of glucosamine and N-acetyl-D-glucosamine, has 
been used in this project as metallic nanoparticles coating in order to improve their colloidal 
stability and in vivo biodistribution. 
For this purpose, two different organic functionalization have been carried out by following 
reported method in literature.112,113 In one case the chitosan chains has been modified with 
thioglycolic acid (TGA), introducing thiol groups onto its chain (chitosan-TGA) in order to 
bind the surface of noble metallic nanostructures. The reaction consisted in the formation of 
amide bond between the free amine groups of chitosan chains and the carboxylic acid of 
thioglycolic activated by using the 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) as 
coupling reagent (Scheme 5). 
 
 
Scheme 5. Synthesis of thiol-modified chitosan chains (Chitosan-TGA) 
 
In the other case, by using EDC as coupling reagent, hydrocaﬀeic acid (HCA) has been linked 
to amine moieties of chitosan chains, leading to the formation of catechol-functionalized 
chitosan (chitosan-HCA), able to coat the metal oxide nanoparticles surface. 
 
 
Scheme 6. Synthesis of catechol-modified chitosan chains (Chitosan-HCA) 
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3.1.3 Preparation of copolymers for polymeric nanocarriers  
Poly(d,l-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) is a di-block 
copolymer constituted of an hydrophobic portion made of poly(d,l-lactic-co-glycolic acid) 
(PLGA) and an hydrophilic one, made of poly(ethylene glycol) (PEG) used for the synthesis 
of polymeric nanoparticles (PNPs). The synthesis has been achieved through the formation of 
an amide bond between carboxylic ending group of PLGA (PLGA-COOH) and the amine 
group of bi-functionalized PEG. 
In this project, PLGA-b-PEG has been synthetized either by using α,ω-bis-amino PEG  
(PLGA-b-PEG-NH2) or by using ɑ-amino-ω-carboxy PEG (PLGA-b-PEG-COOH). 
Depending on the bi-functionalized PEG, nanoparticles characterized on the surface by 
different functional groups can be obtained. 
The synthesis of PLGA-b-PEG-NH2 is a one-pot synthesis, consisting of the preparation of an 
organic solution by dissolving PLGA-COOH in anhydrous tetrahydrofuran with N,N’-
dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS), agents able to activate 
the carboxylic group.  The mixture has been kept under magnetic stirring for one hour; then, 
the α,ω-bis-amino PEG  (H2N-PEG-NH2) has been introduced in the reaction environment 
and the obtained solution has been reacted for 24 hours at room temperature.  In order to 
avoid amide bonds formation at both the extremities of PEG, a larger amount of H2N-PEG-
NH2 compared to PLGA-COOH has been used. The so-obtained PLGA-b-PEG-NH2 has been 
purified by filtration of dicyclohexylurea (DCU) and precipitation in diethylether (Scheme 7). 
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Scheme 7. Synthesis of PLGA-b-PEG-NH2 
 On the other hand, the synthesis of PLGA-b-PEG-COOH is carried out in two steps. In the 
first step, the activation of carboxylic group of PLGA-COOH is achieved in anhydrous 
dichloromethane in the presence of the activating reagents (DCC\NHS). The reaction is left to 
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react for 24 hours and then the polymer PLGA-NHS has been purified by filtration of 
dicyclohexylurea (DCU) and precipitation in diethyl ether (Scheme 8). 
 
 
Scheme 8. Synthesis of PLGA-b-PEG-NHS 
 
In a second step, the ɑ-amino-ω-carboxy PEG hydrochloride (H2N-PEG-COOH•HCl) is 
added to a solution of the pre-activated PLGA-NHS in anhydrous chloroform, in the presence 
of an organic base like N,N-Diisopropylethylamine (DIPEA) (Scheme 9). 
The reaction is left to react for one day and the resulting co-polymer is purified by 
precipitation, washings in diethylether and subsequently in water. 
 
 
Scheme 9. Synthesis of PLGA-b-PEG-COOH 
The copolymers have been characterized by mean of 1H-NMR and stored in freezer at -18 °C, 
where they are stable for several months. 
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3.2. Polymeric nanoparticles as drug delivery systems against Glioblastoma Multiforme  Glioblastoma Multiforme (GBM) is the most common type of primary brain tumour and the 
astrocytoma of the highest grade. It is characterized by highly proliferative and invasive 
properties, remarkable biological heterogeneity and poor response to traditional therapies, 
which make it the most aggressive primary brain tumour. The main causes of poor prognosis 
of GBM are its tendency to recur and the impediment represents by the blood−brain barrier 
(BBB).  Regarding the tendency to recur, clinical results have shown that for over 90% of the 
cases the area of recurrence develops at the borders of the surgical cavity, within 2 cm of the 
original tumour, or at distant sites when the tumour is at later stage.  
On the other hand, the BBB limits the passage of pharmaceutical molecules into the brain 
tissue, representing the major hurdle in the clinical management of GBM. Although, large and 
advanced brain tumours exhibit disrupted BBB integrity, the presence of peripheral areas of 
brain tumours that contain regions with intact BBB, leading to the spreading glioma cancer 
cell and treatment resistance. For this reason, the median overall survival of GBM patients 
with the best currently available therapy is approximately 15 months, and the 5-year survival 
rate is only 9.8% at present. Thus, the reaching of the dispersed and invading GBM cells 
remains a big challenge for the successful treatment of GBM. 
Given the intrinsic difficulty for most conventional drugs to reach the brain, in this project the 
use of nanoparticles has been investigated as an innovative therapeutic strategy. The 
conducted researches led to the development of two different polymeric nanosystems 
characterized by the presence of active targeting on their surface, in order to investigate their 
ability of the transporting of the loaded agents within the cerebral tissue with minimal off-
target toxicity. Due to its well-known properties and its ability to create micelle-like 
nanocarriers (paragraph 1.2.2), poly(lactic-co-glycolic)- block-poly ethylene glycol (PLGA-
b-PEG) copolymer has been used for the synthesis of the two developed nanosystems.  
The first system consisted in the polymeric nanoparticles conjugated to a peptide able to bind 
selectively glioma cells (chlorotoxin, CTX), in which silver nanoparticles were entrapped to 
allow detection and quantification of the cellular uptake by confocal microscopy, both in vitro 
and in vivo (Ag-PNP-CTX).114 In the other system, a chemotherapeutic drug has been 
entrapped into polymeric nanoparticles functionalized with an aptamer (Gint4.T) able to 
recognize platelet-derived growth factor receptors β on the blood−brain barrier (BBB).115 
Both the developed nanosystems have been tested in vitro and in vivo biological assays.  
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3.2.1. Synthesis of chlorotoxin functionalized polymeric nanovectors for the treatment of Glioblastoma Multiforme in a combined approach with radiation therapy  All the procedures and results about the development of chlorotoxin targeted polymeric 
nanovectors for GBM treatment are completely described in:  
 
 A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation 
To Reach Infiltrating Tumor Niches in Glioblastoma; ACS Nano 2016, 10, 
2509−2520. 
 3.2.1.1 Synthesis and surface functionalization of silver nanoparticles (Ag-nps)   
Silver nanoparticles have been synthetized following a reported procedure optimized by our 
the research group, based on the so called “salt-reduction method”, in which a strong reducing 
agent and a stabilizing agent are required.111 
The synthesis is based on the use of polyvinylpyrrolidone (PVP), selected as surfactant agent 
because its good ability able to stabilize nanoparticles during their formation, avoiding the 
aggregation phenomena, and allowing the nanoparticles to growth with high uniformity. 
Moreover, because PVP is a non-ionic surfactant, it shows a less toxicity compared with 
surfactant positively charged, that could interfere with DNA, characterized by a globally 
negative charge.  Hydrophilic silver nanoparticles (Ag-nps-PVP) have been synthetized by 
preparing a water solution made of PVP, glucose and sodium hydroxide (NaOH) in water. 
Glucose is used as reducing agent, in order to completely reduce silver ions. The solution is 
warmed and when the temperature reached 70°C, a solution of silver nitrate (AgNO3) is 
rapidly added into the reaction mixture (Scheme 10). 
 
Scheme 10.schematic representation of the Ag-nps-PVP synthesis 
After only three minutes at the same temperature, the nanoparticles formation was completed, 
and the colloidal solution was purified and concentrated with high-speed centrifugation, 
washing with fresh water. Once purified, the Ag-nps-PVP were characterized by using UV-
66  
Vis spectroscopy, transmission electron microscopy (TEM) analysis and dynamic light 
scattering (DLS) (Figure 37).  
 
 
Figure 37. UV-VIS spectrum (on the left) and TEM image (on the righ) of Ag-nps-PVP. 
UV-Vis spectroscopy revealed the typical absorption band of Ag NPs at 410 nm, attributed to 
the surface plasmon resonance, which confers the intense yellow colour to these particles. 
TEM analysis confirmed the obtainment of silver nanospheres with great uniformity and in 
high concentration, without the presence of macro-aggregates.  
DLS analysis showed also that Ag-nps-PVP have an average diameter of 35.4 ± 5.3 nm and a 
polydispersity index (PDI) value of 0.21 ± 0.011. Moreover, an elemental analysis by atomic 
absorption spectroscopy (AAS) gave an Ag value of 34064 ppm (315.8 mM). 
In order to achieve the entrapment in polymeric nanoparticles of the obtained silver 
nanoparticles, a self-assembled monolayer has been formed on the Ag-nps-PVP by using 11-
(4-mercaptobenzamido)undecanoate (ligand 1) as organic ligand (paragraph 3.1.1). Through 
the thiol group, the ligand 1 can interact with the silver nanoparticles surface, replacing the 
PVP (ligand exchange reaction) and conferring lipophilic properties to Ag-nps-1.  
The reaction consisted in the preparation of a reaction mixture made of an organic solution of 
ligand 1 in ethanol, which has been added to a diluted aqueous solution of Ag-nps-PVP. The 
reaction mixture has been left to react under mechanical stirring for 24 hours; then, the 
obtained Ag-nps-1 have been purified and concentrated with high-speed centrifugation 
washing with fresh ethanol, in order to remove PVP and the excess of ligand 1. 
The collected lipophilic Ag-nps-1 showed a good solubility in organic solvents, as 
demonstration of the successful of the ligand exchange reaction that was confirmed thought 
the 1H-NMR analysis. Indeed, 1H-NMR spectrum of Ag-nps-1 showed the characteristic 
signals of ligand 1, demonstrating its presence on the metallic surface. In particular, the 
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disappearance of signal of -SH (3.47 ppm), confirm its anchoring on Ag-nps surface though a 
covalent bond (Figure 38). 
 
 
Figure 38. 1H-NMR spectrum of ligand 1 (above) and of Ag-nps-1 (below). 
 The DLS results for Ag-nps-1 showed an increased diameter after the coating of 40 ± 7.6 nm, 
with a polidispersity index (PDI) of 0.24. The determination of the metal content has been 
done with atomic absorption spectroscopy (AAS) giving a yield for the ligand exchange step 
of 80%, while the thermogravimetric analysis shows a 16% loss in organic compound 
(corresponding to the ligand anchored on the surface of Ag-nps-1). 
 
3.2.1.2 Entrapment of lipophilic silver in targeted polymeric micelles (Ag-PNP-CTX)  Once obtained, lipophilic silver nanoparticles (Ag-nps-1) have been entrapped into polymeric 
nanoparticles. For this purpose, the copolymer PLGA-b-PEG, synthetized by using ɑ-amino-
ω-carboxy PEG (paragraph 3.1.3), has been synthetized and used for the formation of the 
micelles. Due to the high solubility of Ag-nps-1 in dimethylformamide (DMF), a solvent 
miscible with water, the nanoprecipitation technique has been applied for this step. 
The procedure consists in the preparation of an organic phase, by dissolving Ag-nps-1 in 
dimethylformamide (DMF) with PLGA-b-PEG-COOH, that was mixed with an aqueous 
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phase in a vigorously stirred reactor, maintaining the water/organic ratio constantly 10/1 with 
removal of the resulting colloidal solution. The obtained water solution, containing the Ag-
PNP, was maintained under magnetic stirring for 30 minutes, in order to allow the system to 
reach the stability. Indeed, the nanoprecipitation process led to polymeric nanoparticles 
formation through an interfacial desolvation of the polymer and subsequent aggregation of 
small nuclei into nanometric particles. Because in this case the aggregation process requires 
time to form and reach a stable state, the system must be left to incubate until this process is 
completely ended. After the necessary time, the colloidal solution resulted completely stable 
and with an opal, yellow-brownish coloration.  
The Ag-PNP have been purified with centrifugation, washing several times with fresh water 
in order to remove the dimethylformamide and characterized in order to verify the effective 
entrapment. 
The DLS results show a hydrodynamic diameter of 71.0 nm, a PDI value of 0.19 and a Z-
potential of −51.5 mV (at pH = 7.4), features considered suitable for biomedical applications. 
Then, TEM image clearly show the entrapment of the lipophilic Ag-nps-1 into the PLGA core 
(Figure 39). 
 
 
Figure 39. On the left, DLS characterizations of the size and Zeta Potential of Ag-PNP; on the right, TEM image of Ag-PNP. 
Once obtained the Ag-PNP, chlorotoxin (CTX), a 36-amino acid peptide originally isolated 
from Leiurus quinquestriatus venom, has been selected as active targeting and conjugated 
onto the their outer shell because its ability to specifically and selectively bind glioma 
cells.116,117  CTX, as well as many other peptides, presents a free-amino group at one end, 
which can be exploited for amidation reaction with carboxylic acids present on the Ag-PNP, 
derived from PEG chains.  
The reaction of conjugation has been achieved thought EDC/NHS chemistry, that consists in 
the activation of the carboxylic acids by using 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) hydrochloride and N-hydroxysulfosuccinimide (sulfo-NHS) in water. As 
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shown in the scheme 11, EDC reacts with carboxylic acids to form an active O-acylisourea 
intermediate that is unstable in water and subjected to hydrolysis, with restoration of the 
carboxylic acid and the consequent release of urea by-products. Therefore, O-acylisourea 
must react immediately with a primary amino group, which easily displaces the activating 
agent by a nucleophilic attack, leading to the formation of an amide bond and the release of 
the EDC by-product as a soluble urea derivative.118 
 
 
Scheme 11. Schematic Representation of amide bond formation between a amide functionalized peptide (2-green) and polymeric nanoparticles (1-red) using EDC and Sulfo-NHS. 
Although EDC can be used in neutral conditions, optimal effectiveness is achieved under 
moderate acidic media (pH = 4-6). When a phosphate buffer (pH 7.2) or simple water is used, 
the efficiency of EDC is reduced, and a water-soluble N-hydroxysuccinimide (Sulfo-NHS) 
has to be added in the reaction mixture. The formation of an NHS ester instead of O-
acylisourea increases the stability of the system also at neutral pH values. 
Following this procedure, the conjugation has been realized by dissolving the activating 
reagents (EDC/NHS) in a water solution containing Ag-PNP, followed by the addiction of 
CTX (Figure 40). After 24 hours of reaction, the Ag-PNPs-CTX were purified with 
centrifugation to remove small molecules and aggregates. 
Ag-PNP-CTX characterized by DLS, showed a diameter equal to 114 ± 2 nm, a low 
polydispersity index (PDI) of 0.21 (± 0.01), and a negative Zeta potential of −31.6 mV.  
In addition, silver concentration determined with AAS resulted to be 3.81 mM. 
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Figure 40. Schematic procedure of the synthesis of Ag-PNP-CTX 
 
3.2.1.3 In vitro and in vivo biological studies  
In collaboration with the Laboratory of pharmacology and brain pathology at the Humanitas 
Research Hospital in Milan, the developed chlorotoxin-targeted nanosystem has been tested 
thought in vitro and in vivo studies in order to investigate its potential for the treatment of 
Glioblastoma (GMB) combined with radiotherapy. 
Radiotherapy represents one of the traditional therapy used for GBM treatment, and as 
reported in literature, the use of ionizing radiations seems to damage BBB integrity and 
induce matrix metalloproteinase-2 (MMP-2) expression.119,120 These phenomena can enhance 
the BBB permeabilization to nanovectors, that usually show a limited mobility and diffusion 
through the brain interstitial spaces, which are 38−64 nm in normal brain and 70−100 nm in 
regions with tumour.121,122  
In the biological studies carried out, the enhancement of the Ag-PNP-CTX in brain tissue and, 
in particular, in the infiltrating niches of GBM, after applying ionizing radiations has been 
investigated. In these experiments, Ag-nps were used as contrast agents for optical 
microscopy detection and imaging of PNPs without needing to add fluorescent dyes, thus 
avoiding chemical modification of the outer shell of the nanocarriers, which can modify PNPs 
behaviour inside the body. Due to their high stability and the absence of photobleaching, Ag-
nps represent a valuable imaging tool with superior quality and precision respect to standard 
fluorescence. Moreover, a fluorescent moiety linked or adsorbed onto the external surface, 
may undergo leakage phenomena from the nanosystem once in the body environment, which 
can lead in turn to unspecific fluorescence detection in not really targeted cells; on the 
contrary, Ag-nps, being strongly entrapped inside the polymeric matrix, are stable and not 
subjected to this inconvenience.  
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First of all, the activity of chlorotoxin as active targeting agents has been evaluated in vitro 
thought intracellular quantification of Ag-PNPs in human GBM-derived cell lines, performed 
by confocal microscopy in reflection mode. The results showed that conjugation with CTX 
significantly increases the intracellular accumulation of Ag-nps in GBM cells as shown by 
comparison between Ag- PNP-CTX and Ag-PNP nanocarriers (Figure 41).  
 
   
Figure 41. On the left, human-derived GBM cell lines U87MG, A172 and T98G were incubated in the presence of targeted (Ag-PNP-CTX) or non-targeted (Ag-PNP) nanovectors at Ag concentration of 100 μM. On the right, the images showed the intracellular accumulation in of Ag-PNP (a) and Ag-PNP-CTX (b) determined by confocal laser scanning microscopy. Ag-nps have been acquired in reflection mode upon 488 nm excitation and are shown in red. In green is the human nestin immunostaining, and the nuclei are in blue (DAPI). 
After that, to exploit the bio-distribution of Ag- PNP-CTX in vivo, the amount of Ag-nps 
accumulating into the tumour and the healthy brain tissue was evaluated in an orthotopic 
mouse model of human GBM. The experiment consisted in the intra-peritoneally 
administration of Ag-PNP-CTX at a dose of 1 mg/mouse, in one case to a group of mice not 
treated with brain radiation, and in the other case after brain radiation treatment.  
About the intensity of radiation, a dosage of 2 gray (Gy) has been used by considering that the 
clinical protocol of radiation therapy used to treat patients affected by GBM is of 60 Gy 
delivered in fractions of 2 Gy.  
The Ag-nps quantification, performed in brain tissues via confocal microscopy showed a 
significant higher level of accumulation (4-6 fold)  in the GBM-tumor after the brain radiation 
treatment compared to the animals not treated with radiation (Figure 42 a), and also showed 
that no Ag-nps were present in healthy brain tissues (Figure 42 b). 
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Figure 42. (a) Cryosections of U87MG tumour mass from irradiated (2 Gy) and non-irradiated (0 Gy) mice injected with Ag-PNP-CTX. Ag-nps have been acquired in reflection mode upon 488 nm excitation and are shown in red. In green is the human nestin immunostaining, and the nuclei are in blue (DAPI). (b) Ag-nps quantification in healthy and in tumour brain tissues expressed as mean number of Ag-nps ± SE in a fixed volume of 6500 μm3. About 60 microscopy fields randomly taken from 4 mice in each experimental group were acquired and analysed.  
The obtained results revealed that despite CTX allows the Ag-PNP-CTX nanovectors 
internalization into GBM cells, it is not an agent for BBB crossing, limiting the nanovectors 
biodistribution in the brain tissue where the barrier is not damaged.  
Further studies have been conducted on the cytotoxic effect of silver nanoparticles. The 
results shown in Figure 43 show that tumour areas of the animals treated with a combination 
of radiations and CTX-nanovectors caused the inhibition of tumour growth and progression. 
On the other hand, no inhibitory effect was observed in mice treated with either radiations or 
Ag-PNP-CTX alone. The observed increased level of apoptosis together with the in vivo 
inhibition of tumour growth would suggest a positive antitumor effect of Ag-nps. 
In conclusion, the investigation conducted on the biological properties of the developed Ag-
PNP-CTX nanovectors provide the proof- of-concept of the therapeutic validity of a 
combination strategy based on radiation therapy and CTX-targeted polymeric nanovectors, 
which is expected to enhance the antitumor efficacy of any cytotoxic molecules entrapped 
into PNP-CTX nanovectors. 
 
73  
 
Figure 43. (a) Luciferase imaging of representative mice: untreated (CTRL, 4 mice); injected with Ag-PNP-CTX nanovectors as single agent (2 doses of 1 mg/mouse followed by 2 doses of 0,5 mg/mouse, administration interval: 48−72 h, 5 mice); irradiated (2 Gy single dose, 6 mice); treated with radiations and concomitant Ag-PNP-CTX nanovectors (6 mice). Treatments started 11 days after U87MGluc2 cell implantation (T0 = D11). (b) Tumor growth during 11 days of observation measured by area detected setting automatic ROI (50%).
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3.2.2. Synthesis of aptamer functionalized polymeric nanovectors for the treatment of Glioblastoma thought the BBB  All the procedures and results about the development of aptamer functionalized polymeric 
nanovectors for GBM treatment are completely described in:  
 
 Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the 
Blood−Brain Barrier; J. Med. Chem. 2017, 60, 4510−4516 
 
3.2.2.1. Entrapment of the chemotherapeutic drug NVP-BEZ235 in aptamer functionalized polymeric nanoparticles  
NVP- BEZ235 (Dactolisib) is an imidazo[4,5-c]quinoline derivative that have shown 
promising anticancer therapeutic activity as inhibitor the phosphatidylinositol 3-
kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway deregulation, 
common in human cancer and associated with tumour cell proliferation, growth, and 
apoptosis. As the PI3K/Akt/ mTOR pathway is highly activated in most human cancers, this 
pathway has become a favourable therapy target of cancer. 
Currently, NVP-BEZ235 is in phase I/II clinical trials and is showing great results in the 
inhibition of PI3K and mTOR catalytic activity by competitively binding to the ATP-binding 
cleft, allow the controlling of solid tumours in preclinical mouse models 
However, NVP-BEZ235 is characterized by a low water-solubility, which reduces its 
bioavailability and makes necessary a huge administration doses for ascertaining a significant 
effect. In order to overcome this challenge, NVP-BEZ235 has been entrapped in polymeric 
nanovectors characterized on the surface by the presence of an aptamer as active targeting. 
Aptamer are short, artificial, single- stranded oligonucleotides that, similarly to antibodies, 
interact at high affinity with their targets by recognizing a specific three- dimensional 
structure. Gint4.T is a novel platelet-derived growth factor receptors β (PDGFRβ) specific 
antagonist represented by a nuclease-resistant RNA-aptamer, generated by the systematic 
evolution of ligands by exponential enrichment (SELEX) method. Recently Gint4.T showed a 
great potential in the inhibition of cell migration and proliferation, induction of 
differentiation, and in obstruction of the tumour growth in vivo.123 For this purpose, Gint4.T 
aptamer has been selected as active targeting for its ability to interact with platelet-derived 
growth factor receptors β (PDGFRβ) overexpressed on the BBB, that make it able to cross the 
blood−brain barrier (BBB). 
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As well as for the polymeric nanosystem described in the previous paragraph, the copolymer 
PLGA-b-PEG-COOH has been synthetized and used for the formation of polymeric micelles. 
Because of the high solubility of NVP-BEZ235 in chloroform, double-emulsions water-in-oil-
in-water technique (w/o/w) has been used in this case. The double emulsion technique has 
been selected instead of the single emulsion because the inner aqueous core can offer the 
opportunity to further encapsulate a hydrophilic agent, such as a diagnostic agent.  
With the intent to visualize the developed aptamer-targeted nanovector in the biological 
tissues, a nanosystem containing the lipophilic dye BODIPY505-515 (BODY-PY@PNPs) has 
been synthetized as described in the next paragraph. Indeed, the use of a fluorescent dye 
encapsulated in the polymeric nanoparticles leads to a detection of the effective particles 
localization, instead of a dye conjugated or adsorbed on the surface. 
The water-in-oil-in-water procedure consisted in a first emulsion step, in which an organic 
phase, containing the NVP-BEZ235 and PLGA-b-PEG-COOH dissolved in chloroform, was 
emulsionated with an aqueous phase (w1) with a tip probe sonicator, able to furnish the 
necessary energy for the self-assembling process to the system. In this step, the organic phase 
was used in larger amount than the water phase, leading to the formation of inverse polymeric 
micelles. In the second step of w/o/w, a second water phase (w2) has been prepared by 
dissolving a surfactant agent (sodium cholate) in water. This solution has been added to the 
organic phase in larger amount, obtaining a biphasic solution that was emulsionated with a tip 
probe sonicator for 3 minutes, leading to the formation of water-soluble micelles (Figure 44). 
Once terminated the process, chloroform has been evaporated and the obtained NVP-
BEZ235@PNPs have been purified with centrifugation and washed several times with fresh 
water. The DLS characterization revealed that the obtained polymeric nanoparticles were 
characterized by a hydrodynamic diameter of 76.0 nm, a PDI value of 0.22 and a Zeta 
potential of −28.5 mV.  
After purification, the amino-terminated aptamer (Gint4.T) has been conjugated on the 
obtained NVP-BEZ235@PNPs, by exploiting the superficial residual carboxylic groups onto 
the PNPs surface, derived from PEG chains, as described in the previous paragraph (Scheme 
11). NVP-BEZ235@PNPs-Gint4.T was then purified and characterized by DLS, which 
revealed particles with diameter equal to 52 ± 1 nm, a low polydispersity index (PDI = 0.169), 
and negative zeta potential value of −13.1 mV due to unreacted carboxylic acid groups. 
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Figure 44. Schematic representation of the procedure for the obtainment of the NVP@PNPs-Gint4.T. 
 
The amount of NPV-BEZ235 entrapped in the polymeric nanoparticles NVP-
BEZ235@PNPs-Gint4.T, has been quantified with fluorescence quantitative determination by 
using an excitation wavelength of 270 nm and an emission wavelength of 425 nm (Figure 
45).124 The amount of NVP-BEZ235 entrapped resulted to be 25.2 μM. 
 
 
Figure 45. Fluorimetric determination of NVP-BEZ235. The calibration line has been obtained with the conts per second (c.p.s.) measured for different molar concentrations of NVP-BEZ235 in dichloromethane (λem = 450 nm).  
On the other hand, the amount of aptamer conjugated to the NVP-BEZ235@PNPs-Gint4.T 
was evaluated by a real-time quantitative polymerase chain reaction (RT-qPCR) analysis on 
NVP-BEZ@PNPs-Gint4.T that revealed a Gint4.T concentration of 1.4 nM, corresponding to 
a conjugation efficiency of 5.4%.  
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To prove a direct correlation between obtained results and the presence of a specific aptamer 
onto the surface of the nanoparticles, NVP-BEZ235@PNPs were also conjugated with a 2′F-
Py RNA with no affinity for PDGFRβ receptor, consisting in the scrambled (SCR) sequence 
of a previously generated anti-EGFR aptamer and herein used as negative control (indicated 
as NVP-BEZ235@PNPs-SCR.123 The obtained NVP-BEZ235@PNPs-SCR showed a 
diameter of 48 ± 0.5 nm, a PDI of 0.207 and a Zeta potential value of - 23.7 mV, and an 
entrapped NVP-BEZ235 concentration of 22.3 µM. 
 
3.2.2.2. Entrapment of a lipophilic dye BODIPY 505-515 in aptamer functionalized polymeric nanoparticles  
In order to achieve fluorescence-based studies, such as internalization studies performed by 
confocal laser microscopy and in vivo tumour targeting studies, a lipophilic dye 
(BODIPY505-515) has been encapsulated in aptamer targeted polymeric nanoparticles. 
Due to its high solubility in chloroform, BODIPY505-515 has been encapsulated in polymeric 
nanoparticles though the w/o/w technique as described in the previous paragraph. 
The DLS characterization showed that of BODI-PY@PNPs were characterized by a 
hydrodynamic diameter of 82.0 nm, a PDI value of 0.23 and a Z-potential of −25.5 mV. 
After that, the Gint4.T and the scambled aptamers have been conjugated on the BODI-
PY@PNPs though the EDC/NHS chemistry (Scheme 11). 
The DLS analysis revealed that a BODI-PY@PNPs-Gint4.T were characterized by a 
hydrodynamic diameter of 78 ± 1 nm, a PDI of 0.182 and a zeta potential value of – 44.0 mV, 
while the BODIPY@PNPs-SCR were characterized by a diameter equal to 78 ± 1 nm, 
polydispersity index (PDI) of 0.182 and negative Zeta potential value of – 44.0 mV. 
The concentration of BODIPY®505-515 was estimated by fluorimetric measurements 
acquired at the emission wavelength of 512 nm (λem) by using the excitation wavelength of 
368 nm (λex) (Figure 46). The concentration of the entrapped BODIPY®505-515 in 
BODIPY@PNPs-Gint4.T resulted to be 9.5 µM, while the concentration in BODIPY@PNPs-
SCR resulted to be 8.7 µM. 
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Figure 46. Fluorimetric determination of BODIPY®505-515. The calibration line has been obtained with the conts per second (c.p.s.) measured for different molar concentrations of BODIPY®505-515 in dichloromethane (λem = 512 nm). 
 3.2.2.3. In vitro and in vivo biological studies   
The investigation of the biological activity of the developed nanosystems has been carried out 
through several in vitro and in vivo experiments.  
In vitro studies have been realized in collaboration with the Istituto Toscano Tumori (ITT) in 
Siena, and the Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” 
in Naples.  
First, the targeting efficiency of aptamer conjugated on nanovectors has been tested with 
internalization and cytotoxicity studies. 
For the internalization studies, BODIPY@PNPs conjugated with Gint4.T or scrambled (SCR) 
aptamers, were incubated with GBM cell line (U87MG cells), and nanovectors were 
visualized by confocal microscopy by taking advantage of the BODIPY. The results showed 
that PNPs conjugated with Gint4.T aptamer have been easily internalized in U87MG cells, 
becoming clearly visible 10 min after the beginning of the treatment, while SCR decorated 
nanovectors were undetectable until 50 min (Figure 47). These data demonstrated that the 
conjugation of polymeric nanoparticles with the anti-PDGFRβ aptamer strongly enhanced the 
internalization of the nanovectors in GBM cells. 
To additionally control that the specificity of targeting depended on the recognition of the 
PDGFRβ by the Gint4.T aptamer, U87MG clonal cells depleted from this receptor have been 
used for further internalization studies. The results showed that, after an incubation of 40 min, 
fluorescent BODIPY@PNPs-Gint4.T were clearly internalized exclusively in U87MG clonal 
cells, characterized by a reduced number of PDGFRβ, while untargeted fluorescent 
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BODIPY@PNPs-SCR were not internalized in any of the clonal cells. Thus, these data clearly 
indicated that the Gint4.T aptamer specifically targets PNPs to GBM cells, strongly enhancing 
their intracellular uptake. 
 
 
 
Figure 47. The number of cells that incorporated Bodipy fluorophore after treatment with Bodipy@PNPs-SCR or Bodipy@PNPs-Gint4.T has been evaluated across the time from 0 to 60 minutes. The number of cells with a mean relative fluorescence intensity higher than median fluorescence of control has been evaluated by Volocity software (Quantitation module, PerkinElmer). A minimum of 400 cells for each sample for each experiment (n=3) has been analysed. 
 
On the other hand, the cytotoxicity studies revealed that the efficiency of the drug on its 
specific biochemical targets is unchanged also after its entrapment in polymeric nanoparticles. 
In particular, the ability of drug-loaded nanovectors of killing U87MG target cells was 
investigated through the measure of the EC50 (half maximal effective concentration values) 
for “free” NVP-BEZ235, NVP-BEZ235@PNPs-SCR, and NVP-BEZ235@PNPs-Gint4.T. 
The results reported in table 1, showed that NVP-BEZ235@PNPs-Gint4.T resulted in being 
at least 1000-fold more cytotoxic, comparing with “free” NVP-BEZ235 and about 4-fold 
more effective than NVP-BEZ235@PNPs-SCR, demonstrating a strongly improved 
bioavailability of the drug encapsulated in aptamer functionalized nanoparticles. 
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Table 1. EC50 for free NVP-BEZ235, NVP-BEZ235@PNPs-SCR and NVP-BEZ235@PNPs-Gint4.T were evaluated after continuous incubation (EC50 at 72h) and after 40 minutes incubation followed by washes (WO = washout) and 72 hours recovery.  EC50 (72h)  EC50 (40 min + WO + 72h) NVP-BEZ235  165693 pM 1017.58 nM NVP-BEZ235@PNPs-SCR  156 pM 10.44 nM NVP-BEZ235@PNPs-Gint4.T  38 pM 0.16 nM  
In order to investigate the targeting ability of the developed nanosystems in vivo, further 
experiments have been conducted in collaboration with the NorLux Neuro-Oncology 
Laboratory of Department of Oncology at Luxembourg Institute of Health. 
The aim of these experiments consisted in to prove the ability of the developed nanovectors to 
pass the BBB and to be specifically accumulated into brain tumour.  
For this purpose, BODIPY@PNPs-Gint4.T or BODIPY@PNPs-SCR nanovectors were 
systemically administered to nude mice with intracranial U87MG tumour xenografts.  
After two hours (2h), the mice were sacrificed and the whole brains were analysed with high-
resolution fluorescence microscopy. The collected images showed that a clear fluorescent 
signal was present in the brain of the animals treated with BODIPY@PNPs-Gint4.T, while no 
specific signal was observed in tumours from mice treated with the negative control 
nanovectors (Figure 49a). 
In addition, the fluorescence from the control nanoparticles was almost undetectable also at 
four hours (4h) after injection while the fluorescence from the Gint4.T-nanovectors was 
significantly higher at 4 h than at the 2 h time point (Figure 49b).  
Although the BBB is partially damaged at the tumour core of the intracranial U87MG model, 
in the brain areas distant from the central tumour mass is fully intacted, preventing the drug 
penetration. Therefore, to confirm that the developed delivery system was able to cross an 
intact BBB, the amount of fluorescence in the areas of normal brain distant from the tumour 
has been analysed. The results revealed that a greater fluorescence has been detected in the 
brain from mice that received Gint4.T-PNPs injection compared to those treated with the 
scrambled nanovectors, supporting that conjugation with the anti-PDGFRβ aptamer allows 
the nanoparticles to cross the BBB (Figure 48 a and b).  
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Figure 48.(a) Representative confocal microscopy images of normal brains at 4h post injection of BODIPY@PNPs-Gint4.T or BODIPY@PNPs-SCR. All digital images were captured at the same setting to allow direct comparison of staining patterns. Blue: nuclei; green: aptamer-PNPs. (b) Aptamer-PNPs fluorescence was quantified on 6 separate slices for each experimental group and expressed as mean fluorescence intensity (MFI) ± SD of 10 microscopy fields randomly taken from each slice. **P < 0.01.  
 
Next, to confirm the tumour-specific targeting of nanovectors, we assessed the effectiveness 
of the Gint4.T-PNPs in delivering the drug to mouse brain tumours. To this aim, NVP-
BEZ235@PNPs-SCR and NVP-BEZ235@PNPs-Gint4.T were systemically administered 
daily over five consecutive days to tumour-bearing mice. At the end of the treatment, the 
grade of inhibition of phospho-4EBP1has been measured in the tumours isolated from the 
brains in order to investigate the activity of the drug. Indeed, NVP-BEZ235 as inhibition of 
mTOR pathway can cell cycle arrest in G1/G0 phase in glioma cell lines, thought the 
inhibition of PI3K/Akt/mTOR pathway by decreasing the expression of phospho-4EBP1.125 
The results indicated that also with a short and acute treatment, the phospho-4EBP1 levels 
were significantly lower in Gint4.T-PNPs treated tumors than in the control tumours (Figure 
49c). In conclusion, the results obtained from in vitro and in vivo studies prove the efficacy of 
the developed nanosystems to overcome the BBB and to be accumulated in the tumour and 
suggest that both these processes are mediated by Gint4.T aptamer-dependent recognition of 
the PDGFRβ expressed on these cells. 
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Figure 48. (A) Ex vivo fluorescence imaging of entire brains explanted from mice bearing U87MG orthotopic xenografts 2 h after injection of PBS, BODIPY@PNPs-Gint4.T, or BODIPY@PNPs-SCR. Magnified views of the tumour areas (white square) are indicated in the insets. White arrows indicate fluorescent signals from Gint4.T-PNPs. (B) Aptamer-PNPs fluorescence in the tumour, at 2 and 4 h post injection, was quantified on six separate slices for each experimental group and expressed as mean fluorescence intensity (MFI) ± SD of 10 microscopy fields randomly taken from each slice. (C) Western blot of p4EBP1 and total 4EBP1 in intracranial U87MG xenografts after completion of the 5-day treatment with saline, NVP-BEZ235@PNPs-SCR (1@ PNPs-SCR), or NVP-BEZ235@PNPs-Gint4.T (1@PNPs-Gint4.T). (left) Four representative tumors per group are shown. α-tubulin was used as internal control. (right) Quantitation of p4EBP1/4EBP1. Each data point represents the sample from an individual mouse (n = 8). One-way ANOVA followed by Tukey’s multiple comparison test (C) or student’s t-test (B). **P < 0.01; *P < 0.05; ns, no significance. 
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3.3 Synthesis of nanosystems for hyperthermia therapy  
Hyperthermia therapy is a cancer treatment that consists in the exposition of body tissue to an 
increasing of temperature above the physiological temperature (42-45°C) to induce cytotoxic 
effects on cancer cells.  
Pothothermal therapy (PTT) is a hyperthermia therapy based on the use of near infrared (NIR) 
laser photoabsorbers to generate heat in order to induce thermal ablation of cancer cells upon 
NIR laser irradiation. PTT is a non-invasive, highly efficient and well-tolerated therapy 
against various cancer types. In order to improve its efficiency, new agents able to generate 
therapeutic hyperthermia when irradiated, are needed and must have precise biocompatibility 
in order to avoid damage to healthy tissues and prevent system toxicity-related events. Safe 
metals in the form of nano- (NPs) and micro-particles (MPs) have been studied as potential 
Photo-Thermal (PTT) agents. Among these PTT agents able to absorb the light in the so-
called biological windows, are particularly suitable in order to reduce the non-selective 
heating of healthy tissue and, at the same time allow deeper tissue treatments.  
For this purpose, two different photothermal systems based on metal nanoparticles have been 
developed. The first system consisted in the use of gold nanorods (GNRs) as light activated 
agents, due their well-known ability to absorb and scatter the electromagnetic radiation in the 
near-infrared (NIR) region. By using the oil-in-water technique, GNRs have been surface 
modified and entrapped in polymeric nanoparticles in order to enhance their biocompatibility. 
Also, curcumin has been entrapped in the same system and used as therapeutic agent for its 
potential for prevention, and therapy of cancer. With the intention to study the efficacy of a 
combined photothermal cancer treatment with local drug delivery of curcumin, three different 
systems have been synthetized by entrapping lipophilic GNRs (GNR-1@PMs), Curcumin 
(Curc@PMs) and lipophilic GNRs together with the Curcumin (GNR-1/Curc@PMs). On the 
other hand, chitosan-microparticles containing very small magnesium nanoparticles (Chit–Mg 
MPs) represent the second developed photothermal system. Chit–Mg MPs have been 
synthetized in one-pot reaction through MgCl2 reduction to magnesium nanoparticles with a 
salt reduction methodology. The stability and biocompatibility of the obtained nanoparticles 
(Mg-NPs) have been improved by using chitosan as coating, because of the strong affinity of 
amino and hydroxyl groups for the magnesium nanocrystal surfaces. 
The photothermal behavior for cancer treatments of both the developed systems have been 
tested in vitro and in vivo. 
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3.3.1 Gold nanorods as tools for photothermal therapy of Barrett Oesophagus  All the procedures and results about the development of photothermal nanosystems based on 
the use of gold nanorods, are completely described in:  
 
 Gold nanorods and curcumin-loaded nanomicelles for efficient in vivo photothermal 
therapy of Barrett Esophagus. Nanomedicine (Lond) 1–11 (2015).  
 
3.3.1.1 Synthesis and surface functionalization of gold nanorods (GNRs)   
Gold nanorods have been synthetized by using a methodology fine-tuned of the research 
group where I worked, based on “seed-mediated and surfactant-assisted growth” method 
developed by Nikobakht and El-Sayed.126 This method allows obtaining GNRs characterized 
by different aspect ratio (length/width) and a low amount of spherical particles that could be 
formed during the synthesis as impurities. 
The method consists in the preparation of the "seeds" of the nucleation by reducing a small 
amount of tetrachloroauric acid (HAuCl4) in aqueous solution, in the presence of the 
surfactant with a strong reducing agent, such as sodium borohydrate (NaBH4). 
The formed seeds are later added in a growth solution, constitutes of ions of the adjuvant Ag+, 
a substantial excess of the surfactant and a more abundant amount of HAuCl4 partially 
reduced by Au3+ to Au1+ with ascorbic acid in order to facilitate the deposition of metal atoms 
to the seeds in growth (Scheme 12). In a general procedure, a high concentration of the 
cationic surfactant cetyltrimethylammonium bromide (CTAB) is used to achieve GNRs 
formation and to avoid GNRs aggregation and precipitation once they are synthesized. 
After 24 hours at controlled temperature (27-30 °C) a diluted solution of GNRs coated with 
surfactant is obtained, showing the typical red-purple coloration. Once obtained, GNRs-
CTAB have been purified with high-speed centrifugation and then characterized thought 
transmission electron microscopy (TEM) and UV-Vis spectroscopy.  
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Scheme 12. Schematic representation of the procedure for the obtainment of gold nanorods (GNRs). 
 
TEM analysis confirmed the obtainment of GNRs characterized by an aspect ratio around 4, 
being length 50 nm and width 12-13 nm (Figure 50). UV-Vis spectroscopy showed the 
typical two absorption bands of GNRs, one with a maximum wavelength at 740 nm 
(longitudinal plasmon resonance, LPR) and the other with a maximum at 520 nm (transversal 
plasmon resonance, TPR), typical values for the obtained aspect ratio (Figure 50). 
 
    
Figure 50. On the left, TEM image of GNRS and, on the right, the corresponding UV-Vis spectrum. 
  
The roles played by the surfactant and the silver ions in the mechanism, have been extensively 
investigated but up today is not completely clarified. About the surfactant, several studies 
confirmed that CTAB form a double layer (bilayer) around GNRs in the growth phase, 
constitutes by the first layer, in which the head-group of CTAB is oriented towards the 
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nanorods surface, and a second layer, directed towards water, leaving the two hydrophobic 
tails in the centre, similar to a cellular membrane.127 In addition, the CTAB has an important 
role during the nucleation step, creating a preliminary facial differentiation of the seeds in 
order to allow the preferentially growth in one direction rather than in all the possible 
directions. Once immersed in the growth solution, the seeds undergo a preferential attack by 
the surfactant on the more accessible face {100}, while the face {111} remaining free from 
CTAB can grow, thus leading to the elongated cylindrical structure. For the same reason, the 
{111} face remains more reactive in each stage than the {100} face, which is the fact that 
influences all the surface chemistry of these nanostructures (Figure 51).128 
 
 
Figure 51. Formation mechanism of GNRs.  Figure from J. Phys. Chem. B 109, 13857–13870 (2005). 
 
About the role of silver, it has been shown that within certain limits, by increasing the amount 
of silver ions in the grow solution, GNRs with increased aspect ratio can be obtained. Indeed, 
positively charged silver ions are able to intercalate the negatively charged bromine head 
groups on the surface of the nanostructure, limiting the tendency of the negative charged 
heads to repel each other, and promoting the elongation of the GNRs.  
However, synthetic GNRs with CTAB are toxic to cultured cells and to animals, thus the 
surface modification is the key factor determining the cytotoxicity of GNRs. 
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Indeed, in physiological conditions free CTAB molecules desorb from the surface of the 
GNRs and diffuse across cell membrane. Once into the cells, due to its positive charge, CTAB 
molecules interact with negative charged DNA and RNA molecules, leading to a strong 
cytotoxic effect on healthy cells.  
In order to enhance the GNRs biocompatibility, CTAB replacement appears to be the only 
alternative. However, it represents a great challenge due to the different reactivity of the 
{111} and {100} faces of the nanorods, which can induce to GNRs aggregation after the 
complete elimination of CTAB from the GNRs surface. For this reason, the CTAB removal 
has been achieved through ligand exchange reaction by using 11-(4-
mercaptobenzamido)undecanoate (ligand 1), as well as done for the silver nanoparticles 
surface functionalization (paragraph 3.2.1.1). 
 
NH
NH
NH
 
Figure 52. Representation of ligand exchange reaction performed on GNRs by using ligand 1. 
 
The method requires the preparation of an organic solution obtained by dissolving the ligand 
1 in ethanol that has been further added to an aqueous solution contains GNRs-CTAB (Figure 
52). The obtained hydro-alcoholic solution has been put under slight mechanical stirring for 
24 hours, in order to allow the self-assembled monolayer formation on GNRs. After 
completing the ligand exchange, purification by several washes with ethanol has been carried 
out in order to remove the unreacted ligand molecules and the replaced CTAB. Once formed 
SAM on GNRs, ligand 1 are able to confer high stability to the nanoparticles and a drastical 
change in their solubility, leading the obtainment of lipophilic GNRs soluble in 
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dichloromethane (GNRs-1). GNRs-1 have been characterized by 1H-NMR and infrared IR 
spectroscopy in order to confirm the presence of ligand 1 on GNRs surface.  
 
 
Figure 53. 1H-NMR analysis of GNRs-1, ligand 1 and GNRs-CTAB in CDCl3 
 
The comparison of the 1H-NMR spectra of the ligand 1 and free CTAB with the spectrum of 
GNRs-1 clearly showed that CTAB molecules have been completely removed from the metal 
surface, and that the ligand 1 is clearly attached onto the metal surface.  In particular, the 
presence of all the significant signals of the ligand 1, and the disappearance of the -SH 
hydrogen, meaning that the link with the metal surface has been effective (Figure 53). 
In addition, IR spectroscopy confirmed once again the effective ligand exchange and the 
removal of CTAB (Figure 54). 
In order to estimate the metal content into the solution, Atomic Absorption Spectroscopy 
(AAS) has been used, showing a reaction yield of about 80% meaning that a good amount of 
nanoparticles can be recovered after the ligand exchange. Also, gravimetric analysis revealed 
that the ligand anchored to the surface is about the 35-40% of the entire system, which is 
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satisfactorily high and surely high enough to ensure stability to GNRs during the following 
steps.  
 
 
Figure 54. FTIR spectra of GNRs-1, ligand 1 and GNRs-CTAB in KBr.  
 
3.3.1.2 GNRs-1 and Curcumin loaded in polymeric micelles as a novel theranostic system   Curcumin (diferuloylmethane) is a polyphenol derived from the Curcuma longa plant, 
commonly known as turmeric. Due to its non-toxicity and its variety of therapeutic properties 
including anti-oxidant, analgesic, anti-inflammatory and antiseptic activity, curcumin has 
been used extensively in Ayurvedic medicine for centuries. Currently, curcumin has been 
found to possess anticancer activities ascribed to its effect on a variety of biological pathways 
involved in mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigenesis 
and metastasis. 129 
Clinical trials studies revealed that curcumin could stop the precancerous changes becoming 
cancer, but the main problem laid to its bad bio-distribution.130 Indeed, pharmacokinetic 
studies of curcumin indicated in general a low bioavailability of curcumin following oral 
application. In order to improve its bio-distribution, an injectable form of curcumin, which 
90  
may improve the bio-distribution has been developed.131 Although the results seem 
promising, further clinical trials in humans might be performed in order to know if curcumin 
has any potential to treat cancer in people. 
Taking in account this problematic, in this project the entrapment of curcumin in polymeric 
nanomicelles made of PLGA-b-PEG polymer has been realized. In addition, the synergic 
effects of photothermal properties of GNRs and the anticancer properties of curcumin has 
been investigated by synthetized three different nanosystems: polymeric nanomicelles loaded 
with lipophilic GNRs-1 (GNRs-1@PMs), with curcumine (Curc@PMs) and, with curcumine 
and lipophilic GNRs-1 (GNRs-1/Curc@PMs) (Scheme 13). 
 
 
Scheme 13. Schematic representation of the formation of GNRs-1@PMs, Curc@PMs and GNRs-1/Curc@ PMs 
Because of the high solubility of GNRs-1 and curcumin in dichloromethane, the oil-in-water 
technique has been used to form the polymeric nanomicelles.  
For the synthesis of GNRs-1@PMs and Curc@PMs, the procedure consists in the dissolution 
of PLGA-b-PEG-COOH into dichloromethane solution containing, in one case, GNRs-1, and 
in the other case, curcumin. Once prepared the organic solution, an aqueous phase containing 
a surfactant (sodium cholate) was then slowly added on the top of this, led to the formation of 
a biphasic solution that underwent to sonication with a trip probe sonicator in order to furnish 
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the necessary energy to the system for the self-assembling process.  After a short time (1-2 
minutes), the two phases resulted completely mixed, and the polymeric micelles have been 
obtained. The organic solvent remained entrapped in the lipophilic core was removed by 
evaporation under vacuum and the resulting aqueous solution was purified with centrifuge in 
order to eliminate the small un-reacted molecules. The obtained GNRs-1@PMs and 
Curc@PMs were characterized by dynamic light scattering (DLS), atomic absorption analysis 
(AAS), transmission electron microscopy (TEM), UV-Vis analysis and gravimetric analysis.  
Regarding the GNRs-1@PMs, the entrapment of GNRs into micelles has been confirmed by 
TEM images (Figure 55). 
 
 
Figure 55. TEM images of GNRs-1@PMs 
 
DLS analysis showed that GNRs-1@PMs were characterized by a hydrodynamic radius of 
137.0 ± 1.6 nm, a PDI of 0.227 ± 0.042 and a high negative zeta potential value (-43.9 mV). 
The negative Zeta potential is due to the presence in the micelles outer shell of free carboxylic 
acids groups deriving from the free end of PEG chains.  
In addition, UV-Vis spectrum revealed that the optical properties of GNRs were unchanged 
after the entrapment, showing the typical GNRs maximum absorption peak at 730–740 nm. 
The amount of gold in GNRs-1@PMs measured through the AAS resulted to be 0.158 mg/ml, 
corresponding to a solution 0.802 mM and a GNRs-1 entrapment efficacy of 71.8%.  
On the other hand, dealing with Curc@PMs, DLS result shows a hydrodynamic diameter of 
99.4 ± 0.8 nm with a PDI of 0.210 ± 0.010 and a negative zeta potential of -50.1 mV. Through 
UV-Vis analysis the curcumin amount entrapped into PMs was determined, obtaining a 
concentration value of 2.0 mM with an entrapment yield of 37%. In addition, the UV-Vis 
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spectrum of Curc@PMs showed a blue-shifted of peak of curcumin at 419 nm (instead of 430 
nm) after its entrapped, suggested an effective entrapment in the polymeric micelles.  
Finally, polymeric nanoparticles containing both GNRs-1 and curcumin were prepared. The 
simultaneous entrapment into micelles of two moieties is a challenging aim, due to the 
possible interferences that could arise from the proximity of these two reactive compounds. 
For this reason, to ensure the obtainment of a nanosystem containing both the two active 
agents a similar procedure was exploited: two separated emulsions containing GNRs-1@PMs 
and Curc@PMs not completely stabilized were obtained by using the same described 
procedure but reducing the sonication time (from 2 min to 1 min). Then, the two solutions 
were mixed together and re-emulsified for the remaining time in order to allow complete 
micelles formation and reorganization.132  
With this method, micelles formation proceeds through a fast-initial aggregation of unimers 
into small metastable micelles that can further grow toward the minimum Gibbs energy only 
if some of them shrink, dissolve and release unimers. Metastable phase of micelles has been 
exploited by mixing together the two active moieties without direct interaction between them 
since they are surrounded by unimers.  
The obtained system containing GNRs and curcumin has been completely characterized. The 
DLS showed a hydrodynamic radius for GNRs-1/Curc@PMs of 119.0 ± 1.6 nm with a PDI of 
0.282 ± 0.030 and a zeta potential value of -41.6 mV. The hypothesis of GNRs and curcumin 
entrapped together in one micelle, instead of a mixture of GNRs-1@PMs and Curc@PMs was 
confirmed by the presence of a single population in the DLS analysis and by the UV-Vis 
characterization. Indeed, UV-Vis analysis confirmed, on one hand, the keeping of optical 
properties both for GNRs and for curcumin, and on the other hand, showed a blue-shift in the 
GNRs absorption peak when entrapped with curcumin in comparison to when entrapped alone 
(Figure 56).  
 
Figure 56. UV-Vis spectrum of GNRs-1/Curc@PMs 
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This evidence suggested the proximity of the two moieties, which would bring to the collapse 
of GNRs if not for the double emulsification procedure.  
Also in this case, the gold concentration was measured with AAS and resulted to be 0.098 
mg/mL, corresponding to a solution 0.53 mM, while curcumin concentration was determined 
to be 2.2 mM, meaning that both the two moieties were entrapped into PMs with a yield of 
44% for GNRs and 41% for curcumin.  
 
3.3.1.3. In vitro and in vivo biological studies   
Adenocarcinoma is one of the two common pathologic subtypes of oesophageal cancer, a 
serious malignancy with high mortality particularly common in the United States and certain 
European countries, associated with obesity and gastroesophageal reflux disease.  
The grim statistics highlight the importance of extensive and urgent research on mechanisms, 
prevention, detection and therapy of oesophageal cancer and it premalignant precursor 
Barrett’s Oesophagus (BE).  Surgery and chemoradiation are the usual treatment for patients 
with advanced but resectable oesophageal cancers. However, the prognosis and further 
management largely depends upon the pathologic tumor-node-metastasis. A potential to 
overcome these limitations is through a combined sequential therapy, which exploits the 
synergistic effect of different drugs or agents to enhance their efficacy and avoid the dose 
limiting toxicities and poor response rates. For this purpose, the synergism of photothermal 
behavior of GNRs and the anticancer activity of curcumin for the treatment of Barrett’s 
oesophageal and oesophageal adenocarcinoma (EAC) has been investigated, through a deep 
biological investigation carried out in collaboration with the research group of the Dr. Robert 
Martin of the Division of Surgical Oncology at the University of Louisville (USA). 
First of all, photothermal properties of GNRs have been exploited in combination with 
triggered curcumin release through in vitro studies on Barrett’s oesophageal cell line (BAR-T) 
and an oesophageal adenocarcinoma (EAC) cell line. A BE cell line (BAR-T) and an EAC 
cell line (OE-19) were treated for 12 hours with the three developed systems (GNRs- 1@PMs, 
GNRs-1/Curc@PMs and Curc@PMs). Then, the cell lines were exposed to near-infrared 
spectroscopy (NIR) light laser using a Diode Pumped Solid State laser (DPSSL) system at a 
wavelength of 808 nm and a power density of 3 W/cm2 for 1 min. \ 
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Twelve hours after the laser treatment, the cell viability has been valuated with a 3-(4,5-
dimethyl-thiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT, Sigma- Aldrich) reduction 
assay. 
 
 
Figure 57. In vitro laser irradiation. Upper, a representative images of cells treated with GNRs- 1@PMs at 40 μM (in gold), GNRs-1/Curc@PMs (40 μM in gold and 166 μM in curcumin) and Curc@PMs (166 μM) with or without laser irradiation. (C) Cytotoxicity experiments. The cell viability by 3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. Data present as mean ± SD, *p < 0.05, compared with GNRs-1/Curc@PMs no laser. # p < 0.05, compared with GNRs-1@PMs no laser. Cont: Control; Curc@: Curcumin loaded; GNR: Gold nanorod; MTT: 2,5-diphenyltetrazolium bromide; NIH: Near-infrared spectroscopy; PM: Polymeric nanomicelle 
The results reported in Figure 57, showed that the cells treated with GNRs-1/Curc@PMs 
show a significative mortality after laser treatment, more than GNRs-1@PMs treated cells. 
On the other hand, the cells treated with Curc@PMs showed an anticancer activity but 
demonstrated a less efficacy compared to the other systems, especially after laser treatment. 
The obtained data demonstrated higher efficacy by the synergistic effect between curcumin 
and GNRs using GNRs-1/Curc@PMs on cells that has been confirmed by the results obtained 
through in vivo experiments. 
The in vivo studies have been performed on Barrett’s Oesophagus bearing rats; the GNRs-
1/Curc@PMs and GNRs-1@PMs were delivered at the same concentration tested in vitro 
through precise endoscopy to the lower oesophageal lumen, where the mucosa of Barrett’s 
Oesophagus appeared. Twelve hours after GNRs-1/Curc@PMs and GNRs-1@PMs delivery, 
the lower oesophagus was exposed to NIR light with an output power of the laser of 10 
W/cm2 for 15 seconds. Later, the oesophageal tissues were harvested to investigate GNRs 
localization and histological changes by silver staining.  
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Figure 58. Lipophilic gold nanorods/curcumin loaded polymeric micelles localization by silver staining and Barrett’s Oesophagus mucosal destruction by near infrared light. In the mid-panel, normal rat oesophageal mocosa. In the right-panel, both GNRs-1/Curc@PMs and GNRs-1@PMs distributed into the mesenchyma of Barrett’s Oesophagus mucosal, in which the GNRs were detected by the silver staining. The Barrett’s oesophageal mucosa was destroyed extensively (arrow) and most Barrett’s cells died (arrow) in the GNRs-1/Curc@PMs treatment 24 h after near infrared light exposure. Regional loss of the Barrett’s oesophageal mucosa and Barrett’s cells (arrow head) were found in GNRs-1@PMs treatment 24 h after near infrared light exposure. Curc@: Curcumin loaded; GNR: Gold nanorod; PM: Polymeric nanomicelle. 
The images reported in Figure 58, showed that GNRs from both GNRs-1/Curc@PMs and 
GNRs-1@PMs were detected in the mesenchyme of Barrett’s Oesophagus mucosa but not in 
normal oesophageal mucosa 12 h after the endoscopic delivery, before laser irradiation 
(Figure 58, mid-panel). This phenomenon demonstrated the ability of the developed 
nanosystems to bind tumour tissue without noticeable toxicity to the surrounding normal 
cells. As expected, the Barrett’s oesophageal mucosa with GNRs-1/Curc@PMs treatment was 
eradicated extensively at 24 h after NIR light exposure (Figure 58, top right-panel). However, 
the mucosa destruction in the Barrett’s oesophageal mucosa with GNRs-1@PMs treatment 
and NIR light exposure was limited in some local regions (Figure 58, bottom right-panel) 
The in vivo results confirmed that the extensive mucosa destruction after laser exposure in 
animals treated with GNRs-1/Curc@PMs is ascribed to the synergistic effect of GNRs 
thermal delivery and curcumin released from the micelles. In addition, the obtained data 
suggested that curcumin’s anti-inflammatory and anti-oxidant activities could also help in 
protecting surrounding healthy tissue from laser contingent induced damages. Indeed, a 
positive effect of curcumin on radiation-induced apoptosis has been shown in human cancer 
cells.133 
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3.3.2 Magnesium nanoparticles as a highly biocompatible photothermal agent for hepatocellular carcinoma treatment  All the procedures and results about the development of photothermal nanosystems based on 
the use of magnesium nanoparticles, are completely described in:  
 
 One-pot synthesis of magnesium nanoparticles embedded in chitosan microparticles: a 
highly biocompatible tool for in vivo cancer treatment. J. Mater. Chem. B, 4, 207–211 
(2015). 
 
3.3.2.1. Synthesis of chitosan coated magnesium nanoparticles  In the last decades, magnesium nanoparticles have been investigated in order to realize high 
compatible materials for biomedical applications. In addition, recently the photothermal 
behaviour of magnesium nanoparticles has been largely investigated for hyperthermia 
applications (paragraph 1.3.3).67,68,70,71  
However, the synthesis of magnesium nanoparticles (Mg NPs) is quite challenging because of 
their high reduction potential and high affinity toward oxidation. Indeed, in order to obtain 
magnesium nanoparticles able to respond to laser irradiation, they must exhibit a dark black 
colour, corresponding to their not-oxidized form. On the other hand, the oxidized magnesium 
nanoparticle (MgO nanoparticles) show usually a white colour and are not able to absorb 
light.  Several methods for the preparation of magnesium nanoparticles have been reported in 
literature, such as electrochemical reduction,134 sonoelectrochemistry,135 infiltration of 
nanoporous carbon with molten magnesium, gas phase synthesis,136 deposition from ethereal 
solutions,137 high energy ball milling, and the gas-condensation method. 
In this project, the magnesium nanoparticles synthesis has been achieved through a fine-tuned 
method in our laboratories. This method is based on the reduction of metal salts using alkali 
metal aromatic radical anions, which allows to obtain magnesium crystals in tetrahydrofuran 
(THF) via lithium reduction of the corresponding magnesium salt exploiting naphthalene as 
an electron carrier (Scheme 14).71,138 
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Scheme 14. Schematic representation of the mechanism involves in the reduction of magnesium salts using alkali metal aromatic radical anions 
This developed process involved the dissolution of naphthalene and MgCl2 in anhydrous 
tetrahydrofuran (THF) under a constant flux of argon. After that, lithium bars were added to 
the solution and the reaction was left to react for 24 hours. After 24 hours the nanoparticles 
were centrifuged (6000 rpm) and purified by washing several times with anhydrous THF in 
order to remove lithium-naphthalene complex, LiCl by-product and unreacted MgCl2. 
In order to optimize the process a deep investigation on the reagent ratios was carried out to 
better understand the limits of the reaction. The results showed that, particles formation were 
not influenced by the amount of lithium while the naphthalene concentration is an important 
parameter since no reaction was observed when the concentration was too low. In addition, it 
has been demonstrated that the reaction time also played an important role for the magnesium 
nanoparticles synthesis. Indeed, if the reaction is stopped before than 24 hours, Mg crystals 
are not stable and may form aggregates of more than 5 mm in size.  
The described method allowed to synthetize magnesium nanoparticles highly heterogeneous 
in size and with an average diameter of about 50 nm; however, because of the absence of any 
stabilizing agent, these nanoparticles result usually aggregated in sub-micron clusters. With 
the intent to enhance the magnesium nanoparticles stability, in this project one-pot strategy to 
form chitosan coated magnesium nanoparticles has been developed by slightly modifying the 
previous described method. 
Chitosan has been selected as nanoparticles coating because is a non-toxic, biodegradable and 
biocompatible natural sugar. It is obtained as waste material by shrimps and other crustacean 
shells and its molecular structure is characterized by amino and hydroxyl groups. 
Because these functional groups are not reducible by the lithium-naphthalene complex formed 
during the reaction, chitosan molecules are able to survive to in the strong reducing reaction 
environment of the magnesium nanoparticles reaction. In addition, both amino and hydroxyl 
groups have strong affinity for the magnesium nanocrystals surface, thus chitosan may form a 
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stable linkage onto the surface of magnesium particles stabilizing them either against 
aggregation and oxidation. 
Therefore, the modified synthesis provided the introduction of chitosan-glutamate at the 
beginning of the process, simultaneously with the other reagents, thus having the coating 
agents present during the magnesium nanocrystals formation (Scheme 15).   
 
 
Scheme 15. Representative scheme of Chit–Mg MPs synthesis and photo- graphs of both powder and MPs re-dispersed in acetate buffer. 
After 24 hours, the formed chitosan coated magnesium microparticles (Chit-Mg MPs) have 
been recovered by centrifugation. Also in this case, a good purification is required in order to 
remove all the reaction by-products and in particular naphthalene and LiOH, deriving from 
the reducing agent. For this reason, Chit-Mg MPs were washed three times with THF and 
centrifuged before drying under vacuum. Finally, they can be re-dispersed in acetate buffer 
(pH 4.6) or slightly acidic water (pH 5) without visible agglomeration.  
After the accurate purification, the obtained Chit-Mg MPs have been fully characterized. 
Dynamic light scattering (DLS) of Chit-Mg MPs revealed particles with hydrodynamic 
diameter of 1.15 ± 0.07 μm and a positive surface charge of +38 mV, due to the presence of 
several protonated amino groups in the chitosan chains.  
In order to investigate size and morphology of the magnesium nanoparticles entrapped into 
the chitosan matrix, Transmission Electron Microscopy (TEM) was performed. The TEM 
images showed in Figure 59, revealed the formation of polygonal-shaped nanoparticles with a 
diameter ranging between 5 and 10 nm. By comparing these data with the results obtained 
with the methodology without the introduction of chitosan in the reaction, in this case the 
obtained magnesium nanoparticles are characterized by a smaller size.  
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Figure 59. TEM images of Chit-Mg-MPs  
These results can be ascribed to the presence of a capping agent placed directly into the 
reaction mixture, which allows an immediate stabilization of the particles and avoids their 
uncontrolled growth. Anyway, the DLS findings were in good agreement with scanning 
electron microscopy (SEM) images, which showed well homogeneous particles with 
approximately round shape and size slightly smaller than one μm (Figure 60). The difference 
between DLS and SEM results can be explained by considering the normalcy as DLS can 
only reveal hydrodynamic diameter, while SEM the effectively size.  
 
 
Figure 60. SEM images of Chit–Mg MPs after vacuum drying. Lower magnification (left side) and higher magnification (right side). 
Moreover, X-ray diffraction (XRD) analysis showed crystalline nanoparticles and the typical 
reduced-magnesium pattern (Figure 61). 
 
Figure 61. XRD analysis of Chit–Mg MPs 
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Thought the atomic absorption spectroscopy (AAS) a concentration in magnesium equal to 
589 mg/L (24.2 mM) has been determined in a solution prepared by dissolving 10 mg of 
powder in 1 mL of buffer. In addition, thermogravimetric analysis (TGA) has been carried 
out. The spectrum showed the degradation of the organic layer between 150 and 350 °C, and 
an immediate and intense weight gaining at 600 °C, when the gas flow was changed from 
nitrogen to air. These results can be due to the oxidation of the magnesium core that after the 
complete degradation of chitosan matrix becomes uncoated and prone to oxygen attack. 
 
Figure 62. TGA of Chit-Mg MPs (from r.t. to 600 °C in 60 min in nitrogen flow, then isotherm at 600 °C for 10 minutes in air) 
At the end, Fourier Transform Infrared Spectroscopy analysis confirmed the presence of the 
organic matrix onto the surface of the nanoparticles by showing the characteristic signals of 
chitosan: glycosidic linkage (–C–O–C–) at 1064 cm-1, amines and protonated amines at 
1510-1580 cm-1 and at 2800-2900 cm-1, and intermolecular bonded –OH as broad band 
between 2800 and 3000 cm-1 (Figure 63). 
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Figure 63. FTIR of Chit-Mg MPs. 
 3.3.2.1. In vitro and in vivo biological studies  
The therapeutic effect of the Chit-Mg MPs has been investigated on Hepatocellular carcinoma 
(HCC) tumour model in collaboration with the research group of the Dr. Robert Martin of the 
Division of Surgical Oncology at the University of Louisville (USA). 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and seventh in 
women worldwide, accounts for the third major cause of cancer related deaths. Despite 
advances in prevention techniques, screening, and new technologies in both diagnosis and 
treatment, incidence and mortality continue to rise. Because of the highly vascularization in 
the HCC, the angiogenesis process allows the tumour to develop, invade and metastasize, 
restraining the therapy to limited options.139 For this reason, research into new diagnostic and 
therapeutic fields for HCC offer a wide range of possibilities by trying to adapt to the 
tremendous potential and variability of the nanotechnology field.139 
In this project, the biocompatibility and the photothermal behaviour of the developed 
chitosan-magnesium microparticles (Chit-Mg MPs) have been tested through in vitro and in 
vivo biological studies.  
The photothermal behaviour has been investigated by using a NIR laser illumination able to 
trigger a temperature rise from an aqueous dispersion of Chit- Mg MPs at different 
concentration. The experiments have been conducted by using a 810 nm diode laser operating 
in continuous wave (cw) mode at 13 W cm-2. The results, shown in Figure 64 a, showed an 
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uniform and characteristic temperature profile including a temperature rise as soon as laser 
light is turned on and a fast cooling phase after switching off the laser. Particularly, after 0.5 – 
1 minute of irradiation, the temperature enhancement was enough to reach temperature values 
of interest for photothermal therapy (i.e. ∼40 to 50 °C) despite of the concentration 
considered. An exemplary map of temperature registered after 3 minutes of irradiation (at 13 
W cm-2) is displayed in Figure 64b. The picture highlights the confinement of the 
photothermal effect within the illuminated laser spot immediate outcomes include an effective 
and well-localized photothermal response that can be obtained with particle concentrations 
typically employed within the protocols of photothermal therapies. 
 
 
 
Figure 64. (a) Temperature profiles obtained by illuminating Chit–Mg MP solutions at different concentrations with a laser intensity of 13 W cm-2 and a tirr = 3 min. (b) Exemplary map of temperature registered after 3 min of irradiation of a 10 mM Chit–Mg MP solutions at 13 W cm-2.The illuminated area is displayed by a dashed line. 
After that biocompatibility of Chit-Mg MPs were assessed firstly by cell viability studies on 
hepa1-6 cell line (Figure 65). For this experiment, the cells were incubated with the Chit-Mg 
MPs particles at 48 or 72 hours in a magnesium concentration range of 0-100 μg/mL. The 
results revealed no mortality for both cells lines in this conditions, which are standard time 
points and concentrations values for evaluating the toxicity of a novel nanosystem. 
 
 
Figure 65. 3-(4,5-dimethyl-thiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT, Sigma- Aldrich) reduction assay on hepa1-6 cell lines exposed to Chit-Mg MPs at different concentration for 48 and 72 hours respectively.  
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In vivo photothermal therapy was then performed on xenograft hepa1-6 tumour bearing mice. 
For this experiment, a solution of Chit-Mg MPs at 5 mM was administrated thought an 
intratumoral injection in the animals, and after twelve hours the tumour area was illuminated 
with a near-infrared (NIR) laser irradiation of power density of 1 or 3 W/cm2 for 0.5 or 2 
minutes. The results showed that in the area subjected to photothermal therapy the most 
tumour cells were destroyed. Also, it has been demonstrated that a lower laser intensities were 
required in vivo, as compared to those employed for effective irradiation of nanoparticle 
solutions. These data can be due to the presence of an accumulation of the particles in the 
tumour site, allowing a major heat confinement. Three days after NIR exposure, the tissues 
were harvested for histological analysis. The results showed in Figure 66, clearly showed an 
extensive damage to tumour tissue after only 2 minutes of laser irradiation, while no damage 
was recorded when the tumour was treated with laser and saline alone. 
In addition, the results showed that with an intratumoral injection, the laser exposure for 0.5 
minute and 3 watt/cm2 caused cell death in the tumour instead of the benign muscle, and when 
laser exposure was increased up to 2 minutes, most tumour cells were ablated while the 
benign muscle was unaffected. 
 
 
Figure 66. Histological changes in tumour with Chit–Mg MPs and laser exposure. 
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3.4 Synthesis of multicomponent nanosystems as dual imaging and theranostic agents against cancer  
In the previous paragraphs, the therapeutic potential of metallic nanoparticles in 
nanomedicine applications has been exhaustively described. 
In this last paragraph, the investigation about the employment of metallic nanoparticles in the 
development of imaging tools will be reported. 
For this purpose, the intrinsic chemical-physic properties of different metallic nanomaterials 
have been combined by realizing multicomponent nanosystems suitable for multimodal 
imaging or theranostic agents. Among the several possible metals, iron and gold are the most 
used due to their lack of toxicity and intrinsic properties that are well suited for nanomedicine 
applications. On one hand, the well-known magnetic properties of iron oxide, make these 
nanoparticles able to realize a magnetic-guided delivery towards the target organ, on the other 
hand the optical properties of gold nanomaterials can be exploited for both imaging, such as 
the novel and non-invasive photoacoustic imaging (PAI), and for photothermal therapy 
(PTT). In according of this, in this project two different multifunctional nanomaterials based 
on the incorporation of iron oxide and gold nanoparticles in the same nanosystem, have been 
realized.  
The first systems consisted in dumbbell-like gold iron oxide nanoparticles synthetized in a 
one-step synthesis through the high temperature polyol method. In order to enhance their 
biocompatibility, the obtained nanoparticles have been coated on the surface using chitosan 
chains, previously modified by introducing thiol and catechol moieties, able to interact 
respectively with the gold and iron metallic surfaces.140 The in vitro studies, revealed the 
theranostic potential of the obtained system, that showed a photothermal behaviour and also 
capabilities as photoacoustic imaging contrast agents, due to the presence of gold 
nanoparticles. In addition, the incorporation of iron oxide nanoparticles lead the possibility to 
use these multifunctional nanomaterials in MRI-PAI dual-imaging applications. For this 
purpose, in a different work, the second multifunctional systems based on core−shell 
Fe3O4@SiO2@Au NPs have been synthetized for in vivo active targeting and MRI−PAI dual 
imaging.141 The first step of the synthesis consisted in the formation of a silica shell on 
hydrophobic iron oxide nanoparticles, achieved by using the sol−gel and Stober method. The 
silica shell thickness was controlled by adjusting the methyltriethoxysilane (MTEOS)/Fe3O4 
NPs concentration, after that (3-aminopropyl)trimethoxysilane (APTMS) was added to 
produce a positively charged amino groups onto silica surface. This allowed the 
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electrostatically coating of the gold seeds, obtained by Duff and Baiker’s method, on the 
obtained Fe3O4@SiO2 core−shell system. The formation of an entire shell of gold was 
performed by a shell growth reaction, in which gold is mildly reduced, led to the multilayered 
Fe3O4@SiO2@Au NPs. The obtained nanoparticles were modified on the surface by ligand 
exchange reaction, in which an organic ligand formed a self-assemble monolayer on the outer 
gold shell in order confer hydrophobicity properties to the nanoparticles. The obtained 
hydrophobic nanoparticles were encapsulated in PLGA-b-PEG based polymeric micelles by 
using the oil-in-water single emulsion technique. Finally, the study shows the use of PLGA-b-
PEG based polymeric micelles as delivery platform able to incorporate multifunctional 
metallic structures and also to conjugate on the surface an active targeting moiety, the folic 
acid. The in vivo studies revealed an improving of MRI and PAI signals, due to a higher 
accumulation in the tumor cells of the folic acid targeted nanosystems compared to not-
targeted. 
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3.4.1. Synthesis of Dumbbell-Like Gold-Iron Oxide Nanoparticles (dl-AuFe NPs) as multifunctional nanosystems  
All the procedures and results about the development of multifunctional nanosystems based 
on the use of dumbbell-like gold-iron oxide nanoparticles, are completely described in:  
 
 The one-step synthesis and surface functionalization of dumbbell-like gold–iron oxide 
nanoparticles: a chitosan-based nanotheranostic system. Chem. Commun. 52, 378–381 
(2015). 
 
3.4.1.1 Synthesis of dumbbell-like gold–iron oxide nanoparticles  
Nanoparticles characterized by a dumbbell-like (dl) structure consisted in two different 
functional nanoparticles in intimate contact. In this kind of materials, the interfacial 
interactions originated from electron transfer across the nanometer contact at the interface of 
these two nanoparticles can induce new property that is not present in the individual 
component. 
In this project, dumbbell-like gold–iron oxide nanoparticles (dl-Au/Fe3O4 NPs) have been 
obtained through a one-step synthesis. The reaction is based on the high temperature polyol 
method that involves the reduction of gold acetate and thermal decomposition of iron pent 
carbonyl in the presence of the reducing agent (1,2-hexadecanediol), and oleylamine (OLA) 
and oleic acid (OA) acting as the capping agents (Scheme 16). 
 
 
Scheme 16. Schematic representation of dumbbell-like gold–iron oxide nanoparticles (dl-Au/Fe3O4 NPs) synthesis 
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Briefly, the iron pentacarbonyl and gold acetate were dissolved in dibenzyl ether that 
contained surfactants oleic acid and oleylamine. Finally, 1,2-hexadecanediol was added as 
reducing agent to the reaction mixture that was left to homogenize by stirring at room 
temperature under argon atmosphere for one hour. Then, then the temperature was raised to 
250°C in 45 minutes and the reaction mixture was refluxed for 1 h to form dl-AuFe3O4 NPs. 
Subsequently, the reaction mixture was cooled to room temperature and the obtained 
hydrophobic dl-AuFe3O4 NPs were precipitated by the addition of ethanol and purified with 
centrifugation. In order to study the mechanism of the reaction, an accurate investigation on 
nucleation has been carried out through transmission electron microscopy (TEM). 
The results revealed that during the heating, the high difference in the reduction potential 
between gold and iron leads to a much faster nucleation of gold nanoparticles (Au NPs). 
Moreover, due to the presence of oleic acid, iron forms a very stable complex (presumably, 
iron oleate), which slows the iron nucleation and growth. Therefore, the fast reduction of the 
Au(III) salt enables the Au NPs to be formed first in the reaction mixture. Then, at higher 
temperatures, the presence of the Au NPs catalyses the decomposition of iron pentacarbonyl 
and, consequently, heterogeneous nucleation of iron oxide crystals occur at the surface of the 
formed gold nanoparticles. These nuclei then grow epitaxially and form dl-Au/Fe3O4 NPs.  
 
 
 
Figure 67. Reaction scheme and the TEM images showing the nucleation at a) 120°C, b) at 140°C, where arrows indicate iron oxide phase and at 250°C/1h with a c) lower and d) higher magnification, where the dashed curve indicate iron oxide phase and a solid line the Au phase. 
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In particular, the collected TEM images reported in Figure 67 a and b showed that the dark 
phase constituted by the gold nanoparticles is already form at 120 °C, instead of brighter 
phase, corresponding to iron oxide phase, that is not evident until 140°C. When the 
temperature reaches 200°C, the crystalline iron oxide material start forming as shell around 
gold core and as individual nanoparticles, leading to the formation of dl-Au/Fe3O4 NPs 
(Figure 67 c and d). In addition, the images showed that no agglomerates of the dl-Au/Fe3O4 
NPs are found, due to the steric stabilization with the surfactants agents (oleic acid and oleyl 
amine). TEM characterization allowed measuring the average size of dl-Au/Fe3O4 NPs, which 
resulted be 7 ± 1 nm. Also High-angle annular dark-field (HAADF)-STEM has been 
performed in order to analyse the interface between individual Au and Fe-oxide NPs at the 
atomic-resolution (Figure 68 a and b). The structural analysis of the corresponding crystal 
phases confirmed that the bright particle, shown on the left hand-side of the image, 
corresponds to the Au fcc structure (inorganic crystal structure database ‘‘ICSD’’ 52700) 
observed in the [101] Au zone axis. On the other hand, the crystal structure of the particle 
located on the right hand-side of the interface matches perfectly with cubic Fe3O4 with the 
inverse spinel structure (ICSD 65340), which was also observed in the [101] Fe3O4 
crystallographic projection.  
 
 
Figure 68. a) High-resolution BF-STEM image of Au and Fe-oxide NPs. The dashed contour lines discriminate the Fe-oxide particles from the support carbon film. The inset shows the corresponding composed elemental map (Au: red, Fe: green and O: blue). (b) Atomic resolution HAADF-STEM image of interface between Au and Fe3O4 particles observed in [101] zone axis. The red and blue dashed parallel lines represent the (111) lattice planes for Au and Fe3O4 crystal structure, respectively. The corresponding diffraction spots for Au and Fe3O4 phase are indicated in the FFT (inset image) by the rectangle and circle, respectively 
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3.4.1.2. Synthesis of chitosan coated dumbbell-like gold–iron oxide nanoparticles (dl-AuFe3O4@Chit)  The capping agents present on the as-synthesized dl-Au/Fe3O4 NPs enabled good steric 
stabilization in organic solvents. However, for biomedical applications nanoparticles soluble 
in water-based suspensions are required. For this reason, a chemical modification of the dl-
Au/Fe3O4 NPs surface have been performed by using specially designed chitosan chains. The 
highly biocompatible chitosan has been selected as coating agent in order to enhance 
biocompatibility and confer hydrosolubility to the obtained dl-AuFe3O4@Chit. 
However, in order to form a stable layer on the dl-Au/Fe3O4 NPs, the chitosan chains have to 
be modify by introducing functionalized moieties able to bind the nanoparticles surface, such 
as catechol groups, characterized by an high affinity for metal oxide surface, and thiol groups 
able to well interact with noble materials (paragraph 3.1.2). 
Therefore, the chitosan biopolymer was modified either with thioglycolic acid (TGA), thus 
introducing thiol groups onto its chain (chitosan-TGA), or with hydrocaffeic acid (HCA), thus 
introducing cathecol moieties (chitosan-HCA). Both reagents were linked to the amine groups 
of chitosan by the formation of an amide bond exploiting the 1-ethyl-3-(3-
dimethylaminopropyl)- carbodiimide (EDC) coupling reagent (Scheme 17).  
 
 
Scheme 17. Schematic representation of the synthesis of thiolated modified chitosan chains (Chitosan – TGA) and chatecol modified chitosan chains (Chitosan – HCA). 
The anchoring of the two modified chitosan biopolymers onto the NPs surface and 
consequently nanocarrier formation were performed using a single, one-pot step, through an 
oil-in-water emulsion technique (Scheme 18). In this process the hydrophobic dl-Au/Fe3O4 
NPs dispersed in chloroform were mixed with a water-solution containing both the modified 
chitosan chains. The two phases were emulsified with a tip probe sonicator, thus ensuring the 
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ligand exchange reaction on the dl-Au/Fe3O4 NPs surface and the formation of a stable 
nanosystem. Chitosan-TGA and chitosan-HCA alone, as well as a mixture of the two, were all 
tested in order to establish the best formation of a stable nanosystem. All the obtained 
nanosystems were easily purified by magnetic decantation taking advantage of the properties 
of iron-oxide and redispersed in water before analysis: notably, they are perfectly soluble in 
water at neutral pH (6.5–7).  
 
Scheme 18. Schematic representation of the chitosan coating formation on dl-Au/Fe3O4 NPs 
The obtained dl-AuFe3O4@Chit NPs have been completely characterized by using dynamic 
light scattering (DLS), z-potential, atomic absorption spectroscopy (AAS), thermo-
gravimetric analysis (TGA), infrared spectroscopy (IR), UV-Vis and transmission electron 
microscopy (TEM). 
The DLS results revealed that dl-Au/Fe3O4 NPs embedded in the chitosan-HCA showed a 
diameter of 140.0 nm but also a high polydispersity index (PDI of 0.560) and a poor zeta 
potential value of + 0.46 mV. On the other hand, it was not possible to synthesize dl-
Au/Fe3O4 NPs embedded only in chitosan-TGA since any attempt to do so led to the 
aggregation of the particles. The best nanosystem was obtained by the use of both chitosan-
HCA and chitosan-TGA together (50/50 w/w), which showed a diameter of 121.2 nm, a PDI 
of 0.212 and zeta potential of +37.0 mV. For this system, the high zeta potential value could 
be ascribed to the protonated amino group of chitosan, and suggested a better coating of the 
dl-Au/Fe3O4 NPs surface than Chitosan-HCA alone. The stability of this system in 
physiological medium and at various pH values was also checked, by incubating the obtained 
nanoparticles in phosphate buffered saline (PBS) at pH 7.4 for two weeks. The DLS results 
showed a slight increase of the mean hydrodynamic diameter, which moved from 120 nm to 
130–140 nm, demonstrating the stability of the particles under the tested conditions. 
Moreover, the stability of the particles at various pH values was checked by recording the 
change in the zeta potential value and diameter against pH. The results showed a good 
stability of the particles between a large interval of pH 3.5 and 9.5.  
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In particular, the dl-Au/Fe3O4 NPs modified with both chitosan-TGA and Chitosan-HCA 
(denoted from now on as dl-AuFe3O4@Chit) showed the best features in terms of size, 
polydispersity and stability, resulting from the fact that the iron and gold atoms were exposed 
on the external, reactive surface of the NPs. The presence of chitosan on the nanoparticles has 
been confirmed with the FT-IR spectrum of dl-Au/Fe3O4@Chit in which the signal of 
chitosan glycosidic linkage (–C–O–C–) appeared at 1150–1040 nm (Figure 69). 
 
 
Figure 69. FTIR analysis comparing dl-AuFe3O4 NPs and dl-AuFe3O4@Chit spectra. 
 
In addition, thermogravimetric analysis showed a typical weight loss (30.3 %) in temperature 
range between 100 and 270 °C due to the presence of chitosan on the dl-Au/Fe3O4 NPs 
surface.  AAS analysis revealed the incorporation of high payloads into the chitosan matrix 
whereas the concentration was found to be 2.8 mM in iron and 8.0 mM in gold.  
The optical properties of dl-Au/Fe3O4 NPs, before and after the formation of chitosan coating, 
have been investigated through UV-Vis spectroscopy (Figure 70). The recorded spectra 
showed the typical maximum absorption peak of gold nanoparticles at 550 nm, which 
remained unchanged after the surface functionalization. 
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Figure 70. UV-Vis spectra of dl-AuFe3O4 NPs and dl-AuFe3O4 NPs@Chit 
 
On the other hand, the magnetic properties of the chitosan-coated dl-Au/Fe3O4 NPs were 
measured using a vibrating-sample magnetometer (VSM) at room temperature (298 K) and 
are presented in Figure 71. The results showed that dl-AuFe3O4@Chit were characterized by a 
saturation magnetization value of 4.3 emu/g. This value is lower than for the pure iron oxide 
nanoparticles of similar size, which is expected due to the dilution of the magnetic phase by 
the presence of the nonmagnetic components in the sample, Au and chitosan. 
 
 
Figure 71. Magnetic properties of the dl-AuFe3O4@Chit sample. 
 
In the end, the morphology of the dl-Au/Fe3O4@Chit NPs has been investigated with TEM.  
The collected image (Figure 72) showed dl-Au/Fe3O4 NPs aggregates in an amorphous matrix 
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of chitosan. The Au and Fe3O4 NPs are shown by arrows, where AuNPs can be observed as 
objects of a dark contrast, enclosed by the relatively bright Fe-oxide. The measured size of the 
capsules was in the range of 60 to 150 nm, in good agreement with the results obtained by 
DLS. Also, no free-standing dl-Au/Fe3O4 NPs could be found, which indicates the successful 
entrapment of all NPs by the chitosan. 
 
 
Figure 72. TEM image of dl-Au/Fe3O4@Chit 
  3.4.1.3. In vitro biological studies  Once synthetized and fully characterized, the dl-AuFe3O4@Chit NPs have been tested in 
biological studies in order to investigate their potential as dual imaging and theranostic agents 
in nanomedicine applications. For this purpose, in vitro experiments have been performed in 
collaboration with the department of Molecular Biotechnology and Health Sciences, Center of 
Excellence for Preclinical Imaging (CEIP) at University of Torino. 
First of all, the photothermal heating properties of dl-AuFe3O4@Chit have been characterized 
to investigate the photothermal therapy (PTT) performance of the nanocomposite. The 
experiment consisted in the formation of aqueous solution in which dl-AuFe3O4@Chit NPs 
have been dissolved at different concentrations (8 mM, 4 mM, and 0.4 mM in gold). 
The obtained solution were irradiated for one minute under three different laser intensities (15 
W/cm2, 5W/cm2 and 1 W/cm2) by using a near-infrared fiber coupled diode laser, with a 
central wavelength of the output radiation is 808 nm and the maximum output power is 25 W.  
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Figure 73. DeltaT induced after irradiation at different laser intensity and gold concentration 
 
The results, shown in Figure 73, demonstrated the decrease of the gold concentrations and the 
laser intensity, led to a decrease of the induced temperature variations. However, the 
photothermal response still remained detectable up to a concentration of 0.4 mM in gold, with 
DeltaT of a few degrees. On the other hand, the highest concentration of gold (8 mM) 
irradiated with 15 W/cm2 caused the highest DeltaT, which almost reaches 60 °C, bringing the 
solution at 85 °C, almost up to the boiling point. These conditions are obviously not necessary 
for future PTT, where DeltaT of only 5–10 °C is generally requested.  
By using a thermocamera, images representing the temperature increase before and after the 
laser irradiation with 5W/cm2 intensity have been collected (Figure 74). 
 
 
Figure 74. Images taken with the thermocamera before and after laser irradiation 
 
After that, photoacoustic imaging analyses were carried out to determine the PA 
characteristics of the dl-AuFe3O4@Chit NPs. For this purpose, in vitro tests have been 
performed to establish the minimum signal intensity threshold exerted by the nanoparticles as 
detected by the PA system. However, the maximum absorption peak of dl-AuFe3O4 NPs is at 
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550 nm, the irradiation was carried out at 680 nm since it could be more suitable for the future 
in vivo biomedical applications.  
 
 
Figure 75. PA intensity signal recorded at 680 nm for dl-AuFe3O4@Chit solutions at different concentrations. 
 As shown in Figure 75, samples with a gold concentration in the range of 8.0 mM to 4.9 mM 
produced signals suitable for PA analyses after an irradiation at 680 nm. Therefore, the 
collected data suggested that a combination of PTT and PAI imaging of dl-AuFe3O4@Chit 
nanocomposites is possible at a concentration of gold around 4 and 5 mM.  
On the other hand, further in vitro studies revealed that the magnetic properties of iron oxide 
nanoparticles constituted the dl-AuFe3O4@Chit were not able to reduce the transversal 
relaxation time (T2) enough to produce a contrast signal suitable for MRI applications. 
This phenomenon can be ascribed to the low saturation magnetization value (4.3 emu/g, 
Figure 71) caused by the dilution of the magnetic phase by the presence of the nonmagnetic 
components in the sample, gold and chitosan. 
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3.4.2. Synthesis of a novel magnetic resonance−photoacoustic dual imaging nanosystem based on core−shell Fe3O4@SiO2@Au NPs   
All the procedures and results about the development of multifunctional nanosystems based 
on the use of Core−Shell Fe3O4@SiO2@Au nanoparticles, are completely described in:  
 
 Synthesis of Lipophilic Core−Shell Fe3O4@SiO2@Au Nanoparticles and Polymeric 
Entrapment into Nanomicelles: A Novel Nanosystem for in Vivo Active Targeting 
and Magnetic Resonance−Photoacoustic Dual Imaging; Bioconjugate Chem. 2017, 28, 
1382−1390 
 
 
3.4.2.1 Synthesis of core−shell iron oxide−silica−gold nanoparticles (Fe3O4@SiO2@Au NPs)  
Iron oxide nanoparticles (Fe3O4 NPs) have been synthetized by following the reported in 
literature by Sun et al.,142 based on the thermal decomposition method. In this method, the use 
of high temperature for the synthesis of magnetic nanoparticles allows a good control of their 
dimensions, leading to obtain nanoparticles characterized by small dimension and a good low 
saturation magnetization value, a fundamental requirement for achieving magnetic properties 
suitable in MRI. The reaction involved the dissolution of iron (III) acetylacetonate in diphenyl 
ether in presence of surfactant agents, oleic acid and oleylamine, and 1-2 hexadecanediol, as 
reducing agent.  The mixture was heated to reflux (267°C) for 60 minutes under nitrogen 
atmosphere, to prevent unwanted oxidation. The reaction was then cooled down to room 
temperature and the formed Fe3O4 NPs were purified by magnetic precipitation with excess of 
cold ethanol, in order to remove the excess of surfactant agents. The surfactant agents used in 
the synthesis conferred hydrophobic properties to Fe3O4 NPs, making them soluble only in 
organic solvents. The morphology of synthetized nanoparticles were investigated through the 
transmission electron microscopy (TEM), showing Fe3O4 NPs characterized by an average 
diameter of 7 nm (Figure 76). 
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Figure 76. TEM image of Fe3O4 NPs 
Once synthesized, a silica shell has been formed on Fe3O4 nanoparticles surface in order to 
confer them hydrophilic properties and enhance their stability.  
For this purpose, a reaction process based on the reverse microemulsion method and the 
Stӧber method (paragraph 1.5.2) has been fine-tuned. The reverse microemulsion method 
has been used in the first step, which consisted in the entrapment of hydrophobic Fe3O4 NPs 
into micelles constituted of cetyltrimethylammonium bromide (CTAB), a surfactant agent.  
The micelles were formed thought oil-in-water technique. Briefly, a biphasic solution has 
been formed by adding an organic phase (Fe3O4 NPs dispersed in hexane) to a water phase, 
containing CTAB, in a volume ratio respectively of 1 to 10. The formed solution has been 
emulsioned though a tip-probe sonicator, until obtaining a homogenous phase. After that, the 
organic solvent has been removed by warming the obtained emulsion at 60°C for 30 minutes. 
Once formed the Fe3O4/CTAB micelles, the silica shell has been formed on the micelles 
surface by using Stӧber method with slightly modifications. This reaction involved two 
consecutive reactions that essentially govern the growth of silica shell. The first step consisted 
in the hydrolysis of methyltriethoxysilane (MTEOS) in aqueous solution containing the 
Fe3O4/CTAB and a basic pH, due the addiction of a small amount of ammonium solution 
(28% NH3 in water) (Scheme 19).  The alkaline environment catalysed the hydrolysis 
between the methoxyl groups (-Si-OMe) of MTEOS monomers and the silanol groups (-Si-
OH) of other MTEO monomers, leading to the formation of a silica shell on the micelles 
surface. By adjusting the ratio between the silica precursor (methyltriethoxysilane, MTEOS) 
and the Fe3O4 NPs concentration, it is possible to control the thickness of a silica shell. 
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Scheme 19. Representative scheme of Fe3O4@SiO2 NPs synthesis 
 
In the second step, 3-aminopropyl-methoxysilane (APTMS) has been added to the reaction 
mixture, taking place in the hydrolysis reaction led to the formation of a silica-shell 
characterized by amino group on the surface (Scheme 19).  The reaction was left under 
magnetic stirring for 3 days at 30°C. After that, Fe3O4@SiO2 NPs were purified by 
centrifugation (6000 rpm) in water for one hour, and the collected precipitate has been washed 
twice with clean water. Because of the cytotoxicity of CTAB, the obtained Fe3O4@SiO2 NPs 
were stirred for 30 minutes in a mixture of ethanol and acetic acid 95/5 (v/v) in order to 
remove the surfactant molecules from the formed micelles. Indeed, once hydrolysis reactions 
of the silica precursors occurred on the Fe3O4/CTAB micelles, the CTAB molecules were not 
necessary to maintain the nanoparticles structure and can be removed without affecting the 
stability of the nanosystem.  
 
 
Figure 77. (a) TEM image of Fe3O4@SiO2 (scale bar 100 nm) and (b) Fe3O4@SiO2 NPs (scale bar 500 nm). 
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Once removed the CTAB, the Fe3O4@SiO2 were further purified though centrifugation, by 
washing several times the collected precipitate with water and ethanol. Then the Fe3O4@SiO2 
NPs morphology has been investigated with transmission electron microscopy (TEM, Figure 
77). TEM images, shown in Figure 77, confirmed the obtainment of Fe3O4@SiO2 NPs, 
characterized by an average diameter of 100 nm and a silica shell thickness about 20 nm.  
On the other hand, dynamic light scattering analysis performed on Fe3O4@SiO2 NPs, 
revealing a hydrodynamic diameter of 180 ± 3 nm and a Zeta potential of +25 mV.  As 
expected, the use of APTMS in the core-shell nanoparticles synthesis allowed obtaining 
Fe3O4@SiO2 characterized by amino groups on the surface, which make them a positive zeta 
potential. This feature assumed great importance in the formation of gold shell on the 
synthetized Fe3O4@SiO2 NPs surface. Indeed, this step involved the electrostatically coating 
formation of negatively charged gold seeds (small gold NPs of 1−3 nm in size) on the positive 
charged Fe3O4@SiO2 NPs surface. The gold seed were synthetized with the Duff and Baiker’s 
method, consisting in the reduction of chloroauric acid (HAuCl4) with tetrakis-
(hydroxymethyl)-phosphonium chloride (THPC).143 After the coating of Fe3O4@SiO2 NPs 
surface with the gold seeds, the formation of an entire shell of gold have been formed thought 
shell growth reaction, in which gold was mildly reduced, leading to the multilayered 
Fe3O4@SiO2@Au NPs (Scheme 20).   
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Scheme 20. Representative scheme of the gold shell formation on of Fe3O4@SiO2@Au NPs 
 
The obtained particles were fully characterized by dynamic light scattering (DLS) and showed 
a hydrodynamic diameter of 222 ± 1.5 nm with a PDI of 0.251 ± 0.4 and a Zeta potential of 
−32 mV. In the meantime, TEM images confirmed the successful of gold shell formation 
indicated by the black spots formed on Fe3O4@SiO2 NPs surface (Figure 80).  
The different results obtained by DLS and TEM characterizations for both Fe3O4@SiO2 NPs 
and Fe3O4@SiO2@Au NPs, can be ascribed to the difference between the hydrodynamic 
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diameter of the nanoparticles dissolved in water and their real size, but also to a slight particle 
aggregation due to the lacking of a steric stabilizer on their surface.  
Energy-dispersive X-ray spectroscopy (EDX) mapping analysis showed a typical profile of 
core-shell systems, confirmed the presence of the three different shells with iron in the core, 
silica in the middle, and gold onto the surface (Figure 78). Metal concentrations were 
calculated through atomic absorption analysis (AAS), revealing an iron and gold 
concentration of 4.1 and 12.3 mM, respectively.  
 
 
Figure 78. EDX mapping of Fe3O4@SiO2@Au NPs.   3.4.2.2 Surface modification Fe3O4@SiO2@Au NPs and entrapment into polymeric nanoparticles  The lacking of a steric stabilizer on the surface Fe3O4@SiO2@Au NPs make them inclined to 
form aggregates. In order to improve their stability, a self-assembled monolayer (SAM) has 
been formed on the core-shell nanosystems by using the organic molecule ethyl 11-(4- 
mercaptobenzamido)undecanoate (ligand 1) (paragraph 3.1.1). 
The SAM has been performed through the ligand exchange reaction; briefly, an organic 
solution, obtained by dissolving the ligand 1 in ethanol, has been added to a water solution 
containing the Fe3O4@SiO2@Au NPs. The reaction mixture has been stirred at room 
temperature for 12 hours. After this time, the Fe3O4@SiO2@Au-1 have been purified with 
centrifugation method, by washing the precipitate with ethanol (2 times). The obtained 
Fe3O4@SiO2@Au-1 exhibited a good solubility in the most common organic solvents, 
especially chloroform and dichloromethane, as demonstration of the successful of the ligand 
exchange reaction, which was further confirmed by thermogravimetric analysis.  
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Figure 79. Self Assembled Monolayer of ligand 1 on Fe3O4@SiO2@Au NPs 
 
In order to confer stability in biological environment, the Fe3O4@SiO2@Au-1 have been 
entrapped in polymeric micelles by using the oil-in-water technique.  
For this purpose, the well-known poly(lactic-co-glycolic)−block−polyethylene glycol 
(PLGA−b− PEG) has been selected. In particular, in this case, PLGA−b−PEG−NH2 was used 
due to the amino functional groups required for the subsequent surface functionalization with 
the active targeting (paragraph 3.1.3). 
For the synthesis of the Fe3O4@SiO2@Au@PMs, the procedure consisted in the dissolution 
of PLGA-b-PEG-NH2 into chloroform solution containing Fe3O4@SiO2@Au-1. Once 
prepared the organic solution, an aqueous phase containing a surfactant (sodium cholate) was 
then slowly added on the top of this, led to the formation of a biphasic solution that underwent 
to sonication with a trip probe sonicator in order to furnish the necessary energy to the system 
for the self-assembling process.  After a short time (1-2 minutes), the two phases resulted 
completely mixed, and the polymeric micelles have been obtained. The organic solvent 
remained entrapped in the lipophilic core was removed by evaporation under vacuum and the 
resulting aqueous solution was purified with centrifuge in order to eliminate the small un-
reacted molecules. The DLS characterization of the Fe3O4@SiO2@Au@PMs particles 
indicated a hydrodynamic diameter of 157 ± 0.4 nm, a PDI value of 0.300 ± 0.3, and a zeta 
potential of -14 mV, while TEM analysis showed the maintenance of the nanoparticles 
morphology and their confinement into an organic matrix (Figure 79).  
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Figure 80. TEM image of Fe3O4@SiO2@Au@PMs (scale bar 100 nm). 
In addition, UV−vis analysis confirmed that the optical proprieties of gold were retained after 
polymeric entrapment (Figures 81). 
In the last preparative step, an active-targeting vector has been chemically conjugated on 
Fe3O4@SiO2@Au@PMs surface. For this purpose, folic acid (FA) was chosen as targeting 
agent due to its high affinity to the folate receptor, which is a membrane-anchored protein 
over-expressed on many cancer cells. The conjugation of folic acid was pursued upon the 
activation of its carboxylic group thought EDC Chemistry, making it suitable for the reaction 
with the amine groups at the polymeric nanoparticles surface (Scheme 21). The so-obtained 
Fe3O4@SiO2@Au@PMs−FA were purified and characterized by DLS, atomic absorption 
spectroscopy (AAS), and UV−vis. DLS analysis showed that the conjugation with FA did not 
significantly affect the diameter of the particles (165 ± 0.3 versus 157 ± 0.4 nm) as well as the 
polydispersion index that was unchanged. 
 
 
Figure 81. UV-Vis characterization of Fe3O4@SiO2@Au@PMs-FA 
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As expected, the Zeta potential of the FA-conjugated particles decreased (from −14 to −23 
mV) due to the free carboxylate group on the FA molecule. AAS analysis indicated that the 
amount of iron and gold in the micelles was 0.1 and 1.2 mM, respectively.  
 
 
Scheme 21. Representation of the entrapment of hydrophobic core-shell Fe3O4@SiO2@Au-1 into polymeric micelles. 
 
3.4.2.3. In vitro and in vivo biological studies  
Photoacoustic imaging (PAI) represents an emerging diagnostic method with non-invasive 
and non-ionizing properties with ease of applicability in clinical setups (paragraph 1.4.1). 
The combination of magnetic resonance imaging (MRI) with PAI, can offer some mutual 
benefits, like the possibility to detect the multimodal nanoparticles overcoming the depth and 
resolution limits of PAI and improving the relatively poor sensitivity of MRI in contrast agent 
detection (paragraph 1.4.4). MRI−PAI dual detectable nanoparticles are of particular interest 
in the theranostic field. For this reason, the potential as bimodal MRI−PAI agent of the so-
obtained Fe3O4@SiO2@Au@PMs-FA and the targetable ability of folic acid has been 
investigated through in vitro and in vivo biological experiments. 
The in vitro studies have been carried out in collaboration with the Institute for Maternal and 
Child Health- IRCCS “Burlo Garofolo” at Trieste (Italy). In order to assess the 
biocompatibility of the developed nanosystems, cytotoxicity assays have been carried out on 
two human carcinoma cell lines characterized by a high expression of folate receptors 
(ovarian (IGROV) and cervical (HeLa) carcinomas) and a healthy cell line of primary human 
fibroblasts. The results revealed that the Fe3O4@SiO2@Au@PMs−FA did not show any 
significant cytotoxicity to HeLa cells at different nanoparticles concentrations (0.5, 2.5, 5, and 
10 μg/mL) after 24 hours. However, IGROV cells were shown to be more sensitive than HeLa 
cells, and, upon increasing nanoparticles concentration above 5 μg/mL, a modest statistically 
significant decrease was noticed in the relative cell viability. On the other hand, fibroblasts 
(HFs) were found to be more sensitive to Fe3O4@SiO2@Au@PMs−FA (Figure 82). 
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Figure 82. In vitro cytotoxicity of nanoparticles at different concentration on IGROV, HeLa, and HF cells after incubation for 24 h. Note that cell viability was evaluated by MTT assay. Results are expressed as means ± SD of experiments performed in triplicate. Significance: *, p < 0.05 and **, p < 0.01. Abbreviations: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide; HF, human fibroblast. 
 
In order to study the targetable ability of folic acid, cellular uptake has been investigated 
through the fluorescent microscopy. For this purpose, a fluorescein dye (fluorescein-NHS) has 
been linked on Fe3O4@SiO2@Au@PMs, in order to trace the nanoparticles in the cells with 
fluorescent microscopy. Figure 83 shows fluorescence images of IGROV cells after 
incubation in media containing 10 μg/mL of Fe3O4@SiO2@Au@PMs−FA/fluo. It can be seen 
that green fluorescence appears to be localized inside the cell, suggesting that the cells are 
effective in taking up Fe3O4@SiO2@Au@PMs−FA (Figure 83). 
 
 
Figure 83. IGROV cells were incubated with Fe3O4@SiO2@Au@PMs−FA (10 μg/mL) at 37 °Cfor 24 h to allow nanoparticle cell internalization before microscopy analysis. Representative cell images are shown. DAPI and Alexa Fluor 350 staining were carried out to visualize nuclei and cell membranes, which appear in blue, while fluorescein-labeled nanoparticles appear in green. (a) DAPI and Alexa Fluor 350 staining; (b) green fluorescence emission; (c) merged images (bar: 20 μm). 
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After that, Fe3O4@SiO2@Au@PMs-FA have been tested in vivo as MRI and PAI agents in 
collaboration with Molecular and Preclinical Imaging Centers at the Department of Molecular 
Biotechnology and Healthy Sciences of the University of Torino.  
First, MRI in vivo experiments were carried out by administrating through intravenous 
injection the Fe3O4@SiO2@Au@PMs and its folate-targeted form, in mice bearing the 
IGROV subcutaneous xenograft. Then, T2w MR images were acquired before (pre) and 1, 4, 
and 24 h after the treatment at a magnetic field strength of 1 ton. 
MR images were analysed to calculate the relative signal intensity (rSI) in liver, spleen, 
kidneys, and tumour according to the following equation: 
 
r = SI(organ) - SI(muscle) / SI(organ) + SI(muscle) 
 
where SI(organ) is the average value obtained from three measurements of each organ, and 
SI(muscle) is the corresponding value measured on the paraspinal muscle.  
Next, the percent signal intensity reduction was calculated by comparing the rSI(organ) before 
and after the injection of the agents.  
The results reported in Figure 84, showed the T2w MR images acquired before and after the 
treatments, revealing that the targeted nanoparticles induced a tumour contrast signal that 
reached the maximum value 4 hours post-injection. In particular, the fraction of contrast-
enhanced pixels in the tumour 4 hours after the nanoparticles injection was almost three-fold 
higher for Fe3O4@SiO2@Au@PMs−FA than the control system (27.5% versus 10%).  
 
Figure 84. T2w MR images acquired at 1T before, and 1 h, 4 h and 24h after the intravenous injection of Fe3O4@SiO2@Au@PMs-FA (upper panel) or Fe3O4@SiO2@Au@PMs (lower panel) at the dose of 0.17 mg Fe/kg bw. The orange-coloured spots correspond to the pixels with a statistically significant T2 contrast enhancement. 
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On the other hand, PAI in vivo experiments have been performed by injecting NPs 
systemically in the tail vein of the tumour-bearing mice at a gold concentration of 8.0 mg 
Au/kg. PA images of the tumour upon excitation at 860 nm were acquired 4 hours post-
injection, when the particles showed the maximum MRI T2 contrast. The results confirmed 
the targetable ability of folic acid, showing the increased accumulation of the FA-targeted 
system in the tumour lesion 4 hours after their injection (Figure 85). 
 
Figure 85. Representative PA (upper) and US (lower) images of the tumour xenograft acquired before (pre) and 
4 h after the injection of Fe3O4@SiO2@Au@PMs-FA. PA excitation wavelength was set at 860 nm. 
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4. Conclusions  
In conclusion, the progresses in nanotechnology led to the different challenges and 
opportunities in nanomedicine.  
In this project, the potential of polymeric nanoparticles as drug delivery systems have been 
deeply investigated. The biocompatibility and biodegradability of PLGA-b-PEG allowed the 
formations of polymeric nanoparticles or nanomicelles characterized by morphological 
properties suitable for drug delivery applications. In addition, the possibility to encapsulate 
lipophilic and/or hydrophilic agents into the inner core of the formed polymeric nanoparticles, 
led to the development of multifunctional nanosystems able to deliver in vivo therapeutics to 
tumours when conjugated to speciﬁc targeting agents. 
Taking advantages of these properties, PLGA-b-PEG based nanoparticles have been studied 
as drug delivery systems in the treatment of glioblastoma multiforme. As reported in the 
previous paragraphs, the conjugation of chlorotoxin peptide as active targeting on the 
developed polymeric nanoparticles provide the proof-of-concept of the therapeutic validity of 
a combination strategy based on radiation therapy and chlorotoxin-targeted polymeric 
nanovectors. 
In addition, the entrapment of chemotherapy drug in polymeric nanoparticles can achieve its 
antitumor efficacy enhancement, as demonstrated with the very promising but low water-
soluble drug NVP-BEZ235. Indeed, after the encapsulation of NVP-BEZ235 in polymeric 
nanoparticles, the obtained systems (NVP-BEZ235@PNPs) showed a strongly enhancement 
of its bioavailability with a 1000-fold augmented cytotoxicity as compared to the free drug. 
Once synthetized, NVP-BEZ235@PNPs have been functionalized on the surface with the 
Gint4.T aptamer, able to speciﬁcally recognize platelet-derived growth factor receptor β 
overexpressed on the blood-brain-barrier (BBB) and to cross the BBB after the interaction 
with these receptors. The results showed the ability of the developed nanovectors to 
speciﬁcally target GBM tumours and demonstrated for the ﬁrst time the in vivo speciﬁc GBM 
tumour uptake on orthotopic cancer-bearing mice after intravenously administration.  
Simultaneously with the investigation of the potential of polymeric nanoparticles as drug 
delivery systems, a deep investigation on the fascinating features of metallic nanoparticles 
have been carried out in order to develop novel multimodality imaging tools and theranostic 
systems for nanomedicine applications.  
Accordingly, several kinds of metallic nanoparticles have been successfully designed, 
synthetized, modified on the surface and characterized, such as silver nanoparticles, gold 
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nanorods, iron oxide nanoparticles, magnesium nanoparticles, and also multifunctional 
nanomaterials as dumbbell-like gold iron oxide nanoparticles and iron-gold core-shell systems 
have been obtained as well. In addition, taking advantage of the features of the developed 
nanomaterials, different diagnostic techniques have been investigated in order to find the 
suitable field of nanomedicine applications. 
Optical properties of gold nanomaterials have been employed for the development of 
photothermal therapy agents as well as photoacoustic imaging contrast agents.  For this 
purpose, one pot-synthesis of chitosan coated magnesium nanoparticle has been fine-tuned in 
order to obtain nanoparticles characterized by high biocompatibility and unexpected 
photothermal behaviour. Also, gold nanorods have been investigated as photothermal agents 
showed the possibility to easily deliver and irradiate the only nanosystem in the site of interest 
giving promising results in terms of destruction of tumour tissue without affecting 
surrounding healthy. 
At the end, the good results achieved by using polymeric nanoparticles as drug delivery 
systems together with the potential of metallic nanoparticles as diagnostic tools, led to the 
development of iron/silica/gold core−shell nanoparticles and their subsequent surface 
functionalization and entrapment into polymeric micelles. The developed systems showed 
great potential as PAI/MRI dual imaging agents in the treatment of ovarian cancer using folic 
acid targeting agent in vivo on tumour-bearing mice. 
In some of the mentioned papers, we demonstrated the advantages that can be achieved 
through the well-fashioned, highly selective and specifically designed surface chemistry 
modifications of these nanostructures. The in vitro and in vivo biological assessments revealed 
the potential in nanomedicine applications of the realized nanosystems and encouraged to 
carry on the aim of this research. By improving the knowledge of tumour biology, it will be 
possible to develop drug delivery and theranostic systems able to overcome big biological 
hindrances and to deal with crucial biological mechanism in order to improve efficacy of 
current therapies. 
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5. Experimental section  5.1 Synthesis of ethyl 12-(4-mercaptobenzamido)dodecanoate (ligand 1)    
5.1.1 Synthesis of 4,4’-disulfanediyldibenzoic acid   
 
 
To a stirred solution of 4-mercaptobenzoic acid (1.00 g, 6.48 mmol) in ethanol (20 mL) a 
saturated solution of iodine in ethanol (3.35 mL) was added drop wise. The reaction was left 
to react for 3 hours at room temperature then the precipitate was filtered and washed with cold 
ethanol (3 x10 mL). 0.87 g (yield 87%) of product were recovered in the form of a white 
powder.  
 
Data:  
 
m.p.: 346 - 348 °C;  
 
1H NMR  (300 MHz, DMSO-d6): δ= 13.0 (bs, 2H), 8.0 (d, 2H), 7.7 (d, 2H) ppm; 
 
13C NMR (75 MHz, DMSO-d6): δ= 166.6, 140.8, 130.3, 129.7, 126.1 ppm; 
 
GC-MS ESI : ES- 305 (M -1). 
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5.1.2 Synthesis of ethyl 11-aminododecanoate   
 
 
To a suspension of 12-aminododecanoic acid (3.0 g, 13.2 mmol) in ethanol (50 mL) was 
added slowly concentrate sulfuric acid (0.8 mL). The mixture was refluxed for 18 h, cooled to 
room temperature, and the solvent was evaporated under reduced pressure. The crude was 
suspended in ethyl acetate (200 mL), washed with 1 M ammonia aqueous solution (3 x 50 
mL). The organic layer was dried over MgSO4 and evaporated to yield 3.2 g (98 %) of 
product as a white solid.  
 
Data:  
m.p. = 56-58 °C;  
 
1H NMR (300 MHz, DMSO-d6): δ= 1.15 (t, 3H), 1.22 (s, 12H), 1.31 (bs, 2H), 1.48 (bs, 2H), 
2.24 (bs, 2H), 2.86 (d, 2H), 4.02 (q, 2H) ppm; 
 
13C NMR (75 MHz, CDCl3): δ= 173.8, 60.0, 41.3, 34.3, 29.4, 29.3, 29.2, 29.1, 26.8, 24.9, 
14.2 ppm; 
 
GC-MS ESI: 244 (M+1). 
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5.1.3 Synthesis of bis-ethyl 11-(4-benzamido)dodecanoatedisulfide   
 
 
To a stirred solution, of 4,4’-disulfanediyldibenzoic acid (1.8 g, 2.47 mmol) under nitrogen, 
in25 mL of anhydrous THF, N,N’-carbonyldiimidazole (595 mg, 3.70 mmol) was slowly 
added. The reaction was stirred for one hour at room temperature and then ethyl 11-
aminododecanoate (1.13 g, 4.94 mmol) in 5 mL of anhydrous THF were added. The reaction 
mixture was stirred for additional 3 hours at room temperature, then the solvent was removed 
under reduced pressure and EtOAc (10 mL) was added. The solution was washed three times 
(3x10 mL) with water and the organic layer was dried over MgSO4 and dried giving 2.31 g 
(78.8%) of product as a white solid.  
 
Data:  
 
m.p. = 145-146 °C;  
 
 
1H NMR  (300 MHz, CDCl3): δ= 7.65 (d, 4H), 7.42 (d, 4H), 6.57 (bs, 2H), 4.09 (q, 4H), 3.35 
(m, 4H), 2.24 (t, 4H), 1.56 (m, 8H), 1.37-1.19 (m, 30H) ppm; 
 
13C NMR (75 MHz, CDCl3): δ= 173.9, 166.6, 140.0, 133.6, 127.7, 126.6, 60.1, 40.1, 34.3, 
29.6, 29.4, 29.3, 29.2, 29.2, 29.0, 26.9, 24.9, 14.2 ppm; 
 
MS: 751 [M+Na]+ 
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5.1.4 Synthesis of ethyl 12-(4-mercaptobenzamido)dodecanoate (ligand 1)   
 
 
After cooling at 0°C, to a stirred suspension of bis-ethyl 11-(4-
benzamido)dodecanoatedisulfide (0.91 g, 1.2 mmol) in a mixture of ethanol/THF (1:1, 50 
mL)was added slowly NaBH4 (0.17 g, 4.4 mmol). After complete addition, the mixture was 
allowed toreach room temperature and react for 4 h. Afterwards, the solvents were evaporated 
under reduced pressure and the crude was suspended in ethyl acetate (40 mL), washed with 
diluted HCl aqueous solution (0.1 M, 3x15 mL) and water (3x15 mL). The organic layer was 
dried over MgSO4, evaporated to yield 0.79 g (87 %) of compound 1 as a white solid.  
 
Data:  
 
m.p. = 86-87 °C;  
 
1H NMR  (300 MHz, CDCl3): δ= 7.61 (d, 2H), 7.26 (d, 2H), 6.25 (bs, 1H), 4.10 (q, 2H), 3.56 
(s, 1H), 3.40 (m, 2H), 2.27 (t, 2H), 1.58 (m, 4H), 1.36-1.21 (m, 15H) ppm; 
 
13C NMR (75 MHz, CDCl3): δ= 173.8, 166.7, 135.7, 131.7, 128.4, 127.6, 60.1, 40.0, 34.3, 
29.5, 29.3, 29.2, 29.2, 29.1, 29.0, 26.9, 24.9, 14.2 ppm; 
 
MS: 388 [M+Na]+ 
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5.2 Synthesis of poly(lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymers   
 
5.2.1 Synthesis of PLGA-b-PEG-NH2   
 
 
PLGA–COOH (0.5 g, 0.071 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL) 
followed by addition of 1,1'-Carbonyldiimidazole (CDI, 0.011 g, 0.071 mmol). After 2 h, 
H2N-PEG-NH2 dissolved in 5 mL of anhydrous tetrahydrofuran ( 0.857 g, 0.285 mmol) has 
been added to the reaction dropwise.  
After 16 h the tetrahydrofuran has been evaporated and the obtained with solid has been 
dissolved in a small amount of methanol (MeOH, 3 x 10 mL) and precipitated by adding cold 
diethyl ether (3 x 20 mL) in order to remove the un-reacted products. The resulting white 
solid PLGA-b-PEG-NH2 (0,554 g, 0,055 mmol) was dried under vacuum and stored at -20 °C, 
where it is stable for more than one year 
 
Data 
 
1H-NMR (300 MHz, CDCl3): δ= 5.28-5.10 (m, 1H), 4.92-4.70 (m, 4H), 3.64 (s, 2H), 1.62-
1.50 (d, 3H).    
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5.2.2 Synthesis of PLGA-NHS   
 
 
 
Poly(D,L-lactide–co–glycolide) (PLGA–COOH, 3 g, 0.43 mmol) and N-
hydroxysuccinimide(NHS, 0.20 g, 1.7 mmol) were dissolved in dichloromethane (15 mL). 
After cooling at 0°C N,N′-dicyclohexylcarbodiimide (DCC, 0.38 mg, 1.8 mmol) was added 
and the mixture was left to warm up at room temperature and react for 24 h. Afterwards, 
dicyclohexylurea (DCU) was removed by filtration and PLGA–NHS was precipitated with 
cold diethylether (20 mL), and repeatedly washed with the same solvent (3 x 10 mL). After 
drying, the resulted white solid PLGA-NHS (2.91 g, 0.42 mmol) was collected. The product 
could be stock at -20 °C for no more than one week.  
 
Data  
 
1H-NMR (300 MHz, CDCl3): δ = 5.11-5.31 (m, 1H), 4.63-4.92 (2H, m), 1.50-1.61 (m, 3H). 
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5.2.3 Synthesis of PLGA-b-PEG-COOH   
 
 
PLGA–NHS (2.91 g, 0.42 mmol) was dissolved in chloroform (20 mL) followed by addition 
of NH2-PEG-COOH (1.24 g, 0.42 mmol) and N,N-diisopropylethylamine (0.21 mL, 1.20 
mmol). After 24 h the copolymer was precipitated withcold diethyl ether (30 mL) and washed 
with the same solvent (3 x 10 mL) and cold water (3 x 20 mL) in order to remove the un-
reacted products. The resulting white solid PLGA-b-PEG-COOH (3.36 g, 0.33 mmol) was 
dried under vacuum and stored at -20 °C, where it is stable for more than one year.  
 
Data  
 
1H-NMR (300 MHz, CDCl3): δ = 5.11-5.31 (1H, m), 4.63-4.92 (4H, m), 3.63 (s, 2H), 1.50-
1.61 (m, 3H). 
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5.3 Synthesis of modified chitosan chains  5.3.1 Synthesis of Chitosan-Thioglycolic Acid (Chitosan-TGA)   
 
 
 
Chitosan glutamate (β(1›4) linked N-acetyl-D-glucosamine and D-glucosamine glutamate, 
MW ~ 50 ÷ 150 kDa, DD = 75 ÷ 90 %) (200 mg) has been dissolved in 20 mL of 1% v/v 
CH3COOH solution. After the complete dissolution, 200 µL of TGA (thioglycolic acid, 70% 
in H2O) has been added under moderate magnetic stirring. Then, N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (50 mg) has been added to the 
reaction mixture. The reaction was allowed to take place by stirring at room temperature for 6 
h. Purification of the thiolated product was performed by overnight dialysis against ultrapure 
water (cutoff 3.5 kDa). The final volume of product solution was 22.5 mL).    
 
Data 
1H-NMR (600 MHz, D2O): δ = 4.0- 3.80 (3H, m), 3.8-3.6 (m, 2H), 3.20 (s,2H), 3.2-3.1 (m, 
1H), 2.08 (m, NHAc). 
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5.3.2 Synthesis of Chitosan- Hydrocaffeic Acid (Chitosan-HCA)  
 
 
Hydrocaffeic acid (1.180 g) and N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC, 1866.2 mg) were dissolved in 50 mL of deionized water/ethanol mixture 
(1:1, v/v). This solution was slowly added to a stirred solution (100 mL, pH 5.5) containing 1 
g of chitosan glutamate (β(1›4) linked N-acetyl-D-glucosamine and D-glucosamine 
glutamate, MW ~ 50 ÷ 150 kDa, DD = 75 ÷ 90 %) and reacted for 12 h.  
The solution pH was maintained at 5.5 to avoid irreversible oxidation of catechol group of 
hydrocaffeic acid. The resultant chitosan-HCA conjugate has been purified by extensive 
dialysis against ultrapure water (pH 5.0) for 2 days (Mw cutoff of 3.5 kDa) and then 
lyophilized.  
 
Data 
1H-NMR (400 MHz, D2O): δ = 6.5-6.9 (3H, m), 4.0- 3.80 (3H, m), 3.8-3.6 (m, 2H), 3.2-3.1 
(m, 1H), 2.08 (m, NHAc). 
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5.4 Synthesis of chlorotoxin functionalized polymeric nanovectors for the treatment of Glioblastoma Multiforme in a combined approach with radiation therapy  
5.4.1 Synthesis of AgNPs  
 
A glucose solution (2 mL, 1.11 M) and NaOH (125 mg, 3.13 mmol) were added under 
vigorous magnetic stirring to a solution of polyvinylpyrrolidone k25 (PVP, 1.38 g, 0.055 
mmol) in water (35 mL) and the mixture was heated to 90 °C; subsequently, a solution of 
silver nitrate (10 mL, 0.22 M) was rapidly injected into the hot mixture. The reaction was kept 
at the same temperature for 3 minutes, maintaining magnetic stirring, then it was allowed to 
cool to room temperature. The so formed AgNPs were purified by washing with water (2 x 20 
mL) and concentrated using high speed centrifugation (6000 rpm, 60 min) until the final 
volume of 5mL. 
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5.4.2 Synthesis of AgNPs-1   
To a solution of ligand 1 (75 mg, 0.21 mmol) in ethanol (17 mL) a water suspension of 
AgNPs (5 mL) was slowly added. The mixture was allowed to react one hour in the ultrasonic 
bath then overnight under mechanical stirring at room temperature. After that, the so obtained 
AgNPs-1 were collected and purified by centrifugation (6000 rpm, 30 min) washing with 
ethanol (22 mL) 3 times and re-suspended in chloroform (5 mL). Finally, the solvent was 
gently evaporated under nitrogen flux and the nanoparticles re-suspended again in 
dimethylformamide (DMF, 5 mL). The so-obtained lipophilic silver nanoparticles were 
immediately used in the following steps 
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5.4.3 Synthesis of AgNPs-1-PNPs   
50 mg of PLGA-b-PEG-COOH (7 kDa-3 kDa, 0.005 mmol) were dissolved into a 5 mL 
dispersion of AgNPs-1 in DMF. The organic phase was mixed to 50 mL of ultrapure water 
under vigorous stirring, maintaining water/organic ratio 10/1 with a constant removal of the 
resulting solution. The mixture was kept under magnetic stirring for 30 minutes then purified 
and concentrated using centrifugal filter devices (Amicon Ultra, Ultracell membrane with 
100.000 NMWL, Millipore, USA) until the final volume of 5 mL that was filtered on syringe 
filter SterivexTM-GP 0.22 μm of polyether sulfone (Millipore, USA) and stored at 4 °C. 
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5.4.4 Synthesis of AgNPs-1-PNPs-Cltx   
To a dispersion of AgNPs-1-PNPs (5 mL) in PBS (20 mL, 0.01 M) under magnetic stirring, 
N-hydroxysulfosuccinimide (1.3 mg, 11.0 μmol) and a solution of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide 0.28 M (7.1 mL) were added. The mixture was allowed 
reacting at room temperature for one hour. Subsequently, Chlorotoxin 
(MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR, 150 μg, 0.038 μmol) 
dissolved in 1 mL of water was added and reacted for 24 hours. The mixture was purified 
washing with PBS solution 3 times and concentrated into centrifugal filter devices (Amicon 
Ultra, Ultracell membrane with 100.000 NMWL, Millipore, USA), to a final volume of 5 mL. 
Finally, AgNPs-1-PNPs-Cltx were filtered on syringe filter SterivexTM-GP 0.22 μm of 
polyether sulfone (Millipore, USA) and stored at 4 °C. 
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5.5 Synthesis of aptamer functionalized polymeric nanovectors for the treatment of Glioblastoma thought the BBB  
5.5.1 Synthesis of NVP-BEZ235@PNPs   
100 mg of PLGA-b-PEG-COOH and 6 mg (0.013 mmol) of NVPBEZ-235 were dissolved in 
10 mL of dichloromethane and admixed to 1 mL of water. Then the two-phase mixture was 
emulsified, in an ice bath, with a tip probe sonicator (600 W input, 50% ampl) for 45 s. Then 
40 mL of 1.25% sodium cholate solution in water was slowly added to the obtained emulsion: 
the resulted two-phase mixture was further emulsified for 3 min, in an ice bath, at the above-
reported amplitude. The solvent was evaporated under reduced pressure and the resulting 
particles washed and concentrated by using centrifugal filter devices (Amicon Ultra, Ultracell 
membrane with 100,000 NMWL, Millipore) to a final volume of 2 mL and finally filtered by 
using a syringe filters Phenex-PES of polyether sulfone (26 mm, 0.20 μm, Phenomenex, 
Italy).  
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5.5.2 Synthesis of NVP-BEZ235@PNPs-GintT.4 and NVP-BEZ235@PNPs-SCR   
NVP-BEZ235@PNPs were diluted in PBS (5 mL, 0.01 M) and a solution of N-
hydroxysulfosuccinimide 2.3 mM (4.3 mL), and a solution of 1-ethyl-3-(3-
(dimethylamino)propyl) carbodiimide 0.28 M (1.8 mL) was added. The reaction was carried 
out at room temperature for 15 min, then 102 pmol of 2′F-Py RNA Gint4.T aptamer or the 
scrambled sequence (SCR) of the anti-EGFR aptamers,21 dissolved in 1 mL of water, was 
added and left to react for 24 h 
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5.5.3 Synthesis of BODIPY@PNPs   
100 mg of PLGA-b-PEG-COOH and 0.5 mg (0.02 mmol) of BODIPY505-515 were dissolved 
in 10 mL of dichloromethane and admixed to 1 mL of water. Then the two-phase mixture was 
emulsified, in an ice bath, with a tip probe sonicator (600 W input, 50% ampl) for 45 s. Then 
40 mL of 1.25% sodium cholate solution in water was slowly added to the obtained emulsion: 
the resulted two-phase mixture was further emulsified for 3 min, in an ice bath, at the above-
reported amplitude. The solvent was evaporated under reduced pressure and the resulting 
particles washed and concentrated by using centrifugal filter devices (Amicon Ultra, Ultracell 
membrane with 100,000 NMWL, Millipore)to a final volume of 2 mL and finally filtered by 
using a syringe filters Phenex-PES of polyether sulfone (26 mm, 0.20 μm, Phenomenex, 
Italy). 
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5.5.2 Synthesis of BODIPY@PNPs-GintT.4 and BODIPY@PNPs-SCR   
BODIPY@PNPs were diluted in PBS (5 mL, 0.01 M) and a solution of N-
hydroxysulfosuccinimide 2.3 mM (4.3 mL), and a solution of 1-ethyl-3-(3-
(dimethylamino)propyl) carbodiimide 0.28 M (1.8 mL) was added. The reaction was carried 
out at room temperature for 15 min, then 102 pmol of 2′F-Py RNA Gint4.T aptamer or the 
scrambled sequence of the anti-EGFR aptamers,21 dissolved in 1 mL of water, was added and 
left to react for 24 h. 
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5.6 Gold nanorods as tools for photothermal therapy of Barrett Esophagus  5.6.1 Preparation of GNRs-CTAB   
Water-soluble GNRs-CTAB were prepared by a seed-mediated growth method. This method 
provides the formation of a seed solution consisting of vigorously stirred mixture of cetyl 
trimethylammonium bromide (CTAB, 1 mmol) and  chloroauric acid (HAuCl4, 0.1 M, 0.08  
µmol) was prepared then ice-cold sodium borohydride (NaBH4, 0.1 M, 0.39 mmol) was 
quickly added. Stirring was stopped after 2 min and the seed solution was kept undisturbed 
for 10 min at 25 °C. 
Growth solution was prepared by addition of silver nitrate (AgNO3, 0.4 M, 0.4 mmol) to a 
CTAB (0.1 M, 0.03 mol) and HAuCl4 (0.1 M, 0.17 mmol) aqueous solution. Afterwards 
ascorbic acid aqueous solution was added under vigorous stirring at 25 °C and when the 
growth solution became colorless, the seed solution was added. Stirring was stopped after 5 
min and the growth solution was kept undisturbed overnight at 30 °C.  
At the beginning the purification of GNRs was done by tangential flow filtration, TFF, which 
is driven by a peristaltic pump attached to a commercially available diafiltration membrane 
(Pellicon XL filter device, Biomax membrane with 500.000 NMWL, Millipore, USA), 
washing with an equal amount of water (300 mL). Then GNRs were diluted in water (5 ml in 
50 ml H2O) and centrifuged (6000 rpm, 40 min). This procedure was repeated twice in order 
to obtain GNRs-CTAB. 
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5.6.2 Preparation of GNRs-1   
GNRs-CTAB (2.5 mL, 20 mM) were diluted with 2.5 mL of water then added to a solution of 
ligand ethyl 11-mercaptoundecanoate 1 (30 mg, 0.08 mmol) in 5 mL of ethanol. The mixture 
was left to react firstly one hour into a sonication bath then overnight at room temperature 
under mechanical stirring. After that GNRs-1 were precipitated by centrifugation (6000 rpm, 
30 min) and washed with ethanol (2x10 mL) in order to remove excess ligand and CTAB. 
GNRs-1 were then redispersed in 3.5 mL of chloroform, dried under a stream of nitrogen and 
re-dispersed again in 7 mL of dichloromethane. Finally, the solution was sonicated for 30 
minutes and use immediately for next step. 
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5.6.3 Synthesis of GNRs-1@PMs   
100 mg of PLGA-b-PEG-COOH were solubilized in 10 ml of CH2Cl2 containing GNRs-1 at a 
concentration of 0.11 mg/ml then 100 ml of ultrapure water were slowly added: the mixture 
was emulsified with a tip probe sonicator (600 W input, 1 min, 40% ampl).  
Afterwards, the residual organic solvent was evaporated under reduced pressure. The particles 
were then concentrated and purified with a centrifugal filter device (Amicon Ultra, Ultracel 
membrane with 100,000 NMWL, Millipore, USA) washing with water and filtered on syringe 
filter Sterivex™-GP 0.22 μm of polyether sulfone (Millipore, USA). Finally, the volume was 
adjusted to 5 ml with PBS 0.01 M. 
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5.6.4 Preparation of Curc@PMs  100 mg of PLGA-b-PEG-COOH and 10 mg of curcumin were solubilized in 10 ml of CH2Cl2. 
One milliliters of ultrapure water were slowly added to the previous solution and after mutual 
phase separation, the mixture was emulsified with a tip probe sonicator (600 W input, 2 min, 
80% ampl). Afterward residual organic solvent was evaporated under reduced pressure. The 
so-obtained Curc@PMs were then concentrated and purified with a centrifugal filter device 
(Amicon Ultra, Ultracel membrane with 100,000 NMWL, Millipore, USA) washing with 
water and filtered on syringe filter Sterivex™-GP 0.22 μm of polyether sulfone (Millipore, 
USA). Finally, the volume was adjusted to 5 ml with PBS 0.01 M 
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5.6.5 Preparation of GNRs-1/Curc@PMs  
Solution 1: 100 mg of PLGA-b-PEG-COOH were solubilized in 10 ml of CH2Cl2 containing 
GNRs-1 at a concentration of 0.11 mg/ml then 100 ml of ultrapure water were slowly added: 
the mixture was emulsified with a tip probe sonicator (600 W input, 1 min, 40% ampl).  
Solution 2: 10 mg of curcumin were dissolved in 10 ml of CH2Cl2 then 100 ml of ultrapure 
water were slowly added: the mixture was emulsified with a tip probe sonicator (600 W input, 
1 min, 40% ampl). Afterwards, solution 1 and 2 were mixed together and re-emulsified (600 
W input, 1 min, 40%ampl) in order to allow completing of micelles formation and creation of 
nanocarriers containing both GNRs-1 and curcumin.  
The residual organic solvent was evaporated under reduced pressure. The particles were then 
concentrated and purified with a centrifugal filter device (Amicon Ultra, Ultracel membrane 
with 100,000 NMWL, Millipore, USA) washing with water and filtered on syringe filter 
Sterivex™-GP 0.22 μm of polyether sulfone (Millipore, USA). Finally, the volume was 
adjusted to 5 ml with PBS 0.01 M. 
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5.7 Magnesium nanoparticles as a highly biocompatible photothermal agent for hepatocellular carcinoma treatment  
5.7.1 Synthesis of Chit–Mg MPs  
MgCl2 (142 mg, 1.5 mmol), naphthalene (192 mg, 1.5 mmol) and chitosan glutamate (β(1›4) 
linked N-acetyl-D-glucosamine and D-glucosamine glutamate, MW ~ 50 ÷ 150 kDa, DD = 75 
÷ 90 %, 284 mg) were dispersed under vigorous stirring in anhydrous THF (10 mL) under 
argon. After that, lithium (37 mg, 5.4 mmol) was added: the reaction started after 20 minutes 
highlighted by the colour change from white to black. After 24 hours the microparticles were 
centrifuged (6000 rpm) and purified by washing 3 times with 20 mL of anhydrous THF in 
order to remove all the by-products. The so-obtained Chit–Mg MPs were recovered as black 
powder, dried under vacuum and store at +4 °C.  
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5.8 Synthesis of Dumbbell-Like Gold-Iron Oxide Nanoparticles (dl-AuFe NPs) as multifunctional nanosystems  
5.8.1 Synthesis of dl-AuFe3O4 NPs  
Iron pentacarbonyl (Fe(CO)5, 0.15 mL) and gold acetate (Au(ac)3, 0.18 g) were dissolved in 
20 mL of dibenzyl ether that contained surfactants oleic acid (0.1 mL) and oleylamine (0.1 
mL). Finally, reducing agent (1,2-hexadecanediol, 350 mg) was added to the flask and the 
mixture was homogenized by stirring at room temperature under argon atmosphere for 1 hour. 
Then the temperature was raised to 250°C (in 45 minutes) and the reaction mixture was 
refluxed for 1 h to form dl-AuFe3O4 NPs. Subsequently, the reaction mixture was cooled to 
room temperature and NPs were precipitated by the addition of ethanol. NPs were purified 
with centrifugation (6000rpm/10min/3cycles) and finally dispersed in hexane.  
 
153  
5.8.2 Synthesis of dl-AuFe3O4@Chit  
Chitosan-TGA (16 mg) and chitosan-HCA (16 mg) was dispersed in 10 mL of water and the 
solution was stirred over night to allow the complete dissolution of the polymers. Then dl-
AuFe3O4 NPs (20 mg, dried from hexane in nitrogen flux) have been dissolved in 1 ml of 
chloroform and the obtained suspension has been added dropwise to the chitosan water 
solution. The mixture was sonicated for 3 minutes by using a Branson sonicator 450 equipped 
with a microtip (600 W input, 40% ampl). Organic solvent was removed under vacuum and 
the obtained solution was concentrated and purified washing with water into centrifugal filter 
devices (Amicon Ultra, Ultracel membrane with 100.000 NMWL, Millipore, USA) until a 
final volume of 5 mL.  
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5.9 Synthesis of a novel magnetic resonance−photoacoustic dual imaging nanosystem based on core−shell Fe3O4@SiO2@Au NPs  
5.9.1 Synthesis of Native Iron Oxide Nanoparticles, Fe3O4 NPs.   
Iron triacetylacetonate (0.002 mmol; 1 equiv) was dissolved in diphenyl ether (20 mL). Oleic 
acid (0.0044 mmol; 2.2 equiv), oleyl amine (0.00395 mmol; 2 equiv), and hexadecanediol 
(0.00994 mmol; 5 equiv) were then added, and the mixture was heated to reflux (267 °C) for 
60 min under nitrogen atmosphere to prevent unwanted oxidation. The mixture was then 
cooled to room temperature. The Fe3O4 NPs were purified by magnetic precipitation with 
excess of cold ethanol, dispersed in 5 mL of hexane, and washed by four centrifugations 
(6000 rpm, 45 min) in ethanol. The NPs were redispersed in 5 mL of hexane (30 mg/mL). 
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5.9.2 Synthesis of Core−Shell Iron Oxide−Silica Nanoparticles Fe3O4@SiO2 NPs  
Hydrosoluble cetyltrimethylammonium cetyltrimethylammonium bromide (CTAB) micelles 
loaded with Fe3O4 NPs were prepared. A total of 500 mg of CTAB was dissolved in 25 mL of 
water and sonicated with a tip-probe sonicator (600 W, 50% amplitude, 6 min) with 2.5 mL of 
a solution of Fe3O4 NPs (73 mg) in hexane. The hexane was then removed by heating at 60 °C 
for 30 min. The as-synthesized micelles were diluted with 125 mL of water, and 2.5 mL of 
ethyl acetate and 3.4 mL of a 28% NH3 solution were added under vigorous stirring. After 10 
min, 1.5 mL of MTEOS was added drop-wise, and the mixture was stirred for 3 days at room 
temperature (25−30 °C). Next, 1.3 mL of 3-aminopropyl-methoxysilane (APTMS) were 
added dropwise, and the mixture was stirred for 3 more days at room temperature. 
The Fe3O4@SiO2 NPs were purified by centrifugation (6000 rpm, 1 h) in water. To remove 
the CTAB, the Fe3O4@SiO2 NPs were stirred for 30 min in a mixture of ethanol and acetic 
acid (95:5) and centrifuged (6000 rpm, 30 min) three times. Finally, the last purifications were 
performed by centrifugation in ethanol and water (1:1). The Fe3O4@SiO2 NPs were dispersed 
in 20 mL of ethanol (2 mg/mL). 
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5.9.3 Synthesis of Core−Shell Iron Oxide−Silica−Gold Nanoparticles, Fe3O4@SiO2@Au NPs  
Gold seeds were prepared by reduction of chloroauric acid (HAuCl4) with tetrakis 
(hydroxymethyl)phosphonium chloride (THPC). Briefly, 91 mL of water, 3 mL of a 0.2 M 
NaOH solution, and 2 mL of a THPC solution (120 μL of THPC, 80%, in 10 mL of water) 
were mixed. Next, 4 mL of a 25 mM HAuCl4 solution were added under vigorous stirring. 
Then, 40 mg of Fe3O4@SiO2 NPs were dispersed in 40 mL of ethanol and water (1:1). This 
mixture was diluted with 100 mL of water and vigorously stirred for 10 min. A total of 50 mL 
of the previous gold seeds solution was added, and the mixture was stirred overnight at room 
temperature. The resulting Fe3O4@SiO2−gold seeds NPs were purified by centrifugation 
(6000 rpm, 1 h) in water four times and then dispersed in water (2 mg/mL). The synthesis of 
an entire shell of gold was performed by a shell-growth reaction. HAuCl4 was mildly reduced 
using hydroxylamine as a reducing agent: 101 mg of potassium carbonate was dissolved in 
393 mL of water, and then 7.05 mL of a 25 mM solution of chloroauric acid solution was 
added. The solution was stirred overnight in darkness at room temperature. 
To 100 mL of the so-obtained solution, 10 mL of Fe3O4@ SiO2−gold seeds NPs solution (20 
mg) was added under vigorous stirring. A total of 65 mL of a 1.87 mM hydroxylamine 
hydrochloride solution was added drop-wise in 30 min. The obtained Fe3O4@SiO2@Au NPs 
were purified by centrifugation (6000 rpm, 30 min) in water three times and dispersed in 
water. The size of the gold shell was increased by iteration of the previous shell-growth 
reaction. 
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5.9.4 Synthesis of Lipophilic Fe3O4@SiO2@Au NPs by Ligand Exchange  
The hydrophilic Fe3O4@SiO2@Au NPs were free of any organic coating agent, and they were 
made lipophilic by organic coating with the ligand ethyl 11-(4-  
mercaptobenzamido)undecanoate (ligand 1). A total of 50 mg of ligand 1 was dissolved in 10 
mL of ethanol. A total of 3.5 mg of Fe3O4@SiO2@Au NPs was dispersed in 10 mL of water. 
The two solutions were mixed, sonicated in an ultrasound bath for 45 min, and left to react 
overnight on a vortexer. These lipophilic NPs were purified by centrifugation (6000 rpm, 15 
min) in ethanol and water (1:1) twice and dispersed in chloroform. 
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5.9.5 Synthesis of Fe3O4@SiO2@Au@PMs.   
A solution of lipophilic Fe3O4@SiO2@Au NPs (3 mg) and PLGA−b−PEG−NH2 (50 mg) in 4 
mL of chloroform was prepared. This organic mixture was sonicated (600 W input, 50% 
amplitude, 3 min) with 40 mL of water in an ice bath. The organic solvent was removed under 
vacuum, and the nanoparticles were purified and concentrated to 2 mL with centrifugal filter 
devices (Amicon Ultra, Ultracel membrane with 100.000 NMWL, Millipore). 
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5.9.6 Conjugation of Folic Acid on Fe3O4@SiO2@AuNPs@PMs   
The surface of the PMs was conjugated with the folic acid as a targeting agent. A total of 2 
mg of folic acid was dispersed in 0.1 mL drops of DMSO and diluted in 1mL of water. To 
activate the carboxylic moiety of the active targeting, 1 mL of a 1-ethyl-3-(3-
(dimethylamino)propyl)carbodiimide (EDC) solution (3.5 mg in 5 mL) and 1 mL of N-
hydroxysulfosuccinimide (sulfo-NHS) solution (4.4 mg in 5 mL) were added to the acid folic, 
and the obtained solution was stirred for 30 min. Next, 2 mL of the 
Fe3O4@SiO2@AuNPs@PMs were added, and the mixture was stirred overnight at room 
temperature. The conjugated PMs were purified and concentrated into centrifugal filter 
devices (Amicon Ultra, Ultracel membrane with 100.000 NMWL, Millipore). 
 
 
160  
6. Bibliography 
 
1. Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and 
opportunities. Nat. Rev. Cancer 17, 20–37 (2016). 
2. Bray, F., Jemal, A., Grey, N., Ferlay, J. & Forman, D. Global cancer transitions according to the Human 
Development Index (2008-2030): A population-based study. Lancet Oncol. 13, 790–801 (2012). 
3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA. Cancer J. Clin. 67, 7–30 (2017). 
4. Shi, J., Votruba, A. R., Farokhzad, O. C. & Langer, R. Nanotechnology in drug delivery and tissue engineering: 
From discovery to applications. Nano Lett. 10, 3223–3230 (2010). 
5. Ainslie, K. M. & Desai, T. a. Microfabricated implants for applications in therapeutic delivery, tissue engineering, 
and biosensing. Lab Chip 8, 1864 (2008). 
6. Barenholz, Y. Doxil® - The first FDA-approved nano-drug: Lessons learned. J. Control. Release 160, 117–134 
(2012). 
7. Roser, M., Fischer, D. & Kissel, T. Surface-modified biodegradable albumin nano- and microspheres. II: Effect of 
surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 46, 255–263 (1998). 
8. Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S. & La-Beck, N. M. Meta-analysis of clinical and preclinical 
studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Control. 
Release 232, 255–264 (2016). 
9. Ahn, H. K. et al. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with 
advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 74, 277–282 (2014). 
10. Kato, K. et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated 
advanced or recurrent gastric cancer. Invest. New Drugs 30, 1621–1627 (2012). 
11. Hrkach, J. et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with 
a Differentiated Pharmacological Profile. Sci. Transl. Med. 4, 128ra39-128ra39 (2012). 
12. Jun, Y. W., Lee, J. H. & Cheon, J. Chemical design of nanoparticle probes for high-performance magnetic resonance 
imaging. Angew. Chemie - Int. Ed. 47, 5122–5135 (2008). 
13. Choi, K. Y., Liu, G., Lee, S. & Chen, X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: 
current approaches and future perspectives. Nanoscale 4, 330–342 (2012). 
14. Barreto, J. A. et al. Nanomaterials: Applications in cancer imaging and therapy. Adv. Mater. 23, (2011). 
15. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000). 
16. Iyer, A. K., Khaled, G., Fang, J. & Maeda, H. Exploiting the enhanced permeability and retention effect for tumor 
targeting. Drug Discov. Today 11, 812–818 (2006). 
17. Couvreur, P. & Vauthier, C. Nanotechnology: Intelligent design to treat complex disease. Pharmaceutical Research 
23, (2006). 
18. Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63, 131–135 
(2011). 
19. Xu, X., Ho, W., Zhang, X., Bertrand, N. & Farokhzad, O. Cancer nanomedicine: From targeted delivery to 
combination therapy. Trends Mol. Med. 21, 223–232 (2015). 
20. Gelaye, B., Rondon, M., Araya, P. R. & A, P. M. HHS Public Access. 3, 973–982 (2016). 
21. Corsi, F. et al. HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-
engineered multifunctional nanoparticles in mice. ACS Nano 5, 6383–6393 (2011). 
22. Li, X. et al. Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting. Small 8, 
2505–2514 (2012). 
23. Shahin, M., Ahmed, S., Kaur, K. & Lavasanifar, A. Decoration of polymeric micelles with cancer-specific peptide 
ligands for active targeting of paclitaxel. Biomaterials 32, 5123–5133 (2011). 
161  
24. Wu, X., Chen, J., Wu, M. & Zhao, J. X. Aptamers: Active targeting ligands for cancer diagnosis and therapy. 
Theranostics 5, 322–344 (2015). 
25. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 (2007). 
26. Lim, E.-K. et al. Nanomaterials for Theranostics: Recent Advances and Future Challenges. Chem. Rev. 115, 327–
394 (2015). 
27. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161–171 (2005). 
28. Banik, B. L., Fattahi, P. & Brown, J. L. Polymeric nanoparticles: The future of nanomedicine. Wiley Interdiscip. 
Rev. Nanomedicine Nanobiotechnology 8, 271–299 (2016). 
29. Panyam, J. & Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug 
Deliv. Rev. 55, 329–347 (2003). 
30. Duan, X. & Li, Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular 
internalization, and trafficking. Small 9, 1521–1532 (2013). 
31. Champion, J. A., Walker, A. & Mitragotri, S. Role of particle size in phagocytosis of polymeric microspheres. 
Pharm. Res. 25, 1815–1821 (2008). 
32. Davis, M. E., Chen, Z. (Georgia) & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for 
cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008). 
33. Arvizo, R. R. et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. 
PLoS One 6, 3–8 (2011). 
34. Xiao, K. et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar 
nanoparticles. Biomaterials 32, 3435–3446 (2011). 
35. Mohanraj, V., Chen, Y. & Chen, M. &. Nanoparticles – A Review. Trop. J. Pharm. Res. Trop J Pharm Res 5, 561–
573 (2006). 
36. Torchilin, V. P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9, E128–E147 
(2007). 
37. Owens, D. E. & Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. 
J. Pharm. 307, 93–102 (2006). 
38. Li, S. & McCarthy, S. Influence of crystallinity and stereochemistry on the enzymatic degradation of poly(lactide)s. 
Macromolecules 32, 4454–4456 (1999). 
39. Gross, R. A., MacDonald, R. T. & McCarthy, S. P. Enzymatic degradability of poly(lactide): Effects of chain 
stereochemistry and material crystallinity. Am. Chem. Soc. Polym. Prepr. Div. Polym. Chem. 37, 436–437 (1996). 
40. Muthu, M. Nanoparticles Based on PLGA and its Co-Polymer: An Overview. Asian J. Pharm. 3, 266–273 (2009). 
41. Locatelli, E. & Franchini, M. C. Biodegradable PLGA-b-PEG polymeric nanoparticles: Synthesis, properties, and 
nanomedical applications as drug delivery system. J. Nanoparticle Res. 14, 1–17 (2012). 
42. Rao, J. P. & Geckeler, K. E. Polymer nanoparticles: Preparation techniques and size-control parameters. Prog. 
Polym. Sci. 36, 887–913 (2011). 
43. Anton, N., Benoit, J. P. & Saulnier, P. Design and production of nanoparticles formulated from nano-emulsion 
templates-A review. J. Control. Release 128, 185–199 (2008). 
44. Rao, J. P. & Geckeler, K. E. Polymer nanoparticles: Preparation techniques and size-control parameters. Prog. 
Polym. Sci. 36, 887–913 (2011). 
45. Schubert, S., Delaney, Jr, J. T. & Schubert, U. S. Nanoprecipitation and nanoformulation of polymers: from history 
to powerful possibilities beyond poly(lactic acid). Soft Matter 7, 1581 (2011). 
46. Lepock, J. R. Cellular effects of hyperthermia: Relevance to the minimum dose for thermal damage. Int. J. Hyperth. 
19, 252–266 (2003). 
47. Song, C. W. Effect of Local Hyperthermiaon BloodFlow and Microenvironment : (1984). 
48. Hildebrandt, B. et al. The cellular and molecular basis of hyperthermia. 43, 33–56 (2002). 
162  
49. Wust, P. et al. Review Hyperthermia in combined treatment of cancer. 487–497 
50. Behrouzkia, Z., Joveini, Z., Keshavarzi, B., Eyvazzadeh, N. & Aghdam, R. Z. Hyperthermia: How can it be used? 
Oman Med. J. 31, 89–97 (2016). 
51. Hervault, A. & Thanh, N. T. K. Magnetic nanoparticle-based therapeutic agents for thermo-chemotherapy treatment 
of cancer. Nanoscale 6, 11553–11573 (2014). 
52. Maier-Hauff, K. et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles 
combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103, 
317–324 (2011). 
53. Jaque, D. et al. Nanoparticles for photothermal therapies. Nanoscale 6, 9494–9530 (2014). 
54. O’Neal, D. P., Hirsch, L. R., Halas, N. J., Payne, J. D. & West, J. L. Photo-thermal tumor ablation in mice using 
near infrared-absorbing nanoparticles. Cancer Lett. 209, 171–176 (2004). 
55. Weissleder, R. A clearer vision for in vivo imaging Progress continues in the development of smaller , more 
penetrable probes for biological imaging . Toward the phosphoproteome. Nat. Biotechnol. 19, 316–317 (2001). 
56. West, J. L. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. 100, 
(2003). 
57. Kreibig, U. & Vollmer, M. Optical Properties of Metal Clusters. J. Am. Chem. Soc. 118, 6098–6098 (1995). 
58. Mulvaney, P. Surface Plasmon Spectroscopy of Nanosized Metal Particles. Langmuir 12, 788–800 (1996). 
59. Sharma, V., Park, K. & Srinivasarao, M. Colloidal dispersion of gold nanorods: Historical background, optical 
properties, seed-mediated synthesis, shape separation and self-assembly. Mater. Sci. Eng. R Reports 65, 1–38 
(2009). 
60. Burrows, N. D. et al. Surface Chemistry of Gold Nanorods. Langmuir 32, 9905–9921 (2016). 
61. Jain, P. K., Lee, K. S., El-Sayed, I. H. & El-Sayed, M. A. Calculated absorption and scattering properties of gold 
nanoparticles of different size, shape, and composition: Applications in biological imaging and biomedicine. J. Phys. 
Chem. B 110, 7238–7248 (2006). 
62. Locatelli, E., Monaco, I. & Comes Franchini, M. Surface modifications of gold nanorods for applications in 
nanomedicine. RSC Adv. 5, 21681–21699 (2015). 
63. Maguire, M. E. & Cowan, J. A. Magnesium chemistry and biochemistry [Review]. BioMetals 15, 203–210 (2002). 
64. Saris, N.-E. L. E. A. Magnesium An update on phsyiological, clinical and analytical aspects. Clin. Chim. Acta 294, 
1–26 (2000). 
65. Witte, F. Reprint of: The history of biodegradable magnesium implants: A review. Acta Biomater. 23, S28–S40 
(2015). 
66. Walker, J., Shadanbaz, S., Woodfield, T. B. F., Staiger, M. P. & Dias, G. J. Magnesium biomaterials for orthopedic 
application: A review from a biological perspective. J. Biomed. Mater. Res. - Part B Appl. Biomater. 102, 1316–
1331 (2014). 
67. Jeong, H.-H., Mark, A. G. & Fischer, P. Magnesium plasmonics for UV applications and chiral sensing. Chem. 
Commun. 52, 12179–12182 (2016). 
68. Sanz, J. M. et al. UV plasmonic behavior of various metal nanoparticles in the near- and far-field regimes: Geometry 
and substrate effects. J. Phys. Chem. C 117, 19606–19615 (2013). 
69. Sterl, F. et al. Magnesium as novel material for active plasmonics in the visible wavelength range. Nano Lett. 15, 
7949–7955 (2015). 
70. comes franchini,  mauro et al. One-pot synthesis of magnesium nanoparticles embedded in chitosan microparticles: 
a highly biocompatible tool for in vivo cancer treatment. J. Mater. Chem. B 4, 207–211 (2015). 
71. Locatelli, E. et al. Surface chemistry and entrapment of magnesium nanoparticles into polymeric micelles: a highly 
biocompatible tool for photothermal therapy. Chem. Commun. 50, 7783 (2014). 
72. Wang, Q., Xie, L., He, Z., Di, D. & Liu, J. Biodegradable magnesium nanoparticle-enhanced laser hyperthermia 
163  
therapy. Int. J. Nanomedicine 7, 4715–4725 (2012). 
73. Jin, C., He, Z.-Z., Zhang, J., Yang, X.-Y. & Liu, J. Enhanced Thermographic Detection of Skin Cancer Through 
Combining Laser Scanning and Biodegradable Nanoparticles. J. Nanotechnol. Eng. Med. 4, 11004 (2013). 
74. Lee, D.-E. et al. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem. Soc. Rev. 41, 2656–
2672 (2012). 
75. Weber, J., Beard, P. C. & Bohndiek, S. E. Contrast agents for molecular photoacoustic imaging. Nat. Methods 13, 
639–650 (2016). 
76. Louie, A. Multimodality Imaging Probes: Design and Challenges. Chem. Rev. 110, 3146–3195 (2010). 
77. Wang, L. V & Yao, J. A practical guide to photoacoustic tomography in the life sciences. Nat. Methods 13, 627–638 
(2016). 
78. Wang, L. V. & Gao, L. Photoacoustic Microscopy and Computed Tomography: From Bench to Bedside. Annual 
Review of Biomedical Engineering 16, (2014). 
79. van den Berg, P. J., Bansal, R., Daoudi, K., Steenbergen, W. & Prakash, J. Preclinical detection of liver fibrosis 
using dual-modality photoacoustic/ultrasound system. Biomed. Opt. Express 7, 5081 (2016). 
80. Ermilov, S. A. et al. Laser optoacoustic imaging system for detection of breast cancer. J. Biomed. Opt. 14, 24007 
(2009). 
81. Heijblom, M. et al. Visualizing breast cancer using the Twente photoacoustic mammoscope: What do we learn from 
twelve new patient measurements? Opt. Express 20, 11582 (2012). 
82. Luke, G. P., Myers, J. N., Emelianov, S. Y. & Sokolov, K. V. Sentinel Lymph Node Biopsy Revisited : Ultrasound-
Guided Photoacoustic Detection of Micrometastases Using Molecularly Targeted Plasmonic Nanosensors. 5397–
5409 (2014). doi:10.1158/0008-5472.CAN-14-0796 
83. Yao, J. & Wang, L. V. Photoacoustic brain imaging: from microscopic to macroscopic scales. Neurophotonics 1, 
11003 (2014). 
84. Huang, C. Aberration correction for transcranial photoacoustic tomography of primates employing adjunct image 
data. J. Biomed. Opt. 17, 66016 (2012). 
85. Levi, J. et al. Molecular Photoacoustic Imaging of Follicular Thyroid Carcinoma. Clin. Cancer Res. 19, 1494–1502 
(2013). 
86. Li, P. et al. In vivo Photoacoustic Molecular Imaging with Simultaneous Multiple Selective Targeting Using 
Antibody-Conjugated Gold Nanorods. 16, 18605–18615 (2008). 
87. Laufer, J. et al. In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy. J. Biomed. 
Opt. 17, 56016 (2012). 
88. Wang, P., Wang, P., Wang, H.-W. & Cheng, J.-X. Mapping lipid and collagen by multispectral photoacoustic 
imaging of chemical bond vibration. J. Biomed. Opt. 17, 960101 (2012). 
89. Wu, C., Liang, X. & Jiang, H. Metal nanoshells as a contrast agent in near-infrared diffuse optical tomography. Opt. 
Commun. 253, 214–221 (2005). 
90. Erickson, T. a & Tunnell, J. W. Gold Nanoshells in Biomedical Applications. Nanomaterials for the life Science Vol. 
3: Mixed Metal Nanomaterials 3, (2007). 
91. Huang, H.-C., Barua, S., Sharma, G., Dey, S. K. & Rege, K. Inorganic nanoparticles for cancer imaging and therapy. 
J. Control. Release 155, 344–357 (2011). 
92. Preston, T. C. & Signorell, R. Growth and Optical Properties of Gold Nanoshells Prior to the Formation of a 
Continuous Metallic Layer. 3, 
93. Mody, V., Siwale, R., Singh, A. & Mody, H. Introduction to metallic nanoparticles. J. Pharm. Bioallied Sci. 2, 282 
(2010). 
94. Na, H. Bin, Song, I. C. & Hyeon, T. Inorganic nanoparticles for MRI contrast agents. Adv. Mater. 21, 2133–2148 
(2009). 
164  
95. Ai, T. et al. A historical overview of Magnetic Resonance Imaging, focusing on technological innovations. Invest. 
Radiol. 47, 725–741 (2012). 
96. Bellin, M.-F. MR contrast agents, the old and the new. Eur. J. Radiol. 60, 314–323 (2006). 
97. Lohrke, J. et al. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. 
Adv. Ther. 33, 1–28 (2016). 
98. Shokrollahi, H. Contrast agents for MRI. Mater. Sci. Eng. C 33, 4485–4497 (2013). 
99. Rogosnitzky, M. & Branch, S. Gadolinium-based contrast agent toxicity: a review of known and proposed 
mechanisms. BioMetals 29, 365–376 (2016). 
100. Manuscript, A. Molecular MR Contrast Agents for the Detection of Cancer: Past and Present. Semin. Oncol. 38, 42–
54 (2011). 
101. Bashir, M. R., Bhatti, L., Marin, D. & Nelson, R. C. Emerging applications for ferumoxytol as a contrast agent in 
MRI. J. Magn. Reson. Imaging 41, 884–898 (2015). 
102. Lee, J.-H. et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 13, 
95–99 (2007). 
103. Smolensky, E. D., Park, H. Y. E., Berquó, T. S. & Pierre, V. C. Surface functionalization of magnetic iron oxide 
nanoparticles for MRI applications - effect of anchoring group and ligand exchange protocol. Contrast Media Mol. 
Imaging 6, 189–199 (2011). 
104. Vasanawala, S. S. et al. Safety and technique of ferumoxytol administration for MRI. Magn. Reson. Med. 75, 2107–
2111 (2016). 
105. Love, J. C., Estroff, L. A., Kriebel, J. K., Nuzzo, R. G. & Whitesides, G. M. Self-assembled monolayers of thiolates 
on metals as a form of nanotechnology. Chemical Reviews 105, (2005). 
106. Nallathamby, P. D., Hopf, J., Irimata, L. E., McGinnity, T. L. & Roeder, R. K. Preparation of fluorescent Au–SiO 2 
core–shell nanoparticles and nanorods with tunable silica shell thickness and surface modification for 
immunotargeting. J. Mater. Chem. B 4, 5418–5428 (2016). 
107. Jana, N. R., Earhart, C. & Ying, J. Y. Synthesis of water-soluble and functionalized nanoparticles by silica coating. 
Chem. Mater. 19, 5074–5082 (2007). 
108. Ding, H. L. et al. Fe3O4@SiO2 core/shell nanoparticles: The silica coating regulations with a single core for 
different core sizes and shell thicknesses. Chem. Mater. 24, 4572–4580 (2012). 
109. Chen, Y., Frey, W., Kim, S., Kruizinga, P. & Emelianov, S. Amplifiers. 11, 348–354 (2012). 
110. Harris-Birtill, David;Singh, Mohan;Zhou, Yu;Shah, A; Ruenraroengsak, P; Gallina, M; Hanna, G;Cass, Anthony; 
Porter, Alexandra; Bamber, Jeffrey;Elson, D. Gold nanorod reshaping in vitro and in vivo using a continuous wave 
laser. PLoS ONE PONE-D-17-19585 (In Press. 1–21 (2017). doi:10.1371/journal.pone.0185990 
111. Locatelli, E. et al. Lipophilic silver nanoparticles and their polymeric entrapment into targeted-PEG-based micelles 
for the treatment of glioblastoma. Adv. Healthc. Mater. 1, 342–347 (2012). 
112. Bae, K. H. et al. Chitosan Oligosaccharide-Stabilized Ferrimagnetic Iron Oxide Nanocubes for Magnetically 
Modulated Cancer Hyperthermia. 5266–5273 (2012). 
113. Guo, L. et al. Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide 
nanoparticles. ACS Nano 8, 5670–5681 (2014). 
114. Tamborini, M. et al. A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation to 
Reach Infiltrating Tumor Niches in Glioblastoma. ACS Nano 10, 2509–2520 (2016). 
115. Monaco, I. et al. Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain 
Barrier. J. Med. Chem. 60, 4510–4516 (2017). 
116. Soroceanu, L., Gillespie, Y., Khazaeli, M. B. & Sontheimer, H. Use of Chlorotoxin for Targeting of Primary Brain 
Tumors Use of Chlorotoxin for Targeting of Primary Brain Tumors1. 4871–4879 (1998). 
117. DeBin, J. A., Maggio, J. E. & Strichartz, G. R. Purification and characterization of chlorotoxin, a chloride channel 
165  
ligand from the venom of the scorpion. Am. J. Physiol. 264, C361-9 (1993). 
118. Bartczak, D. & Kanaras, A. G. Preparation of peptide-functionalized gold nanoparticles using one pot EDC/Sulfo-
NHS coupling. Langmuir 27, 10119–10123 (2011). 
119. Yuan, H. et al. Radiation-induced permeability and leukocyte adhesion in the rat blood-brain barrier: Modulation 
with anti-ICAM-1 antibodies. Brain Res. 969, 59–69 (2003). 
120. Baumann, B. C. et al. Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation 
therapy. Oncotarget 4, 64–79 (2013). 
121. Sawyer, A. J. et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of 
intracranial tumors. Drug Deliv. Transl. Res. 1, 34–42 (2011). 
122. Thorne, R. G. & Nicholson, C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain 
extracellular space. Proc. Natl. Acad. Sci. U. S. A. 103, 5567–72 (2006). 
123. Camorani, S. et al. Inhibition of Receptor Signaling and of Glioblastoma-derived Tumor Growth by a Novel 
PDGFRβ Aptamer. Mol. Ther. 22, 828–841 (2014). 
124. Lin, F., Chandrasekaran, G., de Gooijer, M. C., Beijnen, J. H. & van Tellingen, O. Determination of NVP-BEZ235, 
a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase 
high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Anal. Technol. Biomed. Life 
Sci. 901, 9–17 (2012). 
125. Xin, P. et al. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate 
against chronic myelogenous leukemia cell lines. Drug Des. Devel. Ther. 11, 1115–1126 (2017). 
126. Nikoobakht, B. & El-Sayed, M. A. Preparation and growth mechanism of gold nanorods (NRs) using seed-mediated 
growth method. Chem. Mater. 15, 1957–1962 (2003). 
127. Nikoobakht, B. & El-Sayed, M. A. Evidence for bilayer assembly of cationic surfactants on the surface of gold 
nanorods. Langmuir 17, 6368–6374 (2001). 
128. Murphy, C. J. et al. Anisotropic metal nanoparticles: Synthesis, assembly, and optical applications. J. Phys. Chem. B 
109, 13857–13870 (2005). 
129. Wilken, R., Veena, M. S., Wang, M. B. & Srivatsan, E. S. Curcumin: A review of anti-cancer properties and 
therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer 10, 12 (2011). 
130. Sharma, R. A. et al. Phase I Clinical Trial of Oral Curcumin : Biomarkers of Systemic Activity and Compliance 
Phase I Clinical Trial of Oral Curcumin : Biomarkers of Systemic Activity and Compliance. 10, 6847–6854 (2004). 
131. Park, S. H. et al. An intratumoral injectable, electrostatic, cross-linkable curcumin depot and synergistic 
enhancement of anticancer activity. NPG Asia Mater. 9, e397 (2017). 
132. Dormidontova, E. E. Micellization kinetics in block copolymer solutions: scaling model. Macromolecules 32, 7630–
7644 (1999). 
133. Baatout, S. et al. Effect of curcuma on radiation-induced apoptosis in human cancer cells. 321–329 (2004). 
134. Mary, Q., Kingdom, U. & Madrid, D. Synthesis of Colloidal Magnesium : A Near Room. 400–402 (2007). 
135. Haas, I. & Gedanken, A. Synthesis of metallic magnesium nanoparticles by sonoelectrochemistry. Chem. Commun. 
(Camb). 1795–1797 (2008). doi:10.1039/b717670h 
136. Kooi, B. J., Palasantzas, G. & De Hosson, J. T. M. Gas-phase synthesis of magnesium nanoparticles: A high-
resolution transmission electron microscopy study. Appl. Phys. Lett. 89, 1–4 (2006). 
137. Aurbach, D. et al. Prototype systems for rechargeable magnesium batteries. Nature 407, 724–727 (2000). 
138. Song, M. R., Chen, M. & Zhang, Z. J. Preparation and characterization of Mg nanoparticles. Mater. Charact. 59, 
514–518 (2008). 
139. Balogh, J. et al. Hepatocellular carcinoma: a review. J. Hepatocell. carcinoma 3, 41–53 (2016). 
140. Kostevsek, N. et al. The one-step synthesis and surface functionalization of dumbbell-like gold–iron oxide 
nanoparticles: a chitosan-based nanotheranostic system. Chem. Commun. 52, 378–381 (2015). 
166  
141. Monaco, I. et al. Synthesis of Lipophilic Core-Shell Fe3O4@SiO2@Au Nanoparticles and Polymeric Entrapment 
into Nanomicelles: A Novel Nanosystem for in Vivo Active Targeting and Magnetic Resonance-Photoacoustic Dual 
Imaging. Bioconjug. Chem. 28, 1382–1390 (2017). 
142. Sun, S. & Zeng, H. Size-controlled synthesis of magnetite nanoparticles. J. Am. Chem. Soc. 124, 8204–8205 (2002). 
143. Duff, D. G., Baiker, A. & Edwards, P. P. A new hydrosol of gold clusters. J. Chem. Soc. Chem. Commun. 272, 96 
(1993). 
 
